CREMA TRATTAMENTO PSORIASI OFFERTA -50% !

Home Blog

Psorilax:migliori |creme per psoriasi artropatica

0

Psorilax: prezzo, funziona, recensioni, opinioni, dove si compra

Il sondaggio sulla consegna di farmaci topici di Global Rx Dermatology fornisce informazioni chiave sul settore, compresi fatti e cifre molto utili e importanti, opinioni di esperti e gli ultimi sviluppi in tutto il mondo. Il rapporto sul mercato globale è un documento importante per ogni appassionato di mercato, decisore politico, investitore e giocatore. Il rapporto fornisce fluttuazioni del valore CAGR durante il periodo di previsione 2019-2026 per il mercato. I rapporti di mercato di Rx Dermatology Topical Drug Delivery forniscono dati su modelli e miglioramenti e indirizzano settori e materiali aziendali, limiti e avanzamenti. In questo rapporto, viene fornita un'analisi SWOT e un'analisi degli investimenti approfondite che prevedono opportunità imminenti per gli operatori del mercato di Rx Dermatology Topical Drug Delivery.

Il mercato globale della consegna di farmaci per dermatologia Rx globale dovrebbe raggiungere 40.646,26 milioni di USD entro il 2026 da 29.475,18 milioni di USD nel 2018, con un CAGR del 4,2% nel periodo di previsione dal 2019 al 2026.

Scarica PDF gratuito Copia di esempio del rapporto @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-rx-dermatology-topical-drug-delivery-market

Analisi competitiva:

Alcuni dei principali attori che operano in questo mercato sono Galderma Laboratories, LP, Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc., LEO Pharma A / S, GlaxoSmithKline plc., ALLERGAN, Bayer AG, 3M, Bausch Health Companies Inc., The Lubrizol Corporation, Cipla Inc., Kaken Pharmaceutical Co., Ltd. tra gli altri.

I farmaci topici svolgono un ruolo importante nella terapia delle malattie dermatologiche. I farmaci per dermatologia topica incorniciano una grande percentuale di prodotti nel mercato dei farmaci. Questi prodotti sono fabbricati attraverso processi di produzione specializzati come riempimento di volume preciso, miscelazione su larga scala, riscaldamento e imballaggio.

La somministrazione topica di farmaci può essere effettuata nel corpo attraverso percorsi oftalmici, rettali, vaginali e cutanei come vie topiche. Nel settore della dermatologia, la pelle svolge un ruolo importante nella somministrazione di farmaci topici per il trattamento delle malattie della pelle nei pazienti. I preparati topici vengono applicati sulla pelle per effetti superficiali, locali o sistemici. Le formulazioni topiche includono ingredienti terapeuticamente attivi che aiutano a trattare le malattie della pelle nei pazienti.

Il rilascio topico di farmaci è uno dei modi più efficaci di rilascio di farmaci in quanto fornisce risultati terapeutici ottimali. A poco a poco, il sistema topico di consegna dei farmaci è diventato sempre più importante nell'industria farmaceutica. La risposta farmacologica, sia l'effetto terapeutico desiderato sia l'effetto indesiderato indesiderato di un farmaco dipendono dalla concentrazione del farmaco nel luogo di azione, che a sua volta dipende dalla forma di dosaggio e dall'entità dell'assorbimento del farmaco nel sito di azione. Nel settore della dermatologia, molecola di farmaco applicata sulla pelle che penetra principalmente attraverso il percorso intercellulare tortuoso e continuo. Questi prodotti sono disponibili in diverse forme come unguenti, creme, lozioni, gel e altri che hanno la capacità di essere assorbiti nel corpo e mostrano rispettivamente la risposta positiva nella guarigione della ferita.

Mercato globale di consegna di farmaci topici dermatologici per tipo di prodotto (semisolido, liquido, solido), applicazione (infezioni della pelle, dermatite, antiaging, acne, iperpigmentazione, rosacea, tumore della pelle, psoriasi, onicomicosi, altri), categoria (marchiato, generico ), Geografia (Nord America, Europa, Asia-Pacifico, Sud America, Medio Oriente e Africa) – Tendenze e previsioni del settore fino al 2026

Segmentazione: Mercato globale della consegna di farmaci per dermatologia Rx globale

Il mercato globale della consegna di farmaci topici dermatologici Rx è segmentato in base al tipo di prodotto, all'applicazione e alla categoria.

  • Sulla base del tipo di prodotto, il mercato è segmentato in solido, liquido e semisolido. Il solido è sottosegmentato in polvere e altri. Il liquido viene suddiviso in soluzione, emulsione, sospensione, lozione e altri. Semisolid è sottosegmentato in creme, gel, unguenti, pasta, altri.
    • Nel dicembre 2016, Pfizer Inc. ha ricevuto l'approvazione da parte della Food and Drug Administration (FDA) statunitense per il prodotto chiamato EUCRISATM (crisaborole) unguento al 2%. È un nuovo inibitore topico non steroideo della fosfodieterasi-4 (PDE-4). È usato per il trattamento della dermatite atopica da lieve a moderata (AD). Con questo lancio del prodotto l'azienda ha costruito un patrimonio nel settore dell'infiammazione e dell'immunologia.
  • Sulla base dell'applicazione, il mercato è segmentato in acne, dermatite, psoriasi, infezioni della pelle, antiaging, cancro della pelle, iperpigmentazione, onicomicosi, rosacea, altri.
    • Nel marzo 2017, Galderma Laboratories, L.P., produttori del marchio Cetaphil hanno lanciato sette nuovi prodotti per la cura della pelle del viso. Con questo lancio dei prodotti il ​​portafoglio Cetaphil dell'azienda è aumentato. La società ha ora un'ampia gamma di soluzioni specializzate per i pazienti con problemi di pelle, tra cui idratazione e altri.
  • Sulla base della categoria, il mercato è segmentato in generico e marchiato.
    • Nel febbraio 2016, Allergan plc ha ricevuto un'approvazione per il suo prodotto ACZONE (dapsone) Gel, 7,5% dalla Food and Drug Administration (FDA) degli Stati Uniti. Questo prodotto è un nuovo trattamento topico di prescrizione che è utile per il trattamento dell'acne nei pazienti di età pari o superiore a 12 anni. Il prodotto ha aiutato il paziente a trattare facilmente l'acne che alla fine ha contribuito ad aumentare le entrate.

Richiedi questo rapporto dal nostro esperto @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-rx-dermatology-topical-drug-delivery-market

Recenti sviluppi:

  • Nell'aprile 2016, Allergan plc ha acquisito Topokine Therapeutics, Inc. con un pagamento anticipato di 85,8 milioni di USD ed è stato idoneo a ricevere pietre miliari potenziali di sviluppo e commercializzazione fino a 260,0 milioni di USD.
  • Nel febbraio 2019, Kaken Pharmaceutical Co., Ltd. ha concluso un accordo di licenza e distribuzione esclusiva per la formulazione topica di onicomicosi nella Repubblica popolare cinese. Secondo l'accordo Kaken Pharmaceutical Co., Ltd., ha fornito il diritto esclusivo per lo sviluppo e la commercializzazione del Prodotto in RPC e questo ha portato a un'elevata generazione di entrate.
  • Nell'aprile 2019, The Lubrizol Corporation ha lanciato il suo nuovissimo modificatore di reologia 2 in 1 multifunzionale, polimero Carbopol Style 2.0. Il prodotto ha i benefici per la cura della pelle come l'aspetto liscio lucido, le texture uniche e altro. Con questo lancio è aumentato il portafoglio di prodotti dell'azienda che ha comportato una maggiore generazione di entrate.
  • Nell'agosto 2018, Cipla INC. Ha ricevuto l'approvazione finale per la nuova domanda abbreviata di farmaci (ANDA) per Diclofenac Sodium Topical Gel, 1% dalla Food and Drug Administration degli Stati Uniti (US FDA). Per questo motivo l'azienda ha aumentato il proprio portafoglio di prodotti e una forte posizione sul mercato, specialmente nel campo della dermatologia.
  • Nel novembre 2010, 3M ha rilanciato la linea Cavilon Professional Skin Care. Questo prodotto ha aiutato a prevenire danni alla pelle da umidità, attrito e traumi adesivi. Il portafoglio di prodotti dell'azienda è aumentato per quanto riguarda la dermatologia archiviata e quindi le entrate sanitarie.

Opportunità:

BASSA PENETRAZIONE BIOLOGICA:

I biologici sono i farmaci che sono fatti da proteine ​​animali o umane che hanno la capacità di trattare rispettivamente le malattie. Hanno la capacità di trattare il numero di malattie come la psoriasi, l'artrite psoriasica, altri tipi di artrite e malattie infiammatorie intestinali. A causa della bassa attività dei farmaci biologici nel trattamento di eventuali malattie del derma, i farmaci topici stanno superando il mercato a fini terapeutici e quindi la sua domanda è in aumento sul mercato.

AUMENTO DEL CONCORSO CHE GUIDA AD ALTI INVESTIMENTI IN R&S PER INNOVARE NUOVI PRODOTTI:

La malattia della pelle negli ultimi tempi è una delle principali malattie tra le persone per le quali sono disponibili trattamenti. Uno dei trattamenti avanzati è il sistema topico di rilascio del farmaco in cui la pelle svolge un ruolo importante poiché il farmaco viene applicato sulla pelle che ha la capacità di trattare le aree colpite. Numero di aziende ha preso l'iniziativa nel fornire alta qualità di prodotti o farmaci per il trattamento delle malattie della pelle. Ciò comporta il processo di innovazione nella ricerca farmaceutica. L'aumento del numero di malattie richiede un trattamento adeguato per il quale i farmaci topici svolgono attualmente un ruolo importante. Di conseguenza, molte aziende hanno aumentato le proprie strutture di ricerca e sviluppo al fine di fornire i farmaci che saranno ritenuti un fattore importante per guidare il mercato in futuro.

AUMENTO DI FUSIONI E ACQUISIZIONI:

Le industrie farmaceutiche probabilmente subiscono la maggior parte dell'attività di fusione e acquisizione (M&A) rispetto a qualsiasi altra industria che coinvolge il numero di operazioni e la spesa in denaro. Questa attività è necessaria a causa dell'aumento dello sviluppo di un nuovo farmaco nell'industria farmaceutica. Ad esempio, a luglio 2018, Leo Pharma ha acquisito un'unità globale di dermatologia su prescrizione di Bayer AG (Germania) a un prezzo non divulgato. Lo scopo di questa acquisizione era di espandere il loro prodotto nei farmaci per la pelle. Leo Pharma sviluppa ulteriormente l'attività di dermatologia su prescrizione con questa acquisizione. L'aumento delle acquisizioni e delle fusioni aiuta le aziende a rafforzare i propri ricavi insieme a strutture di ricerca e sviluppo e produzione e questo ultimo aiuto nella crescita di un particolare mercato.

MERCATO EMERGENTE:

L'elevata accessibilità per i pazienti sta portando a maggiori investimenti da parte del settore privato. Molte aziende si stanno concentrando sull'intraprendere sviluppi strategici per aumentare la loro presenza nelle economie emergenti. Insieme a questo, l'invecchiamento della popolazione e l'aumento del reddito disponibile contribuiranno alla crescita del mercato. Il mercato di consegna di farmaci topici ha una grande opportunità in quanto questa piattaforma ha nuovi elementi che sono stati incorporati per il trattamento di malattie della pelle e delle mucose. Le condizioni della pelle stanno aumentando in tutto il mondo, che alla fine richiede un trattamento. Aumentare la consapevolezza delle malattie della pelle è anche un fattore che sta aiutando il mercato a crescere in futuro.

sfide:

EFFETTI COLLATERALI:

L'effetto collaterale dei farmaci si verifica nell'uomo a causa dell'uso a lungo termine dei farmaci. Ci sono alcuni effetti collaterali che possono verificarsi nel corpo del paziente dopo aver consumato farmaci topici. Ad esempio, il consumo a lungo termine di corticosteroidi può causare difetti alla nascita nel feto. I farmaci topici possono fornire un trattamento migliore ma a parte questo anche il prodotto ha effetti collaterali. Ciò accade a causa dell'uso eccessivo di trattamenti topici che aumentano il rischio di effetti collaterali sia cutanei che sistemici e quindi ostacolano la crescita del mercato.

RICHIAMO DEL PRODOTTO:

Negli ultimi anni, il numero di richiami di prodotti nel mercato topico della consegna di droghe è aumentato enormemente. Questi richiami di prodotti possono verificarsi a causa di inadempienza della conformità, come difetti di progettazione o di fabbricazione che possono essere negoziati con la sicurezza, l'efficacia e la purezza del farmaco o dei dispositivi di consegna del farmaco da parte di un'azienda produttrice di farmaci. Ad esempio, a luglio 2016, GlaxoSmithKline (Regno Unito) ha annunciato il richiamo dell'unguento Bactroban e della crema Bactroban a causa della presenza di contaminazione durante la produzione; queste formulazioni sono state usate localmente per le infezioni della pelle. Inoltre, a giugno 2016, il cerotto per emicrania di Teva Phamaceutical chiamato Zecuity è stato ricordato per aver riportato gravi ustioni e potenziali cicatrici permanenti. Il richiamo dei prodotti influisce sui ricavi dell'azienda e, in definitiva, sul mercato particolare.

Nota: se hai esigenze particolari, faccelo sapere e ti offriremo il rapporto come desideri.

Informazioni sulla ricerca di mercato di Data Bridge:

Data Bridge Market Research si è presentata come una società di ricerca e consulenza di mercato non convenzionale e neoterica con un livello di resilienza senza precedenti e approcci integrati. Siamo determinati a scoprire le migliori opportunità di mercato e promuovere informazioni efficienti per far prosperare il tuo business sul mercato. Data Bridge si impegna a fornire soluzioni adeguate alle complesse sfide aziendali e avvia un processo decisionale senza sforzo.

Contatto:

Ricerche di mercato di Data Bridge

Tel: + 1-888-387-2818

E-mail: Corporatesales@databridgemarketresearch.com

Psorilax:Come faccio a |shivax creme psoriasi

0

Psorilax: prezzo, funziona, recensioni, opinioni, ingredienti

PRIMO MODIFICATO E RESTAURATO

ACCORDO DI ACQUISTO DI PATRIMONIO E ATTIVITÀ

datato al 31 marzo 2020

da e tra

GENERAL ELECTRIC COMPANY, in qualità di venditore,

e

DANAHER CORPORATION, come acquirente


Sommario

Pagina

Articolo I DEFINIZIONI

1

Sezione 1.01

Alcuni termini definiti

1

Articolo II ACQUISTO E VENDITA; CHIUSURA

1

Sezione 2.01

Acquisto e vendita di beni trasferiti

1

Sezione 2.02

Cessione di alcuni beni trasferiti

5

Sezione 2.03

Chiusura

6

Sezione 2.04

ritenuta

6

Sezione 2.05

Trasferimenti differiti; Attività specificate

6

Sezione 2.06

Struttura dei trasferimenti

8

Articolo III PREZZO DI ACQUISTO

9

Sezione 3.01.

Prezzo d'acquisto

9

Sezione 3.02

Alcuni risultati finali

10

Sezione 3.03

Dichiarazione di chiusura stimata; Pagamento di chiusura

11

Sezione 3.04

Dichiarazione di chiusura finale proposta e Dichiarazione di chiusura finale

12

Sezione 3.05

Regolazione post-chiusura

13

Sezione 3.06

Alcuni principi di calcolo

13

Sezione 3.07.

Allocazione del prezzo di acquisto

13

Articolo IV DICHIARAZIONI E GARANZIE DEL VENDITORE

13

Sezione 4.01

Formazione e qualificazione delle società

13

Sezione 4.02.

Formazione e qualificazione delle società controllate

14

Sezione 4.03.

Proprietà; Struttura del capitale delle entità trasferite

14

Sezione 4.04.

Formazione e autorità delle parti del venditore; Esecutività

14

Sezione 4.05.

Nessun conflitto

15

Sezione 4.06.

Consensi e approvazioni

15

Sezione 4.07.

Informazioni finanziarie; Assenza di responsabilità non divulgata

15

Sezione 4.08.

Assenza di alcuni cambiamenti o eventi

15

Sezione 4.09.

Assenza di contenzioso

16

Sezione 4.10

Conforme alle leggi; permessi

16

Sezione 4.11

Proprietà intellettuale

16

Sezione 4.12

Questioni ambientali

18

Sezione 4.13

Contratti materiali

18

Sezione 4.14

Questioni relative all'occupazione e ai benefici per i dipendenti

19

Sezione 4.15

Le tasse

22

Sezione 4.16

Proprietà reale

23

Sezione 4.17

Brokers

23

Sezione 4.18

Sufficienza di attività e attività trasferite; Liens

24

Sezione 4.19

Assicurazione

24

Sezione 4.20

Accordi interaziendali

24

Sezione 4.21.

Clienti e fornitori

24

Sezione 4.22.

Nessuna altra dichiarazione o garanzia

24


Articolo V DICHIARAZIONI E GARANZIE DELL'ACQUIRENTE

25

Sezione 5.01.

Formazione e autorità dell'acquirente

25

Sezione 5.02.

Nessun conflitto

25

Sezione 5.03.

Consensi e approvazioni

25

Sezione 5.04

Assenza di restrizioni; Conforme alle leggi

26

Sezione 5.05

Questioni relative ai titoli

26

Sezione 5.06.

Capacità finanziaria

26

Sezione 5.07.

Brokers

26

Sezione 5.08.

Indagine

26

Articolo VI ACCORDI AGGIUNTIVI

27

Sezione 6.01.

Conduzione degli affari prima della chiusura

27

Sezione 6.02

Accesso alle informazioni

29

Sezione 6.03

riservatezza

30

Sezione 6.04.

Autorizzazioni normative e altre; consensi

30

Sezione 6.05.

permessi

32

Sezione 6.06.

garanzie; Altri obblighi

32

Sezione 6.07

Cooperazione

33

Sezione 6.08

Accordi sullo spazio condiviso

33

Sezione 6.09.

Opzioni put giurisdizione soggetto

33

Sezione 6.10.

Termini dell'opzione put della giurisdizione del soggetto

34

Sezione 6.11.

Crediti fatturati; Programma dei debiti commerciali

35

Sezione 6.12.

Cooperazione finanziaria

35

Sezione 6.13

Consegna del bilancio

37

Sezione 6.14

Alcuni accordi

37

Sezione 6.15

Proprietà delle filiali commerciali.

38

Sezione 6.16

Entità commistolate.

38

Sezione 6.17.

Budget Capex.

38

Sezione 6.18

Digital Twin Framework

39

Articolo VII COVENANTI POST-CHIUSURA

39

Sezione 7.01.

Accesso

39

Sezione 7.02.

Diritti sui nomi dei venditori e sui marchi dei venditori

40

Sezione 7.03.

Indennità degli amministratori e dei dirigenti

40

Sezione 7.04.

Assicurazione

41

Sezione 7.05.

Questioni di proprietà intellettuale

42

Sezione 7.06.

Ulteriori garanzie

42

Sezione 7.07.

Ulteriori azioni in materia di proprietà intellettuale e tecnologia

43

Sezione 7.08.

Accordi di trasferimento locali

43

Sezione 7.09.

Non concorrenza

44

Articolo VIII QUESTIONI DEI DIPENDENTI

44

Articolo IX QUESTIONI FISCALI

44

Sezione 9.01.

Deposito delle dichiarazioni dei redditi da parte del venditore

44

Sezione 9.02.

Presentazione delle dichiarazioni dei redditi da parte dell'acquirente

44

Sezione 9.03.

Periodi di straddle

45


Sezione 9.04.

Procedimento fiscale

45

Sezione 9.05.

rimborsi

45

Sezione 9.06.

Azioni post-chiusura

46

Sezione 9.07.

Tasse di trasferimento

46

Sezione 9.08.

Accordi di ripartizione fiscale

47

Sezione 9.09.

Cooperazione fiscale

47

Sezione 9.10.

Sezione 338 Elezioni

47

Sezione 9.11.

Sezione 754 Elezioni

47

Sezione 9.12.

Questioni fiscali svedesi

47

Sezione 9.13

Sopravvivenza

47

Articolo X CONDIZIONI DI CHIUSURA

47

Sezione 10.01.

Condizioni per gli obblighi del venditore

47

Sezione 10.02.

Condizioni per gli obblighi dell'acquirente

48

Articolo XI RISOLUZIONE

48

Sezione 11.01.

fine

48

Sezione 11.02.

Avviso di termine

49

Sezione 11.03.

Effetto della risoluzione

49

Articolo XII INDENNIZZO

49

Sezione 12.01.

Sopravvivenza

49

Sezione 12.02.

Indennizzo da parte del Venditore

49

Sezione 12.03.

Indennizzo da parte dell'acquirente

50

Sezione 12.04.

Notifica di reclami

50

Sezione 12.05.

Rimedi esclusivi

51

Sezione 12.06.

Ulteriori disposizioni di indennizzo

51

Sezione 12.07.

attenuazione

52

Sezione 12.08.

Rimedi di terzi

52

Sezione 12.09.

Limitazione di responsabilità

52

Sezione 12.10.

Trattamento fiscale dei pagamenti

52

Sezione 12.11.

Assicurazione di rappresentanza e garanzia

52

Articolo XIII VARIE

53

Sezione 13.01.

Regole di costruzione

53

Sezione 13.02.

Spese

54

Sezione 13.03.

Avvisi

54

Sezione 13.04.

Annunci pubblici

55

Sezione 13.05.

Invalidità

55

Sezione 13.06.

Incarico

55

Sezione 13.07.

Nessun beneficiario di terze parti

55

Sezione 13.08.

Intero accordo

56

Sezione 13.09.

Modifiche

56

Sezione 13.10.

Rinuncia

56

Sezione 13.11.

Legge governativa

56

Sezione 13.12.

Soluzione della disputa; Consenso alla giurisdizione

56

Sezione 13.13.

Rinuncia alla prova della giuria

57


Sezione 13.14.

Ammissibilità alle prove

57

Sezione 13.15.

Rimedi; Performance specifica

57

Sezione 13.16.

Pro-soluto

57

Sezione 13.17.

Interesse

58

Sezione 13.18.

Orari di divulgazione ed esposizioni

58

Sezione 13.19.

Provvedere al rispetto della rappresentanza legale

58

Sezione 13.20.

Privilegio

58

Sezione 13.21.

controparti

58

Sezione 13.22.

Fonti di finanziamento del debito

59

Sezione 13.23.

pubblicazione

59

MOSTRE

Allegato A

definizioni

Allegato B

Accordo di licenza incrociata per la proprietà intellettuale

Allegato C

Accordo sui servizi di transizione

Allegato D

Non concorrenza

Esibire

Questioni dei dipendenti

Allegato F

Principi contabili di transazione

Mostra G

Contratto di licenza di marchio transitorio


Questo PRIMO CONTRATTO DI ACQUISTO DI PATRIMONIO E ATTIVITÀ MODIFICATO E RESTAURATO, datato al 31 marzo 2020, è stipulato per modificare e riaffermare quel determinato Accordo di acquisto di titoli e attività, datato al 25 febbraio 2019 (il “Data dell'accordo“), Realizzato da e tra General Electric Company, una società di New York (“Venditore“E, insieme ai Designati del Venditore autorizzati ai sensi del presente Accordo, il”Parti del venditore“) E Danaher Corporation, una società del Delaware (“Acquirente e, insieme al Venditore, il “parti“).

DICHIARAZIONI PRELIMINARI

A. Il venditore possiede o controlla, direttamente o indirettamente, ciascuna delle altre parti del venditore.

B. Le Parti del venditore sono impegnate o detengono attività o passività relative all'Azienda.

C. Le Parti del Venditore desiderano vendere all'Acquirente, e l'Acquirente (stesso o tramite i suoi Affiliati designati) desidera acquistare dalle Parti del Venditore, tutte le Attività trasferite (come definito di seguito) e l'Acquirente (stesso o tramite i suoi Affiliati designati) desidera assumere tutte le passività assunte (come di seguito definite), direttamente o indirettamente tramite il trasferimento delle entità trasferite (come di seguito definite), in ogni caso alle condizioni e alle condizioni stabilite nel presente accordo.

ORA, PERTANTO, in considerazione di quanto precede e delle dichiarazioni, garanzie, alleanze e accordi stabiliti nel presente Accordo, e per altre considerazioni valide e valide, la ricevuta e la sufficienza sono riconosciute, le Parti, che intendono essere legalmente vincolate , concordare come segue:

Articolo I.

DEFINIZIONI

Sezione 1.01 Alcuni termini definiti. I termini in maiuscolo utilizzati nel presente Accordo hanno i significati indicati in Allegato A.

Articolo II

ACQUISTO E VENDITA; CHIUSURA

Sezione 2.01 Acquisto e vendita di beni trasferiti.

(un)Attività trasferite. In base ai termini e alle condizioni stabilite nel presente Accordo e negli Accordi di trasferimento locali e fatte salve le esclusioni stabilite in Sezione 2.01 (b) e a Sezione 2.02, alla Chiusura, il Venditore dovrà e farà in modo che ciascuna delle sue Controllate applicabili venda, venda, trasmetta, assegni, trasferisca e consegni all'Acquirente o uno o più degli Affiliati dell'Acquirente designati dall'Acquirente per iscritto e l'Acquirente, o causerà uno di tali Affiliate per acquistare, acquisire e accettare dal Venditore e da tali Controllate, tutti i diritti, titoli e interessi del Venditore e delle sue Controllate, su e sotto i seguenti beni, proprietà e diritti, poiché gli stessi devono esistere immediatamente prima della Tempo effettivo, gratuito e privo di privilegi (diversi dai privilegi consentiti) (collettivamente, il “Attività trasferite“), Direttamente o tramite il trasferimento di un'entità trasferita come previsto da Sezione 2.06:

(io)(A) la proprietà immobiliare di proprietà correlata all'attività (la “Proprietà immobiliari di proprietà trasferite“), Insieme a tutti i miglioramenti, infissi, servitù e altri diritti e interessi ad esso relativi, e (B) gli interessi su beni di terzi, sublocazioni o licenze del Venditore e delle sue Controllate ai sensi di contratti di locazione di proprietà immobiliari, sublocazioni o licenze che riguardano locali correlati al business (il “Proprietà immobiliari in leasing trasferite“);

(Ii)tutti i diritti derivanti da (A) contratti o accordi relativi all'attività di cui il Venditore o una delle sue Controllate è parte (soggetto a Sezione 2.02, esclusi eventuali Contratti condivisi), (B) le locazioni, sublocazioni e licenze di proprietà immobiliari di cui al Sezione 2.01 (a) (i) sopra il “Leasing di proprietà immobiliari trasferiti“) E (C) quei contratti o accordi, il cui scopo principale è ricevere licenze da terzi di proprietà intellettuale correlate all'attività commerciale e tali altri contratti o accordi in relazione alla proprietà intellettuale della società (clausole (A) attraverso (C) collettivamente, il “Contratti Assunti“);

(Iii)tutti i conti e gli altri crediti relativi all'azienda, inclusi i crediti fatturati;

(Iv)tutte le spese o i depositi relativi all'attività che sono stati pagati in anticipo o effettuati dal venditore o dalle sue consociate, compresi i pagamenti o i depositi relativi all'attività di leasing e affitto;


(V)tutti i reclami e le azioni nei confronti di terzi relativi all'attività, compresi eventuali proventi assicurativi o altri recuperi ricevuti in base a qualsiasi polizza assicurativa dal 1 ° gennaio 2019 in relazione a danni o perdite a un bene trasferito (nella misura in cui non siano applicati a tali danni o perdite) ) e, fatto salvo Sezione 7.04, eventuali Reclami relativi alle Attività trasferite nell'ambito di qualsiasi polizza assicurativa;

(Vi)tutta la compagnia Proprietà intellettuale e tecnologia aziendale, insieme a tutti i diritti di (A) riscuotere royalties, entrate e proventi in relazione a ciò, (B) citare in giudizio per violazione passata, presente e futura, appropriazione indebita, diluizione o violazione delle stesse o altri conflitti con esse, e (C) per recuperare danni o perdita di profitti in relazione a ciò;

(Vii)tutti i permessi trasferibili o assegnabili, compresi i permessi ambientali, che sono correlati all'azienda;

(Viii)i libri e i registri trasferiti e i registri dei dipendenti delle imprese;

(Ix)tutti i beni, i diritti e le proprietà espressamente da trasferire ai sensi di Esibire del presente documento (comprese le attività di eventuali piani pensionistici dedicati);

(X)tutti i beni personali e gli interessi materiali ivi inclusi, inclusi macchinari, attrezzature, mobili, arredi, inventario, attrezzature per ufficio, apparecchiature di comunicazione e veicoli, relativi all'attività (compresi i diritti, se presenti, su uno dei precedenti acquisti soggetti a vendite condizionali o contratto di conservazione del titolo a favore di qualsiasi altra persona) e forme tangibili di proprietà intellettuale della società e tecnologia della società (senza limitare i diritti del venditore di conservare copie degli stessi in relazione all'esercizio dei diritti ai sensi dell'accordo di licenza incrociata della proprietà intellettuale e del presente accordo);

(Xi)gli interessi azionari trasferiti;

(Xii)tutte le attività riflesse nella Dichiarazione di chiusura finale (senza duplicazione delle altre voci esposte in questo Sezione 2.01 (a));

(Xiii)gli interessi di JV; e

(Xiv)diverso da qualsiasi Attività esclusa, tutti gli altri beni, proprietà, diritti, avviamento, contratti o accordi o Reclami di ogni tipo e descrizione, ovunque localizzati e in possesso del Venditore o di una delle sue Controllate, siano essi reali, personali o misti, tangibile o intangibile, del Venditore o di una qualsiasi delle sue Controllate collegate all'attività.

(B)Attività escluse. Fermo restando il contrario, i seguenti beni e proprietà di o in possesso del Venditore o di una delle sue Controllate (il “Attività escluse“) Saranno trattenuti dal Venditore o da tali Controllate e saranno esclusi dalle Attività trasferite e, se applicabile, saranno trasferiti dalle Entità trasferite (se detenute da un'entità trasferita) prima della Chiusura, nonostante qualsiasi altra disposizione del presente Accordo :

(io)tutte le disponibilità liquide e mezzi equivalenti (tranne nella misura indicata nel Rendiconto di chiusura finale o secondo quanto stabilito in Sezione 2.01 (a) (iv) (rispetto ai depositi) o Sezione 2.01 (a) (v) (rispetto ai proventi assicurativi)); fornito che il Venditore dovrà compiere i suoi ragionevoli sforzi per rimuovere tutte le disponibilità liquide superiori a $ 110 milioni dall'entità trasferita prima della Chiusura;

(Ii)tutti i diritti sui nomi e sui marchi del venditore, insieme a qualsiasi contratto, accordo o intesa che garantisca i diritti di utilizzo degli stessi (senza limitare i diritti concessi all'Acquirente ai sensi del Contratto di licenza di marchio transitorio);

(Iii)tutti i diritti, titoli e interessi del Venditore e delle sue Controllate nella Proprietà reale trattenuta;

(Iv)diversi da eventuali prestiti o anticipazioni da un'entità trasferita a un'altra entità trasferita, tutti i prestiti o anticipazioni tra il venditore e le sue filiali (compresi gli anticipi effettuati in relazione al programma dei debiti commerciali);

(V)tutte le dichiarazioni dei redditi (diverse dalle dichiarazioni dei redditi esclusivamente di un'entità trasferita) e tutti i rimborsi o i crediti relativi a qualsiasi imposta del venditore o di una sua controllata per periodi imponibili (o parti di essa) che terminano alla o prima della data di chiusura (che rimborsi o crediti, a scanso di equivoci, sono soggetti a Sezione 9.05);

(Vi)i Piani per i dipendenti come espressamente previsto Esibire;


(Vii)senza alcuna limitazione e fatti salvi i diritti dell'acquirente espressamente previsti ai sensi Sezione 7.04 e salvo quanto stabilito in Sezione 2.01 (a) (v), tutte le polizze e i programmi o gli accordi per le assicurazioni e gli interessi in pool e programmi assicurativi (in ogni caso, compresi l'autoassicurazione e le assicurazioni da parte degli affiliati) (collettivamente, “Polizze assicurative“) E tutti i diritti di qualsiasi natura in relazione a qualsiasi polizza assicurativa, inclusi i relativi recuperi e qualsiasi diritto di far valere reclami che richiedono tali recuperi;

(Viii)qualsiasi attività, diritti o proprietà detenuti alla Data del Contratto o acquisiti dopo la Data del Contratto e venduti o altrimenti ceduti prima della Chiusura in conformità al presente Accordo;

(Ix)tutte le cause di azione (comprese le domande riconvenzionali) e le difese (A) contro terzi nella misura relativa a una qualsiasi delle Attività escluse o delle Passività escluse, nonché di eventuali libri, registrazioni e informazioni privilegiate ad esse relative o (B) relative a qualsiasi periodo prima o tramite la Chiusura nella misura in cui l'affermazione di tale causa di azione o di difesa è necessaria o utile nel difendere qualsiasi rivendicazione che sia una responsabilità esclusa e possa essere fatta valere nei confronti del Venditore o di una delle sue Controllate o per la quale può essere richiesto un risarcimento da una delle Parti indennizzate dall'acquirente ai sensi di Articolo XII;

(X)tutta la proprietà intellettuale del venditore e la tecnologia del venditore (senza limitare i diritti concessi all'acquirente ai sensi dell'accordo sulla licenza incrociata della proprietà intellettuale e sull'accordo sui servizi di transizione);

(Xi)attività di qualsiasi piano pensionistico del Venditore o delle sue Controllate diverso dai Piani pensionistici dedicati;

(Xii)tutti i beni, i diritti e le proprietà espressamente esclusi ai sensi di Esibire al presente Accordo;

(Xiii)tutti i permessi non trasferibili o non cedibili, compresi i permessi ambientali non trasferibili e tutti i permessi detenuti dal Venditore o da una delle sue Controllate che non sono correlati al Business;

(Xiv)tutti i diritti del Venditore o di una delle sue Controllate (diverse dalle Entità trasferite) ai sensi degli Accordi di transazione;

(Xv)tutto il personale e i registri delle assunzioni per dipendenti ed ex dipendenti del Venditore o di una delle sue Controllate (diversi dai Libri e registri trasferiti e dai registri dei dipendenti delle imprese);

(Xvi)qualsiasi altra attività, proprietà, diritti, accordi, contratti, strumenti e reclami del Venditore o di una delle sue Controllate non Correlati all'Azienda, ovunque localizzati, materiali o immateriali, reali, personali o misti, tranne nella misura stabilita in Sezione 2.01 (a);

(Xvii)diverso da (A) eventuali crediti esclusivamente tra o tra le entità trasferite e (B) eventuali crediti fatturati, altri crediti (inclusi i crediti commerciali) nei confronti del Venditore o di una delle sue Controllate, i cui crediti devono essere chiusi senza ulteriori pagamento o esecuzione e cesserà di avere ulteriore forza o effetto alla Chiusura;

(Xviii)(A) tutti i libri verbali aziendali (e altri registri societari simili) e i registri azionari del Venditore o di una delle sue Controllate (diversi dai Libri e registri trasferiti), (B) qualsiasi libro e registro nella misura relativa alle Attività Escluse, (C) copie di libri e registri o altri materiali (o parti di essi, se applicabile) esclusivamente nella misura in cui (x) il Venditore o una delle sue Controllate sono tenuti per legge a conservare (copie dei quali, nella misura in cui correlate a l'Azienda e come consentito dalla Legge, sarà messa a disposizione dell'Acquirente), (y) il Venditore o una delle sue Controllate (diverse dalle Entità trasferite) ritiene ragionevolmente necessario per consentire al Venditore o tali Controllate (diverse dalle Entità trasferite) di preparare e / o presentare dichiarazioni dei redditi (copie delle quali, nella misura relativa all'attività commerciale e come consentito dalla legge, saranno rese disponibili all'acquirente) o (z) il venditore o una delle sue filiali sono vietate dalla legge dalla consegna all'acquirente (compreso il trasferimento di equi ty delle entità trasferite), inclusi libri e registri, rapporti, informazioni o altri materiali (o parti di essi, se applicabile) esclusivamente nella misura in cui divulgare in alcun modo il contenuto di altri libri e registri, rapporti, informazioni o altro materiali che il Venditore o una delle sue Controllate (incluse le Entità trasferite) sono proibiti dalla Legge dalla consegna all'Acquirente (incluso mediante trasferimento di capitale delle Entità trasferite) o (D) qualsiasi copia di qualsiasi libro e record che il Venditore e le sue Controllate conservano ai sensi di Sezione 7.01 (b);

(Xix)(A) tutte le registrazioni e le relazioni preparate o ricevute dal Venditore o da una delle sue Controllate in relazione alla vendita dell'Attività o alle transazioni qui contemplate, incluse tutte le analisi relative all'Attività o all'Acquirente così preparate o ricevute, (B) tutte le offerte e manifestazioni di interesse ricevute da terzi nei confronti di potenziali acquirenti dell'azienda o di qualsiasi sua parte e (C) tutte le comunicazioni privilegiate descritte in Sezione 13.20 e tutti i materiali, documenti e record privilegiati che non sono correlati all'azienda;


(Xx)soggetto a Sezione 2.02, tutti i contratti condivisi diversi da quelli indicati Allegato 2.01 (a) (ii);

(Xxi)tutti i contratti di copertura; e

(Xxii)tutte le attività indicate Allegato 2.01 (b) (xxii).

(C)Responsabilità assunte. In base ai termini e alle condizioni stabilite nel presente Accordo e negli Accordi di trasferimento locali e fatte salve le esclusioni stabilite in Sezione 2.01 (d), L'Acquirente dovrà assumere o far sì che sia assunto, efficace nel Tempo effettivo (direttamente o tramite il trasferimento di un'entità trasferita come previsto da Sezione 2.06) e successivamente pagare, scaricare ed eseguire tempestivamente in conformità con i loro termini (o, nel caso di un'entità trasferita, far sì che siano pagati, scaricati ed eseguiti), tutte le responsabilità del venditore e delle sue controllate nella misura derivante o correlata alle Attività trasferite o all'attività commerciale, poiché le stesse devono esistere alla Data di chiusura o successivamente e, salvo quanto stabilito nella Sezione 2.01 (c) (iii), indipendentemente dal fatto che lo stesso debba sorgere prima, alla o dopo la Data di chiusura (il “Responsabilità assunte“). Senza limitare la generalità di quanto sopra, fatto salvo Sezione 2.01 (d), le passività assunte comprendono le seguenti passività di uno qualsiasi dei venditori e delle sue consociate, note o sconosciute, fisse o contingenti, affermate o non verificate e non soddisfatte o estinte:

(io)tutte le passività riflesse nel Rendiconto finale di chiusura (incluse eventuali passività del venditore e delle sue controllate per gli anticipi effettuati nell'ambito del programma dei debiti commerciali);

(Ii)tutte le responsabilità derivanti da uno qualsiasi dei contratti assunti;

(Iii)tutte le passività per imposte imposte in relazione alle Attività trasferite per qualsiasi periodo imponibile (o parte di esse) a partire dalla Data di chiusura;

(Iv)tutte le passività come e nella misura in cui derivano dall'attività (comprese tutte le passività rispetto alle attività trasferite), maturate prima, alla o dopo la data di chiusura, note o sconosciute, fisse o contingenti, affermate o non dichiarate e non soddisfatte o estinto alla Data di chiusura, salvo, in ogni caso, come indicato in Sezione 2.01 (c) (iii);

(V)tutte le responsabilità, sia maturate prima, alla o dopo la Data di chiusura, (A) ai sensi delle Leggi ambientali nella misura relativa a un'attività trasferita o all'attività commerciale (esclusa qualsiasi responsabilità legacy), comprese quelle relative in qualsiasi modo all'ambiente o ai materiali pericolosi o (B) relativi all'uso, all'applicazione, al malfunzionamento, al difetto, alla progettazione, al funzionamento, alle prestazioni o all'idoneità di qualsiasi prodotto venduto o distribuito prima della Chiusura da o per il servizio reso prima della Chiusura da o per conto di, Venditore o una delle sue consociate a qualsiasi Persona (compresi i prodotti per i quali un proprietario o un operatore attuale o futuro delle Attività trasferite o dell'Azienda può essere ritenuto responsabile in materia di legge, contratto o altro), in ogni caso in questa clausola (B), nella conduzione dell'Attività;

(Vi)tutte le responsabilità ai sensi dei piani pensionistici dedicati; e

(Vii)tutte le passività espressamente trasferite ai sensi di Esibire del presente documento.

(D)Responsabilità escluse. L'acquirente non si assume né accetta di pagare o scaricare alcuna delle seguenti responsabilità del venditore o di una delle sue consociate, note o sconosciute, fisse o contingenti, affermate o non dichiarate, e non soddisfatte o estinte (il “Responsabilità escluse“), Nonostante qualsiasi altra disposizione del presente Accordo:

(io)tutti i debiti (tranne nella misura indicata nella dichiarazione finale di chiusura; fornito che il Venditore dovrà fare tutto il possibile per rimuovere tutti i Debiti di un tipo descritto nella clausola (a) della sua definizione dalle Entità trasferite prima della Chiusura);

(Ii)qualsiasi responsabilità nella misura derivante da o relativa a qualsiasi attività esclusa o all'attività condotta dal venditore o da una delle sue consociate (diversa dall'attività), in ciascun caso di questo Sezione 2.01 (d) (ii) se lo stesso si presenterà prima, alla o dopo la Data di chiusura e salvo, in ogni caso, come diversamente stabilito in Sezione 2.01 (d) (iii);

(Iii)qualsiasi responsabilità per le imposte per qualsiasi periodo imponibile (o parte di esso) che termina alla o prima della Data di chiusura; fornito quello ai fini di questo Sezione 2.01 (d) (iii), La responsabilità per le imposte deve essere calcolata senza tener conto di perdite operative nette, crediti d'imposta o altri attributi fiscali delle entità trasferite svedesi altrimenti disponibili per ridurre, compensare o eliminare tali imposte;


(Iv)qualsiasi responsabilità espressamente trattenuta dal Venditore o da una delle sue Controllate ai sensi di Esibire del presente documento (anche con riferimento a qualsiasi Piano padre e piano pensionistico del Venditore o di una delle sue Controllate diverse dai Piani pensionistici dedicati);

(V)diversi dai (A) conti pagabili esclusivamente tra o tra le Entità trasferite e (B) le responsabilità del Venditore o di una delle sue Controllate per gli anticipi effettuati nell'ambito del Programma dei debiti commerciali, qualsiasi Responsabilità per eventuali debiti (inclusi i conti commerciali pagabili) a, o qualsiasi altra responsabilità nei confronti del Venditore o di una delle sue Controllate, i cui debiti o responsabilità siano estinti senza ulteriori pagamenti o prestazioni e cesseranno di avere ulteriore forza o effetto alla Chiusura;

(Vi)qualsiasi responsabilità legacy; e

(Vii)qualsiasi responsabilità di Cardiff.

Inoltre, l'Acquirente non si assume o accetta di pagare o estinguere alcuna Responsabilità della Sezione 75 derivante dalla Transazione, indipendentemente dal fatto che la stessa si presenti prima o alla Data di chiusura, che la Responsabilità della Sezione 75 costituisce responsabilità esclusa a tutti gli effetti di questo accordo. Nonostante quanto diversamente stabilito nel presente Accordo, l'Acquirente dovrà assumersi le Responsabilità derivanti dai Piani pensionistici specificati nella misura in cui tali Responsabilità sorgano nei confronti dei Partecipanti Attivi a partire dal Periodo di validità (che le Passività costituiranno Passività Assunte) e il Venditore dovrà conservare le passività derivanti dai Piani pensionistici specificati nella misura in cui tali passività sorgono nei confronti di tutti gli altri dipendenti o ex dipendenti a partire dal Periodo di validità (che le passività costituiranno passività escluse).

Sezione 2.02 Cessione di alcuni beni trasferiti.

(un)In deroga a qualsiasi altra disposizione contraria del presente Accordo, il presente Accordo non costituisce un accordo per cedere o trasferire qualsiasi Attività trasferita o qualsiasi pretesa o diritto o beneficio derivante dallo stesso o risultante da esso se un tentativo di cessione o trasferimento degli stessi, senza il consenso di una terza parte (inclusa qualsiasi autorità governativa) costituirebbe una violazione o altra violazione della stessa o una violazione della legge. Soggetto a Sezione 6.04 e Sezione 6.05, Il Venditore dovrà, e farà in modo che ciascuna delle altre Parti del Venditore utilizzi, i suoi migliori sforzi ragionevoli per ottenere il consenso necessario per il trasferimento o l'assegnazione di tali Attività trasferite, reclami, diritti o benefici all'Acquirente. Nonostante quanto diversamente stabilito nel presente documento, nessuna Parte del Venditore, né alcuna delle loro Controllate, sarà tenuta a compensare terze parti, iniziare o partecipare a qualsiasi Azione o offrire o concedere un alloggio (finanziario o di altro tipo, incluso qualsiasi alloggio o accordo per risarcire , rimanere secondariamente responsabile o contingentemente responsabile per qualsiasi responsabilità assunta) verso terzi in relazione agli obblighi delle Parti del venditore ai sensi del presente Sezione 2.02 (a), in ogni caso diverso dagli obblighi di pagamento a carico dell'acquirente. Se, alla Data di chiusura, tale consenso non è stato ottenuto, o se un tentativo di trasferimento o cessione di esso fosse inefficace o una violazione della Legge, le Parti del Venditore e l'Acquirente dovranno, fatte salve Sezione 6.04 e Sezione 6.05, stipulare un accordo reciprocamente accettabile (i) in base al quale l'Acquirente, in conformità con la Legge, otterrà i benefici e assumerà gli obblighi e sosterrà gli oneri economici associati a tale Attività trasferita, reclamo, diritto o beneficio in conformità con il presente Accordo, tra cui subappalto, sub-licenza o sub-locazione all'Acquirente o (ii) in base al quale le Parti del Venditore faranno valere a beneficio (ea spese) dell'Acquirente tutti i diritti del Venditore e delle sue Controllate contro una terza parte associata a tale Attività trasferita, reclamo, diritto o beneficio, e le Parti del Venditore pagheranno prontamente all'Acquirente quando ricevessero tutti i fondi o altri benefici ricevuti da loro in virtù di tali Attività, reclami, diritti o benefici trasferiti (al netto delle spese delle Parti del Venditore sostenute in relazione a qualsiasi cessione contemplato da questo Sezione 2.02).

(B)Il Venditore dovrà fare ogni ragionevole sforzo prima della Chiusura per far sì che la controparte di ciascun Contratto Condiviso specificato acconsenta all'assegnazione parziale di tali diritti della Parte Venditore applicabile ai sensi di tale Contratto Condiviso specificato relativo all'Attività, e altrimenti ragionevolmente collaborare con l'Acquirente in buona fede in relazione agli sforzi dell'Acquirente di stipulare un nuovo contratto o accordo con la controparte di qualsiasi Contratto condiviso specificato che fornisce beni o servizi da o verso l'Azienda sostanzialmente alle stesse condizioni esistenti ai sensi di tale Contratto condiviso specificato dal Closing (e in such case, such new contract or agreement shall constitute a Transferred Asset hereunder); provided, however, that nothing in this Section 2.02(b) shall require any of the Seller Parties or any of their Affiliates to make any payment or other concession to such counterparty, or commence or participate in any Action, in each case, in connection with this Section 2.02(b), in each case, other than payment obligations that are borne by Buyer. Any Specified Shared Contract for which the arrangements described in this Section 2.02(b) could not be entered into prior to the Closing shall be subject to Section 2.02(a) and, with respect to any other Shared Contract, (i) Seller and Buyer shall work in good faith to determine the feasibility of separating such Shared Contract and (ii) if, notwithstanding such good-faith efforts, the parties are unable to agree on a mutually satisfactory plan for separating any such Shared Contract, Buyer and Seller will negotiate in good faith appropriate means for Buyer to obtain the benefits and assume the obligations associated with the portion of such Shared


Contract relating to the Business for a transitional period. As used herein, “Specified Shared Contract” shall mean any Shared Contract primarily relating to the Business.

Section 2.03. Closing. The closing of the sale and purchase of the Transferred Equity Interests and the Transferred Assets and the assumption of the Assumed Liabilities (the “Closing”) shall take place at the offices of Paul, Weiss, Rifkind, Wharton & Garrison LLP, 1285 Avenue of the Americas, New York, New York 10019, at 5:00 p.m. (New York City time) on March 31, 2020, subject to the satisfaction or waiver in writing (to the extent permitted by applicable Law) of all Closing Conditions in accordance with Article X. The date on which the Closing occurs is referred to in this Agreement as the “Closing Date.” For all purposes under this Agreement and each other Transaction Agreement, if the Closing has taken place, the sale, conveyance, assignment, transfer and delivery to Buyer of the Transferred Assets and the assumption by Buyer of the Assumed Liabilities (collectively, the “Ownership Transfer”), shall be deemed to occur as of 11:59 p.m. (local time) in each applicable jurisdiction on March 31, 2020 (the “Effective Time”). The payment of the Closing Payment on the Closing Date shall be effected in accordance with the wire and payment schedule set forth on Annex B to this Agreement.

Section 2.04. Withholding. In the event Buyer determines that any portion of the purchase price or any amount otherwise payable under this Agreement would be subject to withholding or deduction under applicable Law, Buyer and its Affiliates shall be entitled to deduct and withhold such amounts from such payments to the extent required under applicable Law; provided that Buyer shall (i) use commercially reasonable efforts to promptly notify Seller of such determination and (ii) shall cooperate with Seller Parties in good faith to reduce or mitigate any such withholding or deduction (including through the provision of forms or other relevant documentation by the Seller Parties). If Buyer withholds on any portion of the purchase price pursuant to the terms of this Section 2.04 and pays over such withheld amount to the appropriate Taxing Authority, such withheld amount shall be treated for all purposes of this Agreement as having been paid to the applicable recipient of such amount otherwise payable.

Section 2.05. Deferred Transfers; Specified Assets.

(a)If all of the conditions to Closing specified in Section 10.01 e Section 10.02 are satisfied or have been waived (other than those which, by their nature, are to be satisfied at the Closing, but subject to such satisfaction), the Parties shall not at the Closing effect the transfer of the Transferred Assets and Transferred Equity Interests and assumption of the Assumed Liabilities in any jurisdiction where such transfer or assumption would give rise to a material violation of any Legal Restraint (each such portion of the Business that is not transferred at Closing, a “Deferred Business”) but, the Closing shall nevertheless occur with respect to the Business (other than any Deferred Business) and, from and after the Closing, each of Buyer and Seller shall use reasonable best efforts to cause such material violation of such Legal Restraint in such jurisdiction to cease to exist with respect to such transfer and assumption as promptly as practicable after the Closing Date, and immediately following such time as the transfer of the applicable Deferred Business can be consummated without giving rise to a material violation of such Legal Restraint, such transfer of the applicable Deferred Business shall be consummated. The Parties will act in good faith to minimize the costs of the transfer of the Deferred Business. The Parties also agree that until the consummation of the transfer of the applicable Deferred Business, the Deferred Business shall be held, managed and operated by Seller (or its Subsidiaries) in the manner provided in Schedule 2.05. For the avoidance of doubt, the Purchase Price paid by Buyer at the Closing shall not be reduced or otherwise adjusted in connection with the delayed transfer of a Deferred Business.

(b)In connection with the matters contemplated by Section 2.05(a) e Schedule 2.05, Seller (or its Subsidiaries) and Buyer shall prepare and negotiate in good faith to enter into on or prior to the Closing (or, if not feasible, as promptly as practicable after the Closing) such supplemental agreements as are reasonably necessary to place the Parties and their Affiliates in the same financial position with respect to the Deferred Business as would have obtained if the Deferred Business were transferred at the Closing; provided, that the execution and delivery of such agreements shall not be a condition to the Closing.

(c)In the event that the failure of the Transferred Assets to include a Specified Asset (as a result of the inclusion of the word “primarily” in clause (c) of the definition of “Related to the Business”) would cause a breach of the representation and warranty set forth in Section 4.18(a), following the request of Buyer delivered within one year following the Closing Date, Seller shall cooperate in good faith with Buyer to remedy such breach, either through the transfer of the applicable Specified Asset or through the provision of appropriate contractual arrangements to provide the benefits and burdens of ownership thereof. “Specified Asset”” means an asset that does not constitute a Transferred Asset, but would constitute a Transferred Asset in accordance with the terms hereof if clause (c) of the definition of “Related to the Business” were revised by removing each instance of the word “primarily.”

(d)Exclusion of Certain Transferred Assets and Assumed Liabilities. Notwithstanding anything to the contrary in this Agreement (including, for the avoidance of doubt, the provisions of Section 2.01 e Section 2.02 hereof), on the Closing Date, that portion of the Business (including the Transferred Assets and Assumed Liabilities) held


in GE India Industrial Pvt Ltd (the “Shared Entity” and such portion of the Business, the “Deferred India Business”) shall not be sold, transferred or assumed (as applicable) by the Buyer, and instead shall be retained by Seller, subject to the terms set forth in this Section 2.05(e)-(i).

(e)Deferred Consideration. On the Deferred Transfer Date, Buyer shall cause to be paid INR₹ 81,278,408.83 (the “Deferred Consideration” ) in immediately available funds to Seller.

(f)Adjustments to Purchase Price. For the purpose of determining the Purchase Price and the adjustments to Purchase Price set forth in Sections 3.03, 3.04, 3.05 e 3.06 of this Agreement, the assets and Liabilities of the Deferred India Business shall (i) for the purposes of the Estimated Closing Statement and calculating the Closing Payment to be paid at Closing, be included in Estimated Net Working Capital, Estimated Closing Cash and Estimated Closing Debt as if it was sold to the Buyer on the Closing Date, and (ii) for the purposes of the Final Closing Statement and calculating the Purchase Price, be included within the Final Net Working Capital, Final Closing Cash and Final Closing Debt as if it was sold to Buyer on the Deferred Effective Date.

(g)Management of Deferred India Business.

i.From and after the Closing and until the Deferred Transfer Date, Seller shall be responsible for the management and operation of the Deferred India Business, which shall provide services to the Buyer at Buyer’s direction to the extent contemplated by and in accordance with the Global Employee Services Agreement, dated as of March 31, 2020, between Seller and Buyer.

ii.Without limiting the foregoing, from and after the Closing and until the Deferred Transfer Date, (A) Seller shall operate the Deferred India Business in the ordinary course consistent with past practice, and (B) Seller shall not cause or permit the transfer of any assets or Liabilities of the Deferred India Business that are subject to transfer pursuant to that certain Business Transfer Agreement between GE India Industrial Private Limited and Hyclone Life Sciences Solutions India Private Limited, in the form agreed upon between the parties.

(h)Transferred Assets; Assumed Liabilities. Buyer and Seller agree that all assets of the Deferred India Business as of the Deferred Transfer Date shall constitute “Transferred Assets” and all Liabilities of the Deferred India Business as of the Deferred Transfer Date shall constitute “Assumed Liabilities.”.

(i)Factored Receivables and Trade Payable Programs. Seller shall ensure that, from and after the Closing Date, the Deferred India Business shall not be included in its and its Affiliates’ factored receivables or Trade Payables Programs.

(j)Deferred Transfers and Deferred Transfer Date.

i.On May 4, 2020 (such date, the “Deferred Transfer Date” ), Seller shall transfer to Buyer, and Buyer shall accept and assume from Seller, the Deferred India Business (the “Deferred Transfer” ), which such Deferred Transfer shall be deemed effective as of May 1, 2020 (the “Deferred Effective Date” ).

ii.Except as otherwise provided in Section 2.05(f) through Section 2.05(i) of this Agreement, references to the “Closing”, the “Closing Date” or the “Effective Time” in this Agreement and all other Transaction Agreements (including, for the avoidance of doubt, the Transition Services Agreement) shall be deemed to be references to the “Deferred Transfer”, “Deferred Transfer Date” or “Deferred Effective Date” (as applicable) as such terms apply to the Deferred India Business. Notwithstanding anything to the contrary in this Agreement, for the purposes of calculating the Final Working Capital, the amount of assets and Liabilities of the Deferred India Business that constitute Net Working Capital shall be measured as of 11:59pm on the Business Day immediately preceding the Deferred Effective Date instead of as of the Effective Time.

(k)New Zealand Property. Notwithstanding anything to this Agreement to the contrary but subject to the last sentence of this Section 2.05(k), the Parties agree that the Purchase Price shall not be adjusted under this Agreement by virtue of whether or not the OIA Consent (as defined in that certain Business Transfer Agreement, dated as of November 1, 2019, between GE Healthcare Limited and Global Life Sciences Solutions New Zealand (the “New Zealand Local Agreement” )) is obtained or whether or not the Subleased Tauranga Lots (as defined in the New Zealand Local Agreement) are retained by GE Healthcare Limited. Further, the Parties agree that, notwithstanding Sections 19.1, 19.2 and 19.3 of the New Zealand Local Agreement, the terms of Section 9 of the New Zealand Local Agreement, as varied by the Letter of Variation entered into between the parties to the New Zealand Local Agreement dated March 31, 2020, shall be treated as the definitive agreement of the Parties with respect to the subject matter of such section, shall be deemed to modify this Agreement


to such extent and shall survive the Closing until the earlier of when the OIA Consent is obtained and when such Section 9 of the New Zealand Local Agreement is fully performed.

Section 2.06. Structure of Transfers.

(a)Notwithstanding anything to the contrary contained in Section 2.01 (and subject to the terms and conditions set forth in this Agreement), each Transferred Asset and Assumed Liability shall at the Closing be sold, transferred, assumed or assigned (a “Transfer”) to Buyer by way of either (i) a Transfer by Seller or its Subsidiaries of equity interests (each such transfer, an “Equity Transfer”) in a Subsidiary (which may be a newly formed Subsidiary) that is either (A) directly owned by one or more of the Seller Parties (each such Subsidiary (excluding, for the avoidance of doubt, the Minority-Owned JVs), a “Company,” and together, the “Aziende,” and the issued and outstanding equity interests in the Companies, the “Transferred Equity Interests”), or (B) directly or indirectly owned by one or more of the Companies (excluding, for the avoidance of doubt, the Minority-Owned JVs, the “Business Subsidiaries,” and together with the Companies, the “Transferred Entities”), or (ii) a direct Transfer of such Transferred Asset or Assumed Liability (each such transfer, an “Asset/Liability Transfer”), as determined in accordance with Schedule 2.06 and this Section 2.06.

(b)Promptly following the Agreement Date, but in no event later than forty-five (45) days following the Agreement Date, Seller shall, following consultation with Buyer (which consultation shall include exchanging such information and providing such assistance as the other Party may reasonably request), deliver to Buyer a notice (the “Seller Transfer Proposal”) setting forth, in reasonable detail, for each Transferred Asset and Assumed Liability (which for purposes of this Section 2.06 may include a designated group of Transferred Assets or Assumed Liabilities) the Transfer of which is not addressed on Schedule 2.06, Seller’s proposal with respect to whether such Transferred Asset or Assumed Liability (or group of Transferred Assets or Assumed Liabilities) shall be Transferred to Buyer by way of either (x) an Equity Transfer or (y) an Asset/Liability Transfer for Buyer’s review and comment. Seller shall consider in good faith any comments provided by Buyer with respect to the Seller Transfer Proposal and Seller shall incorporate into the Seller Transfer Proposal any of Buyer’s comments that do not subject Seller or any Seller Affiliate to any material unreimbursed cost. If, with respect to any Equity Transfer of any individual Transferred Entity, Buyer does not desire for such Equity Transfer to be treated as an asset sale for U.S. income Tax purposes, then Buyer may, at its option, deliver to Seller a notice within thirty (30) days of delivering the Seller Transfer Proposal, electing such treatment (the “U.S. Stock Treatment Election”) but only so long as such election does not subject Seller or any Seller Affiliate to any material unreimbursed cost.

(c)Notwithstanding the foregoing, if it is reasonably anticipated that any Asset/Liability Transfer otherwise required hereunder cannot be completed by the time of the Closing despite Seller’s reasonable best efforts to complete such Asset/Liability Transfer by the time of the Closing, Seller may propose a set of modifications to the Seller Transfer Proposal, Schedule 2.06 e Schedule 3.07, that would provide equivalent aggregate value to Buyer as the Seller Transfer Proposal, Schedule 2.06 e Schedule 3.07 prior to any such modifications, acceptance of such proposal being subject to Buyer’s consent, not to be unreasonably withheld, conditioned or delayed. Buyer and Seller agree that attached hereto as Schedule 2.06(c) is the final version of the Seller Transfer Proposal that has been agreed to by Buyer and Seller prior to the Closing.

(d)At the Closing, Seller shall Transfer or cause to be Transferred all Transferred Assets and Assumed Liabilities addressed in the Seller Transfer Proposal or Schedule 2.06 in respect of which a U.S. Stock Treatment Election has been validly made. At the Closing for any Equity Transfer for which Buyer has not validly made a U.S. Stock Treatment Election, Seller shall be required to effect the Transfer of such Transferred Assets and Assumed Liabilities as an asset sale for U.S. income Tax purposes; provided that Seller may, with Buyer’s prior written approval (not to be unreasonably withheld, conditioned or delayed), determine the manner in which to effect such treatment, including by (1) filing an election pursuant to Treasury Regulation Section 301.7701-3, effective from a date prior to the Closing Date, to cause the applicable Transferred Entities to be treated as one or more disregarded entities, partnerships or other pass-through entities for U.S. federal income Tax purposes at the time of the Closing, (2) filing an election under Section 338(h)(10) of the Code with respect to one or more applicable Transferred Entities, (3) consenting to Buyer filing an election under Section 338(g) of the Code with respect to one or more applicable Transferred Entities, (4) filing an election under Section 754 of the Code with respect to one or more applicable Transferred Entities, (5) an Asset/Liability Transfer or (6) any other manner.

(e)Notwithstanding anything in this Agreement to the contrary, Seller, at its election may or at Buyer’s request shall prior to the Closing, undertake, or cause its applicable Subsidiaries to undertake, certain Transfers of Transferred Assets, Assumed Liabilities, Excluded Assets and Excluded Liabilities among Seller and any of its Subsidiaries as mutually agreed among Buyer and Seller so long as the Transferred Assets and the Assumed Liabilities are Transferred to Buyer in accordance with the Equity Transfers and Asset/Liability Transfers determined by the procedures set forth in clauses (a) through (d) of this Section 2.06 and provided that (i) such Transfers are not inconsistent with Schedule 2.06 or the Seller Transfer Proposal (as finalized pursuant to Section 2.06(b)), (ii) such Transfers would not materially adversely affect the Tax


liability of Buyer or any of its Affiliates (including, after the Closing, any Transferred Entity) with respect to a taxable period (or portion thereof) beginning after the Closing Date, and (iii) in the event that such Transfers would increase the aggregate Transfer Taxes payable by Buyer pursuant to Section 9.07, as compared to the Transfer Taxes payable by Buyer if the Transfers had been undertaken in the most tax-efficient and otherwise cost-effective manner legally available, Buyer provides its prior written consent to such Transfer (not to be unreasonably withheld, conditioned or delayed).

(f)For any Equity Transfer that is to be effected in accordance with this Section 2.06, at the Closing, in lieu of the purchase and sale of Transferred Assets as set forth in Section 2.01(a), each of the applicable Seller Parties shall Transfer to Buyer, and Buyer shall purchase, acquire and accept from each such Seller Party, all of such Seller Party’s right, title and interest in and to the Transferred Equity Interests.

(g)For all purposes of this Article II, any Transfer to Buyer may be made to either Buyer or a designated Affiliate thereof upon prior written notice to Seller to the extent in accordance with Section 13.06, and in such case, any representations and warranties made with respect to Buyer in Article V shall additionally be deemed to be given by such designated Affiliate; provided that in the case of any Transfer that is effected as an Asset/Liability Transfer, the Buyer or designated Affiliate must be organized in and be tax resident in the same jurisdiction as the applicable Seller Party or Subsidiary thereof unless designation of the Buyer or an Affiliate organized or tax resident in a different jurisdiction would not subject Seller or any Seller Affiliate to any material unreimbursed cost, except as set forth on Schedule 2.06.

(h)Prior to the Closing, either Buyer or Seller may propose amendments to the Seller Transfer Proposal, Schedule 2.06 e Schedule 3.07, and the Parties shall consider such proposed amendments in good faith; provided, that neither Buyer nor Seller shall be obligated to agree to any such amendment of the Seller Transfer Proposal, Schedule 2.06, o Schedule 3.07 to the extent such amendment would subject such Person (or their respective Affiliates) to any material unreimbursed cost.

ARTICLE III

PURCHASE PRICE

Section 3.01. Purchase Price.

(a)The aggregate consideration to be paid by Buyer to Seller (for the benefit of the Seller Parties) for the sale of all of the Transferred Equity Interests, the Transferred Assets and the assumption of Assumed Liabilities set forth in this Agreement (the “Purchase Price”) shall be an amount in cash equal to the sum of (a) $21,000,000,000 (the “Base Purchase Price”), più (b) the Final Purchase Price Adjustment (if the Final Purchase Price Adjustment is positive), meno (c) the absolute value of the Final Purchase Price Adjustment (if the Final Purchase Price Adjustment is negative), meno (d) the absolute value of the Specified Adjustment Amount.

(b)If the Final 2018 EBITDA is less than the Target 2018 EBITDA (such shortfall amount, the “EBITDA Shortfall”), the Base Purchase Price shall be reduced by an amount equal to the product of (i) the EBITDA Shortfall and (ii) the Multiplier (such product, the “EBITDA-Based Reduction”), which EBITDA-Based Reduction, if any, shall be reflected in the Final Purchase Price Adjustment.

(c)Buyer and Seller hereby agree and acknowledge that GE Healthcare AS avd Lindesnes (“GEHC”) and GE Healthcare Bio-Sciences AB will enter into the Manufacturing and Supply Agreement at Closing as contemplated by Section 6.14(d) of this Agreement pursuant to the Contract Manufacturing Strategic Supplier Agreement dated March 31, 2020. Buyer and Seller hereby further agree and acknowledge that should GEHC terminate such Agreement pursuant to Section 1(a) of Attachment F thereof, Buyer shall make payment of the Cellulose Termination Amount by wire transfer of immediately available funds to Seller to an account or accounts as directed by Seller within 10 Business Days of such termination.

(d)Buyer and Seller hereby agree and acknowledge that GE Healthcare UK Limited, an Affiliate of Seller, has made a deposit in the amount of EUR £14,670 to Golding Homes Limited on behalf of Buyer and its Affiliates (the “Rent Deposit”), in connection with the assignment of that certain lease between GE Healthcare UK Limited and Golding Homes Limited to Global Life Sciences Solutions Manufacturing UK Limited. Buyer and Seller hereby further agree and acknowledge Buyer shall reimburse Seller the Rent Deposit by wire transfer of immediately available funds to Seller to an account or accounts as directed at Closing.

(e)Notwithstanding anything herein to the contrary, solely for purposes of this Agreement (and without modifying the Swedish IP Transfer Deed or the effect thereof), the transfer of assets contemplated by that certain Deed of Assignment of Drop Device Trademarks between GE Healthcare Bioprocess R&D AB and Global Life Sciences IP HoldCo


LLC dated March 30, 2020 (the “Swedish IP Transfer Deed”, and such transfer, the “Swedish IP Transfer”), shall be treated as though the Swedish IP Transfer occurred on the calendar date after the Closing Date. For the avoidance of doubt, and without limiting the foregoing, the transfer of assets in accordance with the Swedish IP Transfer Deed shall not give rise to any indemnification obligation of Seller under Section 12.02 of this Agreement.

Section 3.02. Certain Closing Deliverables. At the Closing:

(a)Seller shall deliver or cause to be delivered to Buyer the following:

i.to the extent the Transferred Equity Interests are certificated, certificates evidencing the Transferred Equity Interests, duly endorsed in blank or accompanied by stock powers duly executed in blank or other duly executed instruments of transfer as required by applicable Laws or otherwise to validly transfer title in and to the Transferred Equity Interests;

ii.a receipt for the Closing Payment, duly executed by Seller;

iii.a counterpart of an Intellectual Property Cross License Agreement in the form attached hereto as Exhibit B (with such changes as mutually agreed, the “Intellectual Property Cross License Agreement”), duly executed by Seller;

iv.a counterpart of the Transition Services Agreement, in the form attached hereto as Exhibit C (with such changes as mutually agreed, the “Transition Services Agreement”), duly executed by Seller;

v.a counterpart of a transitional trademark license agreement in the form attached hereto as Exhibit G (with such changes as mutually agreed, the “Transitional Trademark License Agreement”), duly executed by Seller;

vi.a counterpart of a bill of sale, assignment and assumption agreement in a form reasonably acceptable to Buyer and Seller (the “Bill of Sale, Assignment and Assumption Agreement”), duly executed by the Seller Parties that are to transfer Transferred Assets to Buyer at the Effective Time;

vii.a counterpart of one or more intellectual property assignment agreements in a form reasonably acceptable to Buyer and Seller (each, an “IP Assignment Agreement”), duly executed by the applicable Seller Parties that is to evidence the transfer of the Registrable IP included in the Company Intellectual Property at the Effective Time;

viii.a certificate of non-foreign status that complies with Section 1445 of the Code and Treasury Regulations Section 1.1445-2(b)(2) duly executed by each Seller Party that is an entity formed or organized in the United States and that is to transfer Transferred Assets or Transferred Equity Interests to Buyer at the Effective Time;

ix.counterparts of the Local Transfer Agreements, if any, duly executed by the applicable Seller Parties;

x.counterparts of assignments and assumptions of the Transferred Real Property Leases in a form reasonably acceptable to Buyer and Seller (the “Lease Assignments”), duly executed by the applicable Seller Parties;

xi.if applicable, a counterpart of each of the Factored Receivables Bill of Sale, duly executed by the Factoring Entities; e

xii.a counterpart of the Manufacturing and Supply Agreement, duly executed by Seller.

(b)Buyer shall deliver or cause to be delivered to Seller the following:

i.the Closing Payment, as specified in the Closing Notice, by wire transfer of immediately available funds, to an account or accounts as directed by Seller in the Closing Notice; provided, however, that the estimate of the aggregate face amount of the Factored Receivables set forth in the Estimated Closing Statement shall be deducted from the amount to be paid to Seller in accordance with the first part of this Section 3.02(b)(i) and instead shall be paid by Buyer by separate wire transfer(s) (as directed by Seller) to the Factoring Entities at the time of Closing, in consideration of the purchase by Buyer of the Factored Receivables;

ii.all Transfer Tax stamps and transfer forms (if any) in Buyer’s possession in accordance with Section 9.07 and required to be delivered to a Seller Party and an amount in cash equal to $979,008.67,


representing Buyer's reimbursement of its share of the Transfer Taxes paid prior to the Closing Date in accordance with Section 9.07;

iii.a receipt for the Transferred Equity Interests, duly executed by Buyer and other duly executed instruments of transfer as required by applicable Laws or otherwise to validly transfer title in and to the Transferred Equity Interests;

iv.a counterpart of the Intellectual Property Cross License Agreement, duly executed by Buyer;

v.a counterpart of the Transition Services Agreement, duly executed by Buyer;

vi.a counterpart of the Transitional Trademark License Agreement, duly executed by Buyer;

vii.counterparts of the Local Transfer Agreements, if any, duly executed by Buyer;

viii.counterparts of the Lease Assignments, duly executed by Buyer;

ix.a counterpart of the Bill of Sale, Assignment and Assumption Agreement, duly executed by Buyer;

x.a counterpart of each IP Assignment Agreement, duly executed by Buyer;

xi.if applicable, a counterpart of each of the Factored Receivables Bill of Sale, duly executed by Buyer; e

xii.a counterpart of the Manufacturing and Supply Agreement, duly executed by Buyer.

(c)In order to effect (i) the Swedish IP Transfer and (ii) the Ownership Transfer at the Effective Time in India and Brazil, Buyer shall pay or cause to be paid (A) the Swedish IP Prepayment Amount on the day prior to the Closing Date and (B) the portion of the Closing Payment allocated to the Transferred Assets and/or Transferred Equity Interests in each of India and Brazil (or a portion thereof as agreed by Seller and Buyer) during local banking hours on March 31, 2020 (together with the Swedish IP Prepayment Amount, the “Prepaid Purchase Price”) and, in the event that the Closing fails to occur on March 31, 2020, (x) Seller shall as promptly as practicable (in any event within two (2) Business Days) return, or cause to be returned, the Prepaid Purchase Price to Buyer or such Affiliates designated by Buyer by wire transfer of immediately available funds in the same currency as the original payment(s) and (y) to the extent that the Swedish IP Transfer or the Ownership Transfer in either India or Brazil, as applicable, has occurred, each of Seller and Buyer shall, and shall cause their respective Affiliates to, take all necessary actions to unwind the Swedish IP Transfer or such Ownership Transfer, as applicable, as soon as practicable.

Section 3.03. Estimated Closing Statement; Closing Payment. No fewer than five (5) Business Days before the Closing Date, Seller shall prepare and deliver to Buyer the Estimated Closing Statement. The Estimated Closing Statement shall include (i) the amount of any Estimated Working Capital Increase or Estimated Working Capital Decrease, (ii) the amount of any Estimated Closing Cash, (iii) the amount of any Estimated Closing Debt, (iv) the amount of Estimated Transaction Expenses, (v) the Estimated 2018 EBITDA, (vi) the Estimated Target Working Capital, (vii) the amount to be paid by Buyer to Seller (for the benefit of the Seller Parties) at Closing (the “Closing Payment”, it being understood and agreed that the portion of the Closing Payment that constitutes Deferred Consideration shall be paid on the Deferred Transfer Date and the portion of the Closing Payment that constitutes the Swedish IP Prepayment Amount shall be paid on the calendar day prior to the Closing Date), which shall be equal to the sum of the following: (A) the Base Purchase Price, plus (B) the Estimated Purchase Price Adjustment (if the Estimated Purchase Price Adjustment is positive), minus (C) the absolute value of the Estimated Purchase Price Adjustment (if the Estimated Purchase Price Adjustment is negative), minus (D) the absolute value of the Specified Adjustment Amount, and (viii) the account or accounts to which Buyer shall pay the Closing Payment, in each case of clauses (i) through (viii), including reasonably detailed supporting information and a detailed itemization of the components thereof. Seller shall, in good faith, consider any adjustments to any such amounts reasonably raised by Buyer. The Closing Payment and other payments made to Seller under this Agreement shall be paid to Seller for its own account and as agent for the account of the other Seller Parties. For the avoidance of doubt, if Buyer accepts the Closing Payment delivered in accordance with this Section 3.03, Buyer shall not waive its rights to challenge such position pursuant to Section 3.04.


Section 3.04. Proposed Final Closing Statement and Final Closing Statement.

(a)Within 90 days after the Closing Date, Buyer shall provide to Seller the Proposed Final Closing Statement, together with reasonable supporting documentation. During such 90 day period, Buyer and its Representatives shall be permitted to review Seller’s work papers and all books and records of Seller used in the preparation of the Estimated Closing Statement and Seller shall promptly, and in any event within such time frame as reasonably required by Buyer, make available the individuals in its and its Subsidiaries’ employ as well as Representatives of its independent accountants responsible for and knowledgeable about the information used in, and the preparation of, the Estimated Closing Statement, to respond to the reasonable inquiries of, or requests for information by, Buyer or its Representatives.

(b)Seller shall have 60 days (the “Review Period”) after Buyer’s delivery of the Proposed Final Closing Statement to review the same. During the Review Period, Seller and its Representatives shall be permitted to review Buyer’s work papers and all books and records of the Business (including, after the Closing, the Transferred Entities) used in the preparation of the Proposed Final Closing Statement and Buyer shall promptly, and in any event within such time frame as reasonably required by Seller, make available the individuals in its and its Subsidiaries’ employ as well as Representatives of its independent accountants responsible for and knowledgeable about the information used in, and the preparation of, the Proposed Final Closing Statement, to respond to the reasonable inquiries of, or requests for information by, Seller or its Representatives. Buyer agrees that, following the Closing through the date that the Final Closing Statement becomes conclusive and binding upon the Parties in accordance with Article III, it will not (and will cause its Subsidiaries not to) take any actions with respect to any books, records, policies or procedures on which the Proposed Final Closing Statement is based or on which the Final Closing Statement is to be based or that would materially impede or delay the determination of the amount of the Final Purchase Price Adjustment or the preparation of the Dispute Notice or the Final Closing Statement in the manner and utilizing the methods required by this Agreement.

(c)If Seller disputes any item set forth in the Proposed Final Closing Statement, Seller shall, during the Review Period, deliver written notice to Buyer of the same, specifying in reasonable detail the basis for such dispute and Seller’s proposed modifications to the Proposed Final Closing Statement (such notice, the “Dispute Notice”). Any matters not identified in the Dispute Notice delivered in accordance with this Section 3.04(c) as being in dispute shall be deemed to have been agreed to and shall be conclusive and binding upon the Parties. During the 30-day period immediately following Seller’s delivery of a Dispute Notice (the “Resolution Period”), Buyer and Seller shall negotiate in good faith to reach an agreement as to any matters identified in such Dispute Notice as being in dispute, and, to the extent such matters are so resolved within the Resolution Period, then the Proposed Final Closing Statement as revised to incorporate such changes as have been agreed between Buyer and Seller shall be conclusive and binding upon all Parties as the Final Closing Statement.

(d)If Buyer and Seller fail to resolve all such matters in dispute within the Resolution Period, then (subject to the last sentence of Section 3.04(e)) such matters (and only such matters) identified in such Dispute Notice that remain in dispute following the expiration of the Resolution Period shall be finally and conclusively determined by Deloitte (and if Deloitte is unable or unwilling to serve in such capacity, such other globally recognized accounting firm as shall be agreed upon in writing by Seller and Buyer) (the “Independent Accounting Firm”).

(e)Seller and Buyer shall instruct the Independent Accounting Firm to promptly, but no later than 40 days after its acceptance of its appointment, determine (it being understood that in making such determination, the Independent Accounting Firm shall be functioning as an expert and not as an arbitrator), based solely on written presentations of Buyer and Seller submitted to the Independent Accounting Firm and not by independent review, only those matters in dispute and will render a written report setting forth its determination as to the disputed matters and the resulting calculations of Final Closing Cash, Final Working Capital, the Final Working Capital Increase (if any), the Final Working Capital Decrease (if any), Final Closing Debt, Final Transaction Expenses, the Final EBITDA-Based Reduction (if any), the Final Purchase Price Adjustment and the Post-Closing Adjustment (if any), which report and calculations will be conclusive and binding upon all Parties and shall constitute the Final Closing Statement for all purposes hereunder absent manifest mathematical error. A copy of all materials submitted to the Independent Accounting Firm pursuant to the immediately preceding sentence shall be provided by Seller or Buyer, as applicable, to the other Party concurrently with the submission thereof to the Independent Accounting Firm. In resolving any disputed item, the Independent Accounting Firm (i) shall be bound by the provisions of this Section 3.04(e) e Section 3.06 and (ii) may not assign a value to any item greater than the greatest value for such item claimed by Buyer or Seller, or less than the smallest value for such item claimed by Buyer or Seller. If, before the Independent Accounting Firm renders its determination with respect to the disputed items in accordance with this Section 3.04(e), (x) Seller notifies Buyer of its agreement with any items in the Proposed Final Closing Statement, (y) Buyer notifies Seller of its agreement with any items in the Estimated Closing Statement or (z) Buyer and Seller otherwise reach mutual agreement with respect to any items subject to dispute, then in each case such items as so agreed will be conclusive and binding on all Parties immediately upon such notice and shall constitute the Final Closing Statement for such items.


(f)The fees and expenses of the Independent Accounting Firm shall be borne by the Party whose aggregate position with respect to Final Purchase Price Adjustment is further from Final Purchase Price Adjustment as determined by the Independent Accounting Firm pursuant to Section 3.04(e) or, if the positions of each Party with respect to Final Purchase Price Adjustment are equidistant from the Final Purchase Price Adjustment as determined by the Independent Accounting Firm pursuant to Section 3.04(e), then the fees and expenses of the Independent Accounting Firm shall be borne equally by the Parties.

Section 3.05. Post-Closing Adjustment. If the Post-Closing Adjustment is a positive amount, Buyer shall pay an amount equal to the Post-Closing Adjustment to Seller. If the Post-Closing Adjustment is a negative amount, Seller shall repay an amount equal to the absolute value of the Post-Closing Adjustment to Buyer. Any payment due under this Section 3.05 shall be paid by wire transfer of immediately available funds to a bank account designated by Seller or a bank account designated by Buyer, as applicable, within five (5) Business Days after the date on which the Final Closing Statement becomes conclusive and binding on the Parties in accordance with the provisions of Section 3.04, and, if not paid within such period, shall bear interest at the Interest Rate. All computations of interest shall be made in accordance with Section 13.17. Notwithstanding anything herein to the contrary, Buyer and Seller agree that (a) if the estimated amount of Liabilities under the Taiwan Labor Standards Act Retirement Plan and Taiwan Supplementary Pension Plan arising with respect to Active Participants as of the Effective Time (as such amount is mutually agreed in good faith after Closing by Buyer and Seller) (the “Trued-Up Taiwan Pension Amount”) is less than $954,000, either (x) the amount of the Post-Closing Adjustment to be paid to Seller shall be increased (if the Post-Closing Adjustment is a positive amount) or (y) the amount of the Post-Closing Adjustment to be paid to Buyer shall be decreased (if the Post-Closing Adjustment is a negative amount), as applicable, by the amount by which the Trued-Up Taiwan Pension Amount is less than $954,000 and (b) if the Trued-Up Taiwan Pension Amount is higher than $954,000, either (x) the amount of the Post-Closing Adjustment to be paid to Seller shall be decreased (if the Post-Closing Adjustment is a positive amount) or (y) the amount of the Post-Closing Adjustment to be paid to Buyer shall be increased (if the Post-Closing Adjustment is a negative amount), as applicable, by the amount by which the Trued-Up Taiwan Pension Amount is higher than $954,000.

Section 3.06. Certain Calculation Principles. Each Closing Statement shall be (a) prepared and determined from the books and records of the Business in accordance with the Transaction Accounting Principles; and (b) consistent with the provisions of this Agreement relating to the Parties’ respective rights and obligations for the payment or reimbursement of costs and expenses.

Section 3.07. Purchase Price Allocation. The Purchase Price shall be initially allocated (before taking into account the Post-Closing Adjustment pursuant to Section 3.04), absent manifest error, among the Transferred Equity Interests or the Transferred Assets in each jurisdiction specifically addressed in Schedule 3.07 (the “Allocation Schedule”) in accordance with the Allocation Schedule, and, further, between the Agreement Date and the Closing Date, the Parties shall use commercially reasonable efforts in good faith to agree on an initial allocation of the Purchase Price (before taking into account the Post-Closing Adjustment pursuant to Section 3.04), based on a “more likely than not” reporting standard, among the Transferred Equity Interests or the Transferred Assets taking into account and not inconsistent with Schedule 3.07. The Parties shall, within sixty (60) days following the determination of the Post-Closing Adjustment pursuant to Section 3.04, use commercially reasonable efforts in good faith to agree on an update to the Allocation Schedule to reflect such Post-Closing Adjustment. In the event of any dispute with respect to matters addressed by this Section 3.07, such dispute shall be referred to the Independent Accounting Firm in accordance with the principles and procedures of Section 3.04(e) e Section 3.04(f), except that the fees and expenses of the Independent Accounting Firm shall be borne fifty percent (50%) by the Buyer and fifty percent (50%) by the Seller.

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF SELLER

Seller hereby represents and warrants to Buyer, as of the Agreement Date and as of the Closing Date, that, except as set forth in the Disclosure Schedules:

Section 4.01. Formation and Qualification of the Companies.

(a)Each Company is a corporation or other organization duly incorporated, formed or organized, validly existing and, to the extent legally applicable, in good standing under the Laws of its jurisdiction of incorporation, formation or organization and has the requisite corporate or other appropriate power and authority to own and lease its properties and to operate its business as now conducted. Each Company is duly qualified as a foreign corporation or other organization to do business, and, to the extent legally applicable, is in good standing, in each jurisdiction in which the character of its owned, operated or leased properties or the nature of its activities makes such qualification necessary, except for


jurisdictions in which the failure to be so qualified or in good standing would not reasonably be expected to have a Material Adverse Effect.

(b)Seller will as of the Closing have made available to Buyer true and complete copies of the Governing Documents of each Transferred Entity and each JV, in each case as in effect as of the Agreement Date, which Governing Documents are in full force and effect and none of the Seller and its Subsidiaries is in violation of any of such Governing Documents.

Section 4.02. Formation and Qualification of the Business Subsidiaries. Each Business Subsidiary is a corporation or other organization duly incorporated, formed or organized, validly existing and, to the extent legally applicable, in good standing under the Laws of its jurisdiction of incorporation, formation or organization and has the requisite corporate or other appropriate power and authority to own and lease its properties and to operate its business as now conducted. Each Business Subsidiary is duly qualified as a foreign corporation or other organization to do business, and, to the extent legally applicable, is in good standing, in each jurisdiction in which the character of its owned, operated or leased properties or the nature of its activities makes such qualification necessary, except for jurisdictions in which the failure to be so qualified or in good standing would not reasonably be expected to have a Material Adverse Effect.

Section 4.03. Ownership; Capital Structure of the Transferred Entities.

(a)The Seller Parties (or in the case of any Transferred Entity to be established after the Agreement Date, will as of the Closing) own all of the Transferred Equity Interests, in each case free and clear of all Liens, except (i) any Lien arising out of, under or in connection with the Securities Act or any other applicable securities Laws or (ii) any Lien created by or through, or resulting from any facts or circumstances relating to, Buyer or its Affiliates.

(b)All of the Transferred Equity Interests have been (or in the case of any Transferred Entity to be established after the Agreement Date, will as of the Closing have been) duly authorized and validly issued, fully paid and nonassessable and not issued in violation of any contract or agreement or in violation of any preemptive or similar rights. There are no options, warrants, “phantom” stock rights, stock based performance units or rights of conversion or other similar rights, agreements, arrangements or commitments obligating any Company to issue or sell or otherwise dispose of or redeem or otherwise acquire any shares of its capital stock, other equity interests or securities convertible into or exchangeable for its shares of capital stock or other equity interests, other than as provided in this Agreement. There are no voting trusts, stockholder agreements, proxies or other agreements or arrangements in effect with respect to the voting or transfer of the Transferred Equity Interests or other equity interests of any Company.

(c)One or more of the Companies and the Business Subsidiaries owns all the outstanding capital stock or other equity interests of each Business Subsidiary, free and clear of all Liens, except (i) any Lien arising out of, under or in connection with the Securities Act or any other applicable securities Laws or (ii) any Lien created by or through, or resulting from any facts or circumstances relating to, Buyer or its Affiliates. All of the outstanding capital stock or other equity interests of each Business Subsidiary have been duly authorized and validly issued and, to the extent applicable, fully paid and nonassessable and not issued in violation of any contract or agreement or is subject to or in violation of any preemptive or similar rights. There are no options, warrants, “phantom” stock rights, stock appreciation rights, stock based performance units or rights of conversion or other similar rights, agreements, arrangements or commitments obligating any Business Subsidiary to issue or sell or otherwise dispose of or redeem or otherwise acquire any shares of its capital shares, other equity interests or securities convertible into or exchangeable for its shares of capital stock or other equity interests, other than as provided in this Agreement. There are no voting trusts, stockholder agreements, proxies or other agreements in effect with respect to the voting or transfer of the shares or other equity interests of any Business Subsidiary. The Seller Parties own all of the JV Interests, in each case free and clear of all Liens, except (i) any Lien arising out of, under or in connection with the Securities Act or any other applicable securities Laws or (ii) any Lien created by or through, or resulting from any facts or circumstances relating to Buyer or its Affiliates.

Section 4.04. Formation and Authority of the Seller Parties; Enforceability.

(a)Seller is, and each other Seller Party is, a corporation or other entity duly incorporated, formed or organized, validly existing and, to the extent legally applicable, in good standing under the Laws of its jurisdiction of incorporation, formation or organization. Seller has, and each other Seller Party has, the requisite corporate or other appropriate power to execute, deliver and perform its obligations under the Seller Transaction Agreements (including the consummation of the Seller Transactions) to which it is a party. Seller has, and each other Seller Party has, the requisite corporate or other power to own and lease its properties and operate its business with respect to the Transferred Assets that it owns as now conducted and is duly qualified as a foreign corporation or other organization to do business, and to the extent legally applicable, is in good standing, with respect to the Business, in each jurisdiction in which the character of its owned, operated or leased properties or


the nature of its activities makes such qualification necessary, except for jurisdictions where the failure to be so qualified or in good standing would not reasonably be expected to have a Material Adverse Effect.

(b)The execution, delivery and performance by each Seller Party of the Seller Transaction Agreements to which it is a party have been (or, in the case of any Seller Party other than Seller or any Seller Transaction Agreement to be entered into after the Agreement Date, will be prior to the Closing) duly authorized by all requisite corporate action on the part of such Seller Party. This Agreement has been duly executed and delivered by Seller, and upon execution and delivery thereof, the other Seller Transaction Agreements will be duly executed and delivered by the Seller Parties party thereto, and (assuming due authorization, execution and delivery thereof by the other parties hereto and thereto) this Agreement constitutes, and upon execution and delivery thereof, the other Seller Transaction Agreements will constitute, legal, valid and binding obligations of the Seller Parties party hereto or thereto, enforceable against the Seller Parties party hereto or thereto in accordance with their respective terms, subject to the Bankruptcy and Equity Exception.

Section 4.05. No Conflict. Except as would not reasonably be expected to have a Material Adverse Effect, assuming that all Required Approvals have been obtained or deemed obtained and except as otherwise provided in this Article IV, the consummation of the Transactions and the execution, delivery and performance by the Seller Parties of the Seller Transaction Agreements do not and will not:

(a)violate or conflict with the certificate or articles of incorporation or bylaws or similar organizational documents of any of the Seller Parties or the Transferred Entities;

(b)conflict with or violate any Law or Order applicable to the Seller Parties, the Transferred Entities or the Business; o

(c)result in any breach of, or constitute a default under, or give to any Person any right to terminate, amend, accelerate or cancel, or result in the creation of any Lien (other than a Permitted Lien) on the Business, the Transferred Equity Interests or any Transferred Asset pursuant to, any note, bond, mortgage, indenture, contract, agreement, lease, license, permit, franchise or other instrument to which any of the Seller Parties (with respect to the Business or the Transferred Assets) or any Transferred Entity is a party or by which any Transferred Equity Interests or Transferred Assets are bound.

Section 4.06. Consents and Approvals. Except as set forth on Schedule 4.06, the execution, delivery and performance by the Seller Parties of the Seller Transaction Agreements do not and will not require any Consent, waiver or other action by, or any filing with or notification to, any Government Authority by any Seller Party or any Transferred Entity, except (a) in connection with applicable filing, notification, waiting period or approval requirements under applicable Regulatory Laws or (b) where the failure to obtain such Consent or waiver, or to take such action or make such filing or notification would not reasonably be expected to have a Material Adverse Effect.

Section 4.07. Financial Information; Absence of Undisclosed Liabilities.

(a)Schedule 4.07(a)(i) sets forth (i) the management-prepared unaudited balance sheets of the Business as of December 31, 2018 and 2017 and (ii) the management-prepared unaudited income statements of the Business for the fiscal years ended December 31, 2018 and 2017 (the balance sheets and income statements referred to in clauses (i) and (ii), collectively, the “Unaudited Financial Statements”). The Financial Statements (A) have been prepared based on the books and records of Seller and its Subsidiaries, (B) have been prepared in accordance with Seller’s reporting and accounting policies and in accordance with GAAP other than as specifically set forth on Schedule 4.07(a)(ii), and (C) present fairly, in all material respects, the financial condition and results of operation of the Business as of the respective dates and for the respective periods presented.

(b)Other than (i) as set forth in the Unaudited Financial Statements, (ii) Liabilities incurred in the ordinary course of business consistent with past practice since January 1, 2019 and (iii) Liabilities that would not reasonably be expected to have a Material Adverse Effect, there are no Liabilities of the Business.

(c)Except as set forth on Schedule 4.07(a)(ii), to the Knowledge of Seller, no facts or circumstances that exist as of the Agreement Date would reasonably be expected to cause the Audited Financial Statements to differ in any material respect from the Unaudited Financial Statements.

Section 4.08. Absence of Certain Changes or Events. Except as contemplated by the Transaction Agreements, in connection with Seller’s exploration of an initial public offering of its healthcare division or in connection with the negotiation and execution of the Transaction Agreements, since January 1, 2019, (a) Seller and its Subsidiaries have conducted the Business in all material respects in the ordinary course of business consistent with past practice, (b) there has not


been any Material Adverse Effect and (c) none of Seller or its Subsidiaries has taken any material actions with respect to the Business that, if taken between the Agreement Date and the Closing Date, would require the consent of Buyer pursuant to Section 6.01(a) (provided, that with respect to Sections 6.01(a)(v) e 6.01(a)(xv), only to the extent such actions were taken outside the ordinary course of business).

Section 4.09. Absence of Litigation. Since January 1, 2017, (a) no Actions have been (i) pending or, to the Knowledge of Seller, threatened in writing against Seller or any of its Subsidiaries or (ii) initiated or threatened by or on behalf of Seller or any of its Subsidiaries, in each case of clauses (i) and (ii), involving the Business, any Transferred Entity, any Transferred Asset or the Assumed Liabilities that individually or in the aggregate would reasonably be expected to be material to the Business, taken as a whole, and (b) none of the Business, the Transferred Entities, the Transferred Assets or the Assumed Liabilities has been subject to or bound by any outstanding Order that individually or in the aggregate would reasonably be expected to be material to the Business, taken as a whole.

Section 4.10. Compliance with Laws; Permits.

(a)Except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole, since January 1, 2017, (i) none of Seller or its Subsidiaries has violated any Laws or Orders applicable to the conduct of the Business and none of Seller or any of its Subsidiaries has been in default under or has violated any Permit, in each case, with respect to the Business and (ii) none of Seller or its Subsidiaries has received any written communication from a Government Authority or any other Person that alleges that the Business or any Transferred Entity is not in compliance with, or in violation of, any Laws or Orders applicable to the Business. Seller and its Subsidiaries validly own, hold or possess all Permits that are necessary for the conduct of the Business, except where the failure to validly own, hold or possess such Permit would not reasonably be material to the Business, taken as a whole.

(b)Except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole, since January 1, 2014, neither Seller nor any of its Subsidiaries, nor any of their respective officers, directors, or employees, nor to the Knowledge of Seller, any of its agents or other Persons acting for or on behalf of any of the foregoing Persons, in each case with respect to the Business (i) is currently, or has been, (A) a Sanctioned Person, (B) organized, resident, or located in a Sanctioned Country, (C) engaging in any dealings or transactions with or the benefit of any Sanctioned Person or in any Sanctioned Country, (D) otherwise in violation of applicable Sanctions Laws, Ex-Im Laws, or the U.S. anti-boycott Laws (collectively, “Trade Control Laws”), (E) convicted for a crime that could lead to debarment under 21 U.S.C. §335a(a) and (b) or listed on the United States Food and Drug Administration Debarment List, (F) debarred, excluded or suspended from participation in any healthcare program administered by a Government Authority or (G) listed on the United States General Services Administration or Department of Health and Human Services Office of Inspector General published list of parties excluded from federal procurement programs and non-procurement programs or (ii) has at any time made or received any unlawful payment or given, offered, promised, or authorized or agreed to give or receive, any money or thing of value, directly or indirectly, to or from any individual acting for or on behalf of any such Government Authority (any such individual, a “Government Official”) or any other Person in violation of any applicable Anti-Corruption Laws. Except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole, since January 1, 2014, neither Seller or any of its Subsidiaries, nor any of their respective officers, directors, or employees, nor to the Knowledge of Seller, any of its agents or other Persons acting for or on behalf of any of the foregoing Persons, has directly or indirectly offered, made or promised to make any unlawful contribution, gift, bribe, rebate, payoff, influence payment, kickback, or other payment or thing of value to any Government Official or other Person regardless of form, whether in money, property, or services, (i) to obtain favorable treatment or any other improper advantage in securing or retaining business, (ii) to pay for favorable treatment for business secured or retained, (iii) to obtain special concessions or for special concessions already obtained for or in respect of the Business in violation of applicable Law or (iv) to unlawfully influence any act or decision of any Person in their official capacity or induce such Person to violate their lawful duties.

Section 4.11. Intellectual Property.

(a)Schedule 4.11(a) contains a complete and accurate list of all material owned Company Intellectual property that constitutes Registrable IP. The Company has maintained all material Registrable IP in the ordinary course. None of the material Company Intellectual Property that constitutes Registrable IP is jointly owned with any third Person, except as identified in the Company’s internal dockets (to the extent accurately reflected therein and made available to Buyer) or in public records of the applicable Intellectual Property registrars or as set forth on Schedule 4.11(a). The Company Intellectual Property that constitutes material Registrable IP is subsisting and, except with respect to applications, to the Knowledge of Seller, valid and enforceable.

(b)All material Company Intellectual Property is owned by Seller or one of its Subsidiaries, free and clear of any Liens (excluding Permitted Liens). All material Intellectual Property, Technology, Software and Data Used


in the operation of the Business will immediately after the Closing either be (i) (x) owned by Buyer or a Transferred Entity and (y) available for use by the Business, on terms and conditions that are in all material respects the same as those under which Seller or any of its Subsidiaries owned or used such Intellectual Property, Technology, Software and Data immediately prior to the Closing or (ii) made available to Buyer and its Affiliates, including the Transferred Entities (solely for use by the Business) under the Transition Services Agreement, the Transitional Trademark License Agreement or the Intellectual Property Cross License Agreement.

(c)The operation of the Business by Seller or its Subsidiaries does not conflict with, infringe upon or misappropriate, and, since January 1, 2017, has not conflicted with, infringed upon or misappropriated, the Intellectual Property, Technology, Software or Data of any third party, except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole.

(d)None of Seller or its Subsidiaries has received any written Claim or notice from any Person since January 1, 2017 (i) alleging that the operation of the Business by Seller or its Subsidiaries conflicts with, infringes upon or misappropriates any Intellectual Property, Software or Data of any third party or (ii) challenging the validity, enforceability, ownership or use of any material Company Intellectual Property. As of the Agreement Date, there are no infringement Actions pending or, to the Knowledge of Seller, threatened in writing against Seller or any if its Subsidiaries alleging that the operation of the Business by Seller or any of its Subsidiaries conflicts with, infringes upon or misappropriates any Intellectual Property, Software or Data of any third party except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole.

(e)To the Knowledge of Seller, as of the Agreement Date, no Person is engaging in any activity that conflicts with, infringes upon or misappropriates any (i) Company Intellectual Property or (ii) Company Technology, in each case except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole.

(f)Neither Seller nor any of its Subsidiaries (i) have disclosed, delivered, or have any duty or obligation (whether present, contingent or otherwise) to disclose or deliver, any source code for any proprietary Software that is included in the Company Intellectual Property to any third party, except subject to reasonable confidentiality agreements or otherwise as would not reasonably be expected to be material to the Business, taken as a whole, or (ii) use, or have used, any “open source” Software under a license and in a manner that would (x) grant or purport to grant to any Person a license or other similar right to any of the material Company Intellectual Property or (y) require the Business to disclose or distribute the source code to any of the material proprietary Software that is included in the Company Intellectual Property, to provide such source code for the purpose of making derivative works, or to make available for redistribution to any Person such source code at no or minimal charge.

(g)None of Seller or any of its Subsidiaries is, or has been since January 1, 2017, in violation of Laws applicable to the conduct of the Business relating to data privacy, data protection and data security or its published privacy policies, or any other Data Security Requirements applicable to the Business, in each case except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole. Since January 1, 2017there have not been any actual incidents of data security breaches, unauthorized access or unauthorized use of any of the Business Systems, or unauthorized acquisition, destruction, damage, disclosure, loss, corruption, alteration, or use of any Company Technology, in each case except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole.

(h)Seller and its Subsidiaries have taken security measures that are commercially reasonable in the industry in which it operates to protect (i) the secrecy and confidentiality of all material Trade Secrets included in the owned Company Intellectual Property and (ii) Personally Identifiable Information that is stored by or under the control of the Business. All current employees who have contributed, developed or conceived any Intellectual Property, Technology, Software or Data that is (x) material to the operation of the Business and (y) owned or purported to be owned by Seller or any of its Subsidiaries have, to the extent not already provided by operation of Law, done so pursuant to a valid and enforceable agreement that protects the Trade Secrets of the Business and under which such Person assigns to Seller or its applicable Subsidiary exclusive ownership of the Person’s contribution, development or conception.

(i)Seller and its Subsidiaries have taken security measures that are commercially reasonable in the industry in which it operates, to protect the integrity of the Business Systems and the Data stored or contained therein or transmitted thereby.


Section 4.12. Environmental Matters.

(a)Except as, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect:

i.each of the Business, the Transferred Assets, and, with respect to the Business or any Transferred Assets, Seller and its Subsidiaries, is and since January 1, 2014 has been, in compliance with Environmental Laws, which compliance includes obtaining, maintaining and complying with Environmental Permits;

ii.there are no Actions pending or, to the Knowledge of Seller, threatened in writing, against the Business, the Transferred Assets, or Seller or any of its Subsidiaries, and, since January 1, 2014, no Action, notice or written report has been received, regarding any violations of Environmental Laws or Liabilities of the Business, the Transferred Assets, or the Seller or such Subsidiaries with respect to the Business or the Transferred Assets, in each case, under Environmental Laws; e

iii.there has been no treatment, manufacture, transportation, distribution, storage, disposal of, arrangement for disposal of, use, handling, Release, exposure of any Person to, or contamination by, any Hazardous Materials, either by the Business, Seller or any of its Subsidiaries with respect to the Business or the Transferred Assets, or on, at or under any facilities or properties currently or formerly owned by Seller or any of its Subsidiaries with respect to the Business or the Transferred Assets, which has resulted or would reasonably be expected to result in Seller or any of its Subsidiaries, or the Business or the Transferred Assets, incurring Liability under Environmental Laws; e

(b)The Seller Parties have furnished to Buyer all environmental assessments, audits, reports and other material environmental documents in their possession or control relating to any current or former facilities, properties or operations of the Business and the Transferred Assets.

Section 4.13. Material Contracts.

(a)The following contracts or agreements Related to the Business to which Seller or any of its Subsidiaries is a party shall constitute “Material Contracts” for the purposes of this Agreement:

i.any material contract or agreement with any Material Customer or any Material Supplier;

ii.any contract or agreement (A) that materially restricts the ability of the Business or the Transferred Entities to compete in any line of business or with any Person or in any geographic area during any period of time, (B) pursuant to which the Business or any Transferred Entity has granted exclusive rights or (C) that contains “most favored nation” provisions in favor of any Person;

iii.any contract or agreement that grants to any Person any right of first refusal, right of first offer or similar right with respect to, or that limits the ability of the Business or any Transferred Entity to transfer, pledge or otherwise dispose of, any asset or business of the Business in any material respect;

iv.any contract or agreement related to the acquisition, disposition of or investment in any business, any equity interests of any Person or any assets (whether by merger, sale of stock, sale of assets or otherwise) other than in the ordinary course of business, in each case under which there are material outstanding obligations (whether or not contingent);

v.any contract or agreement that is a settlement, conciliation or similar agreement with respect to any Action, pursuant to which the Business or the Transferred Entities will have any material payment obligation, or will be subject to any material limitations on the conduct of operations, after the Closing;

vi.any joint venture, partnership, strategic alliance, collaboration or other similar contract or agreement with any third party, including any Governing Documents of the JVs;

vii.any collective bargaining agreement or other contract or agreement with any labor union or organization or works council (each, a “CBA”);

viii.any contract or agreement, the principal purpose of which is to grant any (A) material outbound license by Seller or one of its Subsidiaries to a third party to use Company Intellectual Property or Company Technology (other than any licenses granted to customers, suppliers or service providers in the ordinary course of business), and (B) material inbound license to Seller or any of its Subsidiaries to Intellectual Property, Technology, Software or Data that


is Used primarily in the Business (other than licenses of generally commercially available Intellectual Property, Technology, Software or Data);

ix.any material contract or agreement for the development of any Intellectual Property, Technology, Software or Data to be used in the operation of the Business (other than agreements with employees and independent contractors entered into the ordinary course of business);

x.any material Transferred Real Property Leases; e

xi.any contract or agreement with a third party that involves annual aggregate payments to or from the Seller or any of its Subsidiaries of at least $20,000,000.

(b)Except as would not reasonably be expected to have a Material Adverse Effect, Schedule 4.13(a) sets forth an accurate, correct and complete list of, and Seller has made available to Buyer accurate, correct and complete copies of, each Material Contract referred to in clauses (i), (iv), (v), (vi) and (x) of Section 4.13(a). Except as would not reasonably be expected to have a Material Adverse Effect, (i) each Material Contract is a legal, valid and binding obligation of Seller or its applicable Subsidiary party thereto, as the case may be, and, to the Knowledge of Seller, each other party to such Material Contract, and is enforceable against Seller or such Subsidiary, as the case may be, and, to the Knowledge of Seller, each other party to such Material Contract, in accordance with its terms, subject, in each case, to the Bankruptcy and Equity Exception, (ii) none of Seller or its Subsidiaries or, to the Knowledge of Seller, any other party to a Material Contract is in default under or breach of a Material Contract and (iii) none of Seller or its Subsidiaries has received any notice of breach of a Material Contract.

Section 4.14. Employment and Employee Benefits Matters.

(a)Schedule 4.14(a) sets forth a list (which shall be true and complete within forty-five (45) days following the Agreement Date (or if later with respect to a given Business Employee, as soon as practicable following the date on which such Business Employee is designated as such pursuant to Exhibit E)) of each material Employee Plan that is a Parent Plan, separately identifying each Employee Plan that is a Business Plan and each Business Plan that is a Dedicated Pension Plan. With respect to each material Business Plan, to the extent that Seller has not provided to Buyer prior to the Agreement Date, Seller will provide to Buyer within forty-five (45) days following the Agreement Date, a true and complete copy, to the extent applicable, of (i) the current plan document (with all amendments thereto), or if unwritten, a written summary of the material terms of such plan and the most recent summary plan description (and any summaries of material modifications thereto), or for any employment agreements, offer letters, or similar individualized agreements having terms consistent in all material respects with a “template” or “form” agreement, a copy of such template or form, (ii) the most recent Form 5500 and all schedules thereto and the most recent actuarial report, and (iii) the most recent IRS determination, opinion or advisory letter. With respect to each material Parent Plan, to the extent that Seller has not provided to Buyer prior to the Agreement Date, Seller will provide to Buyer as soon as reasonably practicable following the Agreement Date, a true and complete copy, to the extent applicable, of (x) the current plan document or the most recent summary plan description (with all summaries of material modifications thereto) or a written summary of the material terms and (y) the most recent IRS determination, opinion or advisory letter.

(b)Except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole, neither Seller nor any of its Subsidiaries sponsors or maintains, or in the past six years has sponsored or maintained, or has any Liability under or with respect to, any plan subject to Title IV of ERISA, including a multiemployer plan (within the meaning of Section 3(37) or 4001(a)(3) of ERISA) (a “Title IV Plan” ). No Business Plan provides, and no Transferred Entity has any Liability to provide, for post-termination or post-employment welfare benefits for any Person beyond those required by Section 4980B of the Code and any similar state Law for which the covered Person pays the full cost of coverage.

(c)Except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole, no Transferred Entity has any Liability by reason of at any time being considered a single employer under Section 414 of the Code with any other Person.

(d)None of the Business Plans is a “multiple employer plan” (within the meaning of Section 210 of ERISA or Section 413(c) of the Code), or a “multiple employer welfare arrangement” (as such term is defined in Section 3(40) of ERISA).

(e)With respect to any Title IV Plan, (i) no reportable event (within the meaning of Section 4043 of ERISA) has occurred or, is expected to occur, whether as a result of the consummation of the Transactions or otherwise, (ii) the minimum funding standard under Section 430 of the Code has been satisfied and no waiver of any minimum


funding standard or extension of any amortization periods has been requested or granted, (iii) all amounts due to the Pension Benefit Guaranty Corporation (“PBGC”) pursuant to Section 4007 of ERISA have been timely paid, (iv) with respect to any significant reduction in the rate of future benefit accrual as referred to in Section 204(h) of ERISA, the requirements of Section 204(h) of ERISA have been complied with, (v) no such plan has been or is considered to be in “at risk” status under Section 430 of the Code, (vi) there has been no event described in Section 4062(e) of ERISA, and the Transactions will not result in any event described in Section 4062(e) of ERISA, (vii) no event has occurred or circumstances exist that would result in Liability under or with respect to Section 4069 of ERISA, and (viii) no notice of intent to terminate any such plan has been filed and no amendment to treat any such plan as terminated has been adopted and no proceeding has been commenced by the PBGC to terminate any such plan, in each case except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole.

(f)Except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole, each Employee Plan that is intended to be qualified under Section 401(a) of the Code has received a favorable determination letter, or is entitled to rely on a favorable opinion letter, from the IRS that it is so qualified, and nothing has occurred that would reasonably be expected to adversely affect such Employee Plan’s qualification.

(g) Without limiting the generality of the other provisions of this Section 4.14, with respect to each International Business Plan: (i) each International Business Plan that is required to be registered has been registered in all material respects (and, where applicable, accepted for registration) and has been maintained in all material respects in good standing, to the extent applicable, with applicable Government Authorities and (ii) no International Business Plan is a “defined benefit plan” (as defined in ERISA, whether or not subject to ERISA). All contributions required to have been made by or on behalf of the Transferred Entities with respect to governmental plans or arrangements (including severance, termination indemnities or other similar benefits maintained for employees outside of the U.S.) have been in all material respects timely made or fully accrued.

(h)With respect to any International Business Plan in the United Kingdom that is a defined benefit pension plan (a “Pension Scheme”), and except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole, (i) all contributions that are payable or that shall fall due for payment by Seller or its Affiliates prior to the Agreement Date have been paid, (ii) the Pension Scheme is a registered pension scheme as defined in Section 150(2) of the Finance Act 2004 and (iii) there is no reason why such classification as a registered pension scheme could be withdrawn and HM Revenue and Customs (“HMRC”) might de-register the scheme. Within forty-five days (45) after the Agreement Date (or if later with respect to a given Business Employee, as soon as practicable following the date on which such Business Employee is designated as such pursuant to Exhibit E), Seller shall provide to Buyer a census of Business Employees who currently participate in the Pension Scheme with their date of joining, pensionable pay, length of service and full details of pension contributions payable by the relevant employer and the Business Employees.

(i)With respect to each U.S. Business Plan, neither Seller nor any of its Subsidiaries has any material Liability for any Tax arising under Sections 4971, 4972, 4975, 4979, 4980 or 4980B of the Code or for breach of fiduciary duty as determined under ERISA. Neither Seller nor any of its Subsidiaries has incurred any material Liability under or arising out of Title IV of ERISA that has not been satisfied in full. No Transferred Entity or Transferred Asset is the subject of any Lien arising under ERISA or the Code. Neither Seller nor any of its Subsidiaries has been required to post any security under ERISA or Section 401(a)(29) of the Code with respect to any U.S. Business Plan, and no fact or event exists that would reasonably be expected to give rise to any such Lien or requirement to post any such security.

(j)Except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole, (i) each Employee Plan has been established, funded, administered and operated in accordance with its terms and the requirements of all applicable Laws, and (ii) with respect to each Employee Plan, all contributions, premiums or payments required to be made have been made on or before their due dates. The Transferred Entities are in material compliance with, and have no material Liability for non-compliance under, the Patient Protection and Affordable Care Act, including the Health Care and Education Reconciliation Act of 2010, as amended, and including any guidance issued thereunder, including pursuant to Sections 4980D, 4980H, 6721 and 6722 of the Code.

(k)No Claims or Actions are pending or, to the Knowledge of Seller, threatened in connection with (i) any Employee Plan that could result in a material Liability to Buyer or its Affiliates (including, after the Closing, the Transferred Entities) (other than routine claims for benefits) or (ii) any Business Plan that could result in a material Liability to Buyer or its Affiliates (including, after the Closing, the Transferred Entities (other than routine claims for benefits)).

(l)As of December 31, 2018, there were 5,276 Dedicated Employees.

(m)There are no and, since January 1, 2017, have been no pending or, to the Knowledge of Seller, threatened material organizational activities, petitions or other unionization activities seeking recognition or certification


of a bargaining unit in the Business, and no material unfair labor practice charges or other material complaints or material union representation questions before the National Labor Relations Board or other labor board or Government Authority are pending or, to the Knowledge of Seller, threatened by or on behalf of current or former employees of Seller or its Subsidiaries who provide or provided services to the Business. No material strikes, lockouts, slowdowns, work stoppages, labor-related grievances, labor-related arbitrations or other labor disputes are pending or, to the Knowledge of Seller, threatened with respect to any current or former employees of the Seller or its Subsidiaries who provide or provided services to the Business, or against or affecting any Transferred Entities or the Business, and no such material strike, lockout, slowdown or work stoppage, labor-related grievance, labor-related arbitration or other dispute has occurred within the last three (3) years.

(n)Except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole, (i) the Transferred Entities and, with respect to the Business and any current or former employees and independent contractors of Seller or its Subsidiaries who provide or provided services to the Business, Seller and its Subsidiaries, are and since January 1, 2017, have been in compliance with all applicable Laws relating to labor, employment and employment practices including, without limitation, all Laws respecting terms and conditions of employment, health and safety, wages and hours (including the classification of independent contractors and exempt and non-exempt employees), immigration (including the completion of Forms I-9 for all employees and the proper confirmation of employee visas), employment discrimination, disability rights or benefits, equal opportunity, plant closures and layoffs (including the Worker Adjustment and Retraining Notification Act of 1988, as amended, or any similar Laws), workers’ compensation, labor relations, employee leave issues, affirmative action and unemployment insurance and have paid in full all wages, wage premiums, salaries, commissions, bonuses, fees other compensation and benefits and all fines, Taxes, interest, levies, penalties assessments, contributions and payments to third parties due to or on behalf of any current or former employees or independent contractors of Seller or its Subsidiaries who provide or provided services to the Business, (ii) none of the Transferred Entities, or with respect to the Business, Seller or any of its Subsidiaries is subject to any pending or, to the Knowledge of Seller, threatened, non-routine investigation from any labor inspection or similar Government Authority, and no material Action is currently pending against the Transferred Entities, Seller or any of its Subsidiaries with respect to any Business Employee or former employees or independent contractor of the Business, and (iii) no material obligations of any Transferred Entity, Seller or any of its Subsidiaries to comply with any Order in respect of any Business Employees or former employee or independent contractors of the Business are outstanding or unsatisfied.

(o)Except as, individually or in the aggregate, would not reasonably be expected to be material to the Business, taken as a whole, (i) the Transferred Entities and, with respect to the Business or any current or former employees or independent contractors of Seller or its Subsidiaries who provide or provided services to the Business, Seller and its Subsidiaries, have promptly, thoroughly and impartially investigated all sexual harassment allegations of which any of them are aware, and (ii) with respect to each such allegation with potential merit, the Transferred Entity, Seller or its Subsidiaries (as applicable) has taken prompt corrective action that is reasonably calculated to prevent further harassment. Seller does not reasonably expect any material Liability with respect to any such allegations.

(p)The execution and delivery of this Agreement and the consummation of the Transactions will not (either alone or in conjunction with any other event) (i) cause the accelerated vesting, funding or delivery of, or materially increase the amount or value of, any payment or benefit to any Business Employee, (ii) result in any material payment (whether in cash, property or vesting of property) or benefit becoming due to any Business Employee, or (iii) result in an obligation to fund or otherwise set aside assets to secure to any extent any of the obligations under any Business Plan and other Employee Plan that is being assumed by Buyer or its Affiliates as a result of this Agreement.

(q)Except as set forth on Schedule 4.14(q) (which shall be true and complete within forty-five (45) days following the Agreement Date (or if later with respect to a given Business Employee, as soon as practicable following the date on which such Business Employee is designated as such pursuant to Exhibit E)), the Seller and its Subsidiaries are neither party to, nor bound by, any collective bargaining agreement or works council agreement covering any Business Employees that impacts any material terms and conditions of employment, and no Business Employees of Seller or its Subsidiaries are represented by any labor union, works council, or other labor organization with respect to such employment. Schedule 4.14(q) shall be timely updated by Seller following the Agreement Date to the extent necessary to reflect changes to the list of Business Employees resulting from the parties’ designation of individuals as Business Employees following the Agreement Date in accordance with the terms of the Agreement.

(r)No Business Employee as of the Agreement Date who is at or above the level of Executive Band has provided written notice of his or her intention to terminate their employment prior to the one (1) year anniversary of the Closing or to not accept an offer of employment from Buyer or its Affiliates pursuant to this Agreement. Schedule 4.14(r) shall be timely updated by Seller following the Agreement Date to the extent necessary to reflect changes to the list of Business Employees resulting from the parties’ designation of individuals as Business Employees following the Agreement Date in accordance with the terms of the Agreement.


(s)Schedule 4.14(s) sets forth a list of any Business Employee as of the Agreement Date at the Executive Band or above who works for the Business on a visa, Employment Pass, or any other form of work authorization. Schedule 4.14(s) shall be timely updated by Seller following the Agreement Date to the extent necessary to reflect changes to the list of Business Employees resulting from the parties’ designation of individuals as Business Employees following the Agreement Date in accordance with the terms of the Agreement.

Section 4.15. Taxes. Except as would not reasonably be expected to have a Material Adverse Effect:

(a)(i) The Seller Parties and the Transferred Entities have duly and timely filed, or have had duly and timely filed on their behalf, all Tax Returns required to be filed by the Seller Parties (with respect to the Business) and the Transferred Entities (taking into account extensions to file such Tax Returns), (ii) such Tax Returns are true, correct and complete and (iii) all amounts of Taxes, whether or not shown due on such Tax Returns, owed by the Seller Parties (with respect to the Business) or the Transferred Entities have been duly and timely paid.

(b)No deficiencies for any Taxes have been proposed, asserted or assessed in writing by a Taxing Authority against any Transferred Entity or with respect to the Business that are still pending, other than as a result of any such Transferred Entity being a member of any affiliated, consolidated, combined or unitary Tax group (other than any such group that consists only of Transferred Entities).

(c)No extensions of the period for assessment or collection of any Taxes, nor any extensions or waiver of the statute of limitation, or other agreement that has the effect of extending or waiving the statute of limitations, are in effect with respect to any Transferred Entity, other than solely as a result of any such Transferred Entity being a member of any affiliated, consolidated, combined or unitary Tax group (other than any such group that consists only of Transferred Entities).

(d)As of the Agreement Date, no Tax Return filed by any Transferred Entity is under current audit or examination by any Taxing Authority and no claim, audit, action, suit, proceeding or investigation is threatened in writing with respect to any Transferred Entity in respect of any Tax or Tax Return, in each case, other than as a result of any such Transferred Entity being a member of any affiliated, consolidated, combined or unitary Tax group (other than any such group that consists only of Transferred Entities).

(e)There are no liens for Taxes on the Transferred Assets, the Transferred Equity Interests, or the assets of any Transferred Entity, other than Permitted Liens.

(f)The Seller Parties (with respect to the Business) and the Transferred Entities have complied with all applicable withholding obligations for Taxes required to have been withheld in connection with amounts paid to any employee or independent contractor.

(g)No Transferred Entity is a party to any Tax sharing, indemnification or allocation agreement or arrangement (other than indemnification or allocation agreements or arrangements solely amongst the Transferred Entities or indemnification or allocation agreements or arrangements pertaining to the sale or lease of assets or subsidiaries or where the inclusion of a Tax indemnification or allocation provision is customary or incidental to an agreement the primary subject matter of which is not Taxes) pursuant to which it will have any obligation to make any payments after the Closing.

(h)None of the Transferred Entities, or of the Buyer or its Subsidiaries on behalf of the Transferred Entities, will be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date, as a result of any (i) change in or improper use of any method of accounting for a taxable period ending on or prior to the Closing Date under Section 481 of the Code (or any corresponding provision of state, local or foreign income Tax law), (ii) “closing agreement” as described in Section 7121 of the Code (or any corresponding or similar provision of state, local or non-U.S. income Tax Law) executed on or prior to the Closing Date, (iii) installment sale or open transaction disposition made on or prior to the Closing Date, (iv) deferred intercompany gain described in Treasury Regulations under section 1502 of the Code (or any corresponding or similar provision of federal, state, local or foreign Law) or (v) prepaid amount or deferred revenue received on or prior to the Closing Date.

(i)No power of attorney that is currently in force has been granted with respect to any matter relating to Taxes or Tax Returns of a Transferred Entity other than as a result of any such Transferred Entity being a member of any affiliated, consolidated, combined or unitary Tax group (other than any such group that consists only of Transferred Entities).


(j)None of the Transferred Entities (i) is, nor has been, subject to Tax in a country outside of the country in which it is organized, (ii) currently has nor has had a permanent establishment (as defined in any applicable tax treaty) or other fixed place of business or other connection or nexus in a country other than the country in which it is organized and (iii) is currently nor has been a party to or the beneficiary of any Tax exemption, Tax holiday or other Tax reduction contract or agreement or order.

(k)The Transferred Entities will not be required to pay any amount of Tax after the Closing Date as a result of an election made under Section 965(h) of the Code.

(l)Schedule 4.15(l) lists the U.S. federal income tax classification of each of the Transferred Entities. Except as indicated, each such entity has had such classification at all times since formation.

(m)None of the Transferred Assets, interests in the Transferred Entities, or the assets of such Transferred Entities constitute “United States real property interests” within the meaning of Section 897(c) of the Code, other than “United States real property interests” to be transferred (or deemed transferred for U.S. federal income tax purposes) by a Person providing a certificate described in Section 3.02(a)(viii).

Section 4.16. Real Property. Except as would not reasonably be expected to have a Material Adverse Effect:

(a)One or more of Seller or its Subsidiaries, as applicable, has good and marketable fee simple title to the Transferred Owned Real Property and valid title to the leasehold estate or license interest (as lessee, sublessee or licensee) in the Transferred Leased Real Property, in each case, free and clear of all Liens, except for Permitted Liens.

(b)Schedule 4.16(b) sets forth the address of all Transferred Real Properties, and a true and complete list of all Transferred Real Property Leases (including all amendments and guaranties with respect thereto) for each Transferred Leased Real Property. The Transferred Real Properties identified in Schedule 4.16(b) comprise all of the real property that are Related to the Business.

(c)With respect to each Transferred Owned Real Property: (A) except as set forth in Schedule 4.16(c), neither Seller nor any of its Subsidiaries has leased or otherwise granted to any Person the right to use or occupy such Transferred Owned Real Property or any portion thereof and (B) other than the right of Buyer pursuant to this Agreement, neither Seller nor any of its Subsidiaries has granted any outstanding options, rights of first offer or rights of first refusal to purchase such Transferred Owned Real Property or any portion thereof or interest therein.

(d)Neither Seller nor any Subsidiary is a party to any agreement or option to purchase any real property or interest therein which is used or contemplated to be used in the Business.

(e)Seller has made available to Buyer a true and complete copy of each material Transferred Real Property Lease. All leases, subleases or licenses for the Transferred Leased Real Property under which Seller or any of its Subsidiaries is a lessee, sublessee or licensee are in full force and effect and are enforceable as against Seller or its applicable Subsidiary, and to the Knowledge of Seller, as against any other counterparty thereto in accordance with their respective terms, subject to the Bankruptcy and Equity Exception.

(f)Except as set forth in Schedule 4.16(f), with respect to each of the Transferred Real Property Leases: (i) neither Seller, its Subsidiaries nor, to the Knowledge of Seller, any other party to the Transferred Real Property Lease is in breach or default in any material respect under such Transferred Real Property Lease; (ii) Seller or any Subsidiary has not subleased, licensed or otherwise granted any Person the right to use or occupy such Transferred Leased Real Property or any portion thereof; and (iii) Seller or any Subsidiary has not collaterally assigned or granted any other security interest in such Transferred Real Property Lease or any interest therein, except for Permitted Liens and except for collateral assignments and security interests that will be released at Closing (if any).

(g)None of Seller or any of its Subsidiaries has received any written notice from any Government Authority asserting any violation of applicable Laws with respect to any Transferred Real Properties that remains uncured as of the Agreement Date.

Section 4.17. Brokers. Except for fees and expenses of PJT Partners LP and J.P. Morgan Securities LLC (the “Seller Bankers”), no broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission from the Seller Parties, or any of their respective Affiliates in connection with any Transaction. Seller is solely responsible for the investment advisory fees and expenses of the Seller Bankers and any other such broker, finder or investment bank.


Section 4.18. Sufficiency of Assets and Transferred Assets; Liens.

(a)On the Closing Date, the Transferred Assets will, taking into account all Transaction Agreements (and the rights granted and services to be performed thereunder), constitute all of the assets, rights and properties that are necessary to (x) conduct the Business immediately following the Closing in all material respects as it is conducted on the Agreement Date; provided, however, that nothing in this Section 4.18 shall be deemed to constitute a representation or warranty as to (i) the adequacy of amounts of cash or working capital (or the availability of the same) or (ii) infringement or misappropriation of Intellectual Property, Software or Data, which matters are addressed exclusively in Section 4.11, and (y) perform all of Buyer’s and its Affiliates’ (including, after the Closing, the Transferred Entities’) post-Closing obligations under the Transaction Agreements.

(b)Seller or its Subsidiaries have and, as of the Closing, will have good, valid and enforceable title (or valid lease, license or other applicable right of use) to all Transferred Assets that are material to the Business, taken as a whole (other than the leasehold estate (as lessee or sublessee) in the Transferred Leased Real Properties and the fee estate in the Transferred Owned Real Properties, which are the subject of Section 4.16), free and clear of all Liens (other than Permitted Liens) and, except as has not been and would not be reasonably expected to be material to the Business, taken as a whole, good, valid and enforceable title (or valid lease, license or other applicable right of use) to all other Transferred Assets.

(c)Any failure to obtain a Required Approval, and any action taken as required by Section 6.04, and the consequences thereof, shall not be taken into account in determining the accuracy of any representation or warranty in this Section 4.18.

Section 4.19. Insurance. Except as would not reasonably be expected to have a Material Adverse Effect, all Insurance Policies maintained for, at the expense of or for the benefit of, the Business or any Transferred Assets (the “Business Insurance Policies”) are in full force and effect, all premiums due to date thereunder have been paid in full and neither Seller nor any of its Subsidiaries is in default with respect to any other obligations thereunder, and no written notice of cancellation or nonrenewal, in whole or in part, with respect to any such Business Insurance Policy currently in force has been received by Seller or any of its Subsidiaries as of the Agreement Date. The scope and level of coverage of the Business Insurance Policies are reasonably customary in comparison to the scope and coverage carried by companies similar to Seller in similar lines of business as the Business.

Section 4.20. Intercompany Agreements.

(a)As of the Closing Date, all then existing contracts, agreements or arrangements between the Business and any Transferred Entity, on the one hand, and Seller or any of its Subsidiaries (other than the Transferred Entities), on the other hand (other than (i) the Transaction Agreements, (ii) any intercompany obligations exclusively between or among the Transferred Entities and (iii) any contracts, agreements or arrangements, the rights and obligations of all parties under which will be assigned or transferred to Buyer or its Subsidiaries under this Agreement by Asset/Liability Transfer and/or the transfer of a Transferred Entity, the “Intercompany Agreements”), and other than any Intercompany Agreement on Schedule 4.20, will automatically terminate without further payment or performance and shall cease to have any further force and effect, such that no party thereto shall have any further Liabilities therefor or thereunder or rights therein or thereto.

(b)None of Seller or any of its Affiliates, or to the Knowledge of Seller, any officers, directors or employees of Seller or its Affiliates is a party to any contract or agreement with any Transferred Entity or by which the Business or any Transferred Assets are bound which will not automatically terminate at the Closing, other than employment agreements with any such officers, directors or employees.

Section 4.21. Customers and Suppliers. Schedule 4.21 sets forth a list of (a) the 20 largest customers of the Business (each, a “Material Customer”), as measured by the dollar amount of purchases thereby during the most recent fiscal year, showing the total sales by the Business to each such Material Customer in such fiscal year, and (b) (i) any sole source supplier of the Business for which the total purchases of the Business during the most recent fiscal year exceeded $5,000,000 and (ii) the 20 largest suppliers of the Business (each, a “Material Supplier”), as measured by the dollar amount of purchases therefrom during the most recent fiscal year, showing the total purchases by the Business from each such Material Supplier in such fiscal year. Since January 1, 2019, no Material Customer or Material Supplier has (i) threatened in writing to cancel, terminate, let expire or adversely modify in any material respect, or to the Knowledge of Seller, has otherwise threatened to, cancel, terminate, let expire or adversely modify in any material respect, the relationship of such Material Customer or Material Supplier with the Business or (ii) threatened in writing to decrease materially or, to the Knowledge of Seller, has otherwise threatened to decrease materially, its purchases from, or its services or supplies to, the Business.

Section 4.22. No Other Representations or Warranties. Except for the representations and warranties expressly set forth in this Article IV (as modified by the Disclosure Schedules) or the other Transaction Agreements, none of


the Seller Parties or any other Person has made, makes or shall be deemed to make any other representation or warranty of any kind whatsoever, express or implied, written or oral, at law or in equity, on behalf of the Seller Parties, the Transferred Entities or any of their respective Affiliates, including any representation or warranty regarding any Seller Party, any Transferred Entity or any other Person, the Transferred Equity Interests, any Transferred Assets, any Liabilities of any Seller Party or Transferred Entity, any Assumed Liabilities, the Business, any Transaction, any other rights or obligations to be transferred pursuant to the Transaction Agreements or any other matter, and the Seller Parties hereby disclaim all other representations and warranties of any kind whatsoever, express or implied, written or oral, at law or in equity, whether made by or on behalf of any Seller Party, any Transferred Entity or any other Person. Except for the representations and warranties expressly set forth in this Article IV or the other Transaction Agreements, each Seller Party hereby disclaims all Liability and responsibility for all projections, forecasts, estimates, financial statements, financial information, appraisals, statements, promises, advice, data or information made, communicated or furnished (orally or in writing, including electronically) to Buyer or any of Buyer’s Affiliates or any Representatives or Buyer or any of Buyer’s Affiliates, including omissions therefrom. Without limiting the foregoing, except for the representations and warranties expressly set forth in this Article IV and the other Transaction Agreements, no Seller Party makes any representation or warranty of any kind whatsoever, express or implied, written or oral, at law or in equity, to Buyer or any of its Affiliates or any Representatives of Buyer of any of its Affiliates regarding the success, profitability or value of the Transferred Entities, the Transferred Assets, the Transferred Equity Interests or the Business.

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF BUYER

Buyer hereby represents and warrants to Seller, as of the Agreement Date and as of the Closing Date, that, except as set forth in the Disclosure Schedules:

Section 5.01. Formation and Authority of Buyer. Buyer is a corporation or other entity duly incorporated, formed or organized, validly existing and, to the extent legally applicable, in good standing under the Laws of its jurisdiction of incorporation, formation or organization and has the requisite corporate or other appropriate power to execute, deliver and perform its obligations under the Buyer Transaction Agreements (including the consummation of the Buyer Transactions). The execution, delivery and performance of the Buyer Transaction Agreements by Buyer have been duly authorized by all requisite corporate or organizational action on the part of Buyer, and no shareholder or other similar approval is required in connection with Buyer’s execution, delivery and performance of the Buyer Transaction Agreements. This Agreement has been, and upon execution and delivery thereof, the other Buyer Transaction Agreements will be, duly executed and delivered by Buyer, and (assuming due authorization, execution and delivery by the other parties hereto and thereto) this Agreement constitutes, and upon execution and delivery thereof, the other Buyer Transaction Agreements will constitute, legal, valid and binding obligations of Buyer enforceable against Buyer in accordance with their respective terms, subject to the Bankruptcy and Equity Exception.

Section 5.02. No Conflict. Provided that all Consents and other actions described in Section 5.03 have been obtained, except as may result from any facts or circumstances relating to the Seller Parties, the Companies or their respective Affiliates, the execution, delivery and performance by Buyer of the Buyer Transaction Agreements do not and will not:

(i)     violate or conflict with in any material respect the certificate or articles of incorporation or bylaws or similar organizational documents of Buyer;

(ii)    conflict with or violate in any material respect any Law or Order applicable to Buyer; o

(iii)    result in any breach of, or constitute a default under, or give to any Person any right to terminate, amend, accelerate or cancel, or result in the creation of any Lien on any assets or properties of Buyer pursuant to, any note, bond, mortgage, indenture, contract, agreement, lease, license, permit, franchise or other material instrument to which Buyer or any of its Subsidiaries or Affiliates is a party or by which any of such assets or properties is bound, except for any such breaches, defaults, rights or Liens as would not materially impair or delay the ability of Buyer to consummate the Buyer Transactions or otherwise perform its obligations under the Buyer Transaction Agreements.

Section 5.03. Consents and Approvals. The execution, delivery and performance by Buyer of the Buyer Transaction Agreements do not and will not require any material Consent, waiver or other action by, or any material filing with or notification to, any Government Authority, except (a) in connection with applicable filing, notification, waiting period or approval requirements under applicable Regulatory Laws, (b) where the failure to obtain such Consent or waiver, to take such action or to make such filing or notification would not materially impair or delay the ability of Buyer to consummate the Buyer


Transactions or otherwise perform its obligations under the Buyer Transaction Agreements or (c) as may be necessary as a result of any facts or circumstances relating to the Seller Parties, the Companies or their respective Affiliates.

Section 5.04. Absence of Restraints; Compliance with Laws. As of the Agreement Date, Buyer is not in violation of any Laws or Orders applicable to the conduct of its business, except for violations the existence of which would not reasonably be expected to impair or delay the ability of Buyer to consummate the Buyer Transactions or otherwise perform its obligations under the Buyer Transaction Agreements.

Section 5.05. Securities Matters. Buyer is an “accredited investor” (as such term is defined in Rule 501 of Regulation D under the Securities Act). The Transferred Equity Interests are being acquired by Buyer for its own account, and not with a view to, or for the offer or sale in connection with, any public distribution or sale of the Transferred Equity Interests or any interest in them. Buyer has sufficient knowledge and experience in financial and business matters to be capable of evaluating the merits and risks of its investment in the Transferred Equity Interests, and Buyer is capable of bearing the economic risks of such investment, including a complete loss of its investment in the Transferred Equity Interests. Buyer acknowledges that the Transferred Equity Interests have not been registered under the Securities Act, or any securities Laws or any state or other jurisdiction (U.S. or non-U.S.), and understands and agrees that it may not sell or dispose of any Transferred Equity Interests except pursuant to a registered offering in compliance with, or in a transaction exempt from, the registration requirements of the Securities Act and any other applicable securities Laws of any state or other jurisdiction (U.S. or non-U.S.).

Section 5.06. Financial Ability; Solvency.

(a)Buyer will have at the Closing, (x) sufficient immediately available funds and the financial ability to pay the Purchase Price and to pay any expenses incurred by Buyer in connection therewith and (y) the resources and capabilities (financial and otherwise) to perform its obligations under the Transaction Agreements (including all payments to be made by it in connection herewith). Buyer has not incurred, and is not contemplating or aware of, any obligation, commitment, restriction or other Liability of any kind, in each case, that would impair or adversely affect such resources, funds or capabilities. Notwithstanding anything to the contrary contained herein, Buyer acknowledges and agrees that the obligations of Buyer under this Agreement (including, without limitation, Buyer’s obligations to consummate the Transactions) are not contingent upon Buyer having sufficient funds for the payment of the Purchase Price and the other amounts payable hereunder.

(b)Immediately after giving effect to the Closing, and the consummation of the Financing, and assuming the accuracy of the representations and warranties of Seller (determined without giving effect to materiality or Material Adverse Effect qualifications therein, except as provided in Section 4.08(b)), each of the Buyer and its Subsidiaries, including the Transferred Entities, on a consolidated basis, shall be solvent and shall (a) be able to pay their debts as they become due, (b) own property that has a fair saleable value greater than the amounts required to pay their debts (including a reasonable estimate of the amount of all contingent liabilities), and (c) have adequate capital to carry on their respective businesses.  No transfer of property is being made and no obligation is being incurred in connection with the transactions contemplated hereby with the intent to hinder, delay or defraud either present or future creditors of the Buyer or its Subsidiaries (including any Transferred Entity).

Section 5.07. Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission from Buyer or any of Buyer’s Affiliates in connection with any Transaction for which the Seller Parties would have any Liability.

Section 5.08. Investigation. Buyer acknowledges and agrees that it (a) has completed such inquiries and investigations as it has deemed appropriate into, and based thereon, has formed an independent judgment concerning, the Transferred Entities, the Transferred Equity Interests, the Transferred Assets, the Assumed Liabilities, the Business and Transactions, and any other rights or obligations to be transferred, directly or indirectly, pursuant to the Transaction Agreements and (b) has been furnished with, or given access to, projections, forecasts, estimates, appraisals, statements, data or information about the Seller Parties, the Transferred Entities, the Transferred Equity Interests, the Liabilities of the Transferred Entities, the Transferred Assets, the Assumed Liabilities, the Business and other rights or obligations to be transferred, directly or indirectly, pursuant to the Transaction Agreements, adequate for such purposes. Buyer further acknowledges and agrees that (x) the only representations and warranties made by Seller are the representations and warranties expressly set forth in Article IV (as modified by the Disclosure Schedules) or the other Transaction Agreements and Buyer has not relied upon any other express or implied representations, warranties or other projections, forecasts, estimates, appraisals, statements, data or information made, communicated or furnished by or on behalf of Seller or any of its Affiliates, any Representatives of Seller or any of its Affiliates or any other Person, including any projections, forecasts, estimates, appraisals, statements, advice, data or information made, communicated or furnished by or through the Seller Bankers, or management presentations, data rooms (electronic or otherwise) or other due diligence information, and that, except for the representations and warranties expressly set forth in Article IV or the other Transaction Agreements, Buyer will not have any right or remedy arising out of any such representation,


warranty or other projections, forecasts, estimates, appraisals, statements, advice, data or information and (y) any claims Buyer may have for breach of any representation or warranty shall be based solely on the representations and warranties of Seller expressly set forth in Article IV (as modified by the Disclosure Schedules) or the other Transaction Agreements. Except as otherwise expressly set forth in this Agreement and the other Transaction Agreements, Buyer understands and agrees that the Transferred Entities, the Transferred Equity Interests, the Business, the Transferred Assets and the Assumed Liabilities are being furnished subject only to the representations and warranties contained in Article IV (as modified by the Disclosure Schedules) or the other Transaction Agreements without any other representations or warranties of any nature whatsoever.

ARTICLE VI

ADDITIONAL AGREEMENTS

Section 6.01. Conduct of Business Before the Closing.

(a)Except (x) as required by applicable Law or as otherwise required by the Transaction Agreements and (y) for matters identified on Schedule 6.01, during the Pre-Closing Period unless Buyer otherwise consents in writing in advance (which consent shall not be unreasonably withheld, conditioned or delayed), Seller will, and will cause its Subsidiaries to, (a) conduct the Business in the ordinary course of business, (b) use reasonable best efforts consistent with past practice to preserve existing relationships of the Business with its employees, customers, vendors, suppliers and other material business partners in all material respects, and (c) solely with respect to the Business, not do any of the following:

i.grant any Lien on the Transferred Equity Interests, the equity interests of the Business Subsidiaries or any Transferred Assets (in each case, whether tangible or intangible), other than granting a Permitted Lien on any Transferred Assets in the ordinary course of business;

ii.acquire or dispose of any interest in or liquidate or dissolve (by merger, consolidation, acquisition or disposition of stock or assets or otherwise) any corporation, partnership or other business organization or division;

iii.issue, sell, transfer, grant or otherwise dispose of any shares of the capital stock or other equity interests of any Transferred Entity or securities convertible into or exchangeable thereto (except to the extent contemplated by Section 2.06);

iv.enter into or consummate any transaction involving the acquisition of assets or other properties of any other Person, other than (i) for an amount not exceeding $2,500,000 individually or $10,000,000 in the aggregate (but which shall not include real property) or (ii) in the ordinary course of business;

v.(A) grant or announce any increase in the wages, salaries, compensation, severance, bonuses, deferred compensation or incentives (including, for the avoidance of doubt, equity or equity-based incentives) payable to any Business Employee with an annual base salary above $150,000, (B) establish, adopt, terminate, amend, increase or promise to increase any benefits under any Employee Plan or (C) increase or accelerate the funding, payment or vesting of the compensation or benefits provided under any Business Plan or other Employee Plan that will be assumed by Buyer or its Affiliates as a result of this Agreement, except, in each case, (1) as required by Law, any Employee Plan or any contract in existence on the Agreement Date and made available to Buyer, (2) increases in wages, salaries, bonuses and incentives in the ordinary course of business consistent with past practice in the relevant market and (3) changes to benefits that are applicable to the covered employees of the Business and Seller generally or that result from ordinary course negotiations involving any labor union, works council, or equivalent employee representative body representing any Business Employees;

vi.(A) make any change in any method of accounting or accounting methodology, practice or policy used by the Business in the preparation of its financial statements, other than such changes as are consistent with the Transaction Accounting Principles or changes required by GAAP or applicable Law, (B) change policies, practices and procedures with respect to working capital or cash management, accrual of revenue, collection or accrual of accounts receivable, payment or accrual of expenses, accounts payable or other Liabilities in a manner inconsistent with past practice, (C) accelerate customer product delivery outside of normal purchase order practices, other than at the request of a customer and which do not exceed $15,000,000 in any fiscal quarter, or (D) provide discounts for accelerated product delivery (other than time value of money discounts in accordance with Seller’s accounting policies and consistent with past practice);

vii.enter into any settlement or release with respect to any Action relating to the Business other than (A) any settlement or release that contemplates only the payment of money in an amount not exceeding $2,500,000 individually or $15,000,000 in the aggregate and results in a full release of the claims giving rise to such Action,


(B) any settlement or release of any action relating to and material to the Business involving the payment of Liabilities to the extent that, with respect to any matter, such payment does not exceed the sum of (1) the applicable amount reflected or reserved against in the Financial Statements plus (2) $2,500,000; provided, however, that in the case of (A) and (B) such settlement or release shall not (x) be reasonably expected to have a material and adverse effect on another Action with underlying facts substantially similar to such Action made or, to the Knowledge of Seller, threatened against, the Business, the Transferred Entities or the Transferred Assets (which Seller would not be entitled to settle in accordance with this clause (vii)), (y) involve a criminal Action or admission of wrongdoing or (z) impose material ongoing limitations on the conduct or operation of the Business that will remain in effect after the Closing Date;

viii.other than in the ordinary course of business on an arm’s length basis, enter into any transactions, contracts or understandings with Affiliates that would be binding on the Transferred Entities or the Transferred Assets after the Closing;

ix.amend any Governing Documents of the Transferred Entities or JVs in a manner adverse to Buyer in any material respect;

x.enter into, renew, waive any material provision of, or modify in any material respect or terminate any Material Contract (or any contract or agreement that would qualify as such had such contract or agreement been entered into prior to the Agreement Date) other than (i) in the ordinary course of business, (ii) terminations of such contracts as a result of the material default or breach of any counterparty thereto in accordance with the terms thereof, (iii) auto-renewals of such contracts in accordance with the terms thereof (with applicable conforming amendments of a ministerial nature) or (iv) the expiration or termination of such contracts (other than any license agreement) pursuant to their terms;

xi.sell, transfer, lease, license or otherwise dispose of any Transferred Assets in excess of $1,000,000 individually or $5,000,000 in the aggregate, other than in the ordinary course of business;

xii.make aggregate capital expenditures (i) in excess of 110% of the applicable capital expenditure budget set forth on Schedule 6.01(a)(xii) (the “Capex Budget”), except for unanticipated capital expenditures that are necessary to maintain the value and functionality of the facilities of the Business (whether as a result of casualty or otherwise and whether or not covered by insurance), or (ii) of less than 90% of the applicable capital expenditure budget set forth in the Capex Budget, except for unanticipated interruptions in capital projects that interfere with Seller’s ability comply with this clause (ii), in each case, during any quarterly period;

xiii.(A) incur any Debt related to the Business other than (i) in the ordinary course of business or (ii) any Debt that constitutes Closing Debt or Excluded Liabilities or (B) make any loans or advances to or investment in any other Person in connection with the Business, in each case, in excess of $2,000,000 individually or $5,000,000 in the aggregate, other than routine advances to employees and consultants for business expenses, or extensions of trade credit and supplier advances, in each case, in the ordinary course of business;

xiv.(A) enter into, amend, extend or terminate any CBA (other than ordinary course negotiations involving any labor union, works council, or equivalent employee representative body representing any Business Employees) or (B) voluntarily recognize or certify any labor union or organization, works council, or group of employees as the bargaining representative for any Business Employees;

xv.(A) hire, materially modify the job responsibility of, or terminate (other than for “cause”) any Business Employee with annual base compensation above $150,000, (B) reassign the duties of any employee of Seller or its Subsidiaries with an annual base salary above $150,000 such that such individual ceases to be, or becomes, a Business Employee or (C) implement or effect any reduction in force, lay-off, early retirement program, severance program or other program concerning the termination of employment of Business Employees;

xvi.make, change or revoke any material Tax election, change any annual accounting period for Tax purposes, adopt or change any Tax accounting method, file any amended Tax Return, enter into any closing agreement of any Transferred Entity, settle or compromise any material Tax Claim asserted against any Transferred Entity, except, in each case, as related to Taxes paid on an affiliated, consolidated, combined or unitary basis or except as would not materially adversely affect the Tax liability of any Transferred Entity in a taxable period (or portion thereof) beginning after the Closing Date;

xvii.except in the ordinary course of business, enter into any KUBio Contract that involves, or that is reasonably expected to involve, aggregate payments in excess of $10,000,000 or amend, waive any provision of, or terminate any KUBio Contract; o


xviii.authorize, commit to or enter into any legally binding commitment with respect to any of the foregoing.

(b)Notwithstanding anything in this Agreement to the contrary (but subject to Section 2.05(a)) and without limiting Buyer’s right to receive any cash pursuant to Section 2.01(a)(iv) e Section 2.01(a)(v), the bank accounts maintained by Seller or any of its Subsidiaries in connection with the Business shall continue to be subject to Seller’s and its Subsidiaries’ daily cash sweep in its sole discretion.

(c)Nothing in this Section 6.01 shall be deemed to limit in any manner the transfer of Transferred Assets, Assumed Liabilities, Excluded Assets and Excluded Liabilities among Seller and its Subsidiaries prior to the Closing as contemplated by Section 2.06.

Section 6.02. Access to Information.

(a)During the Pre-Closing Period, upon reasonable prior notice, Seller shall, and shall cause each of its Subsidiaries to, (i) afford the Representatives of Buyer reasonable access, during normal business hours, to the properties, books and records or the portions thereof that relate to the Business and (ii) furnish to the Representatives of Buyer such additional financial and operating data and other information regarding the Business as Buyer or its Representatives may from time to time reasonably request for purposes of consummating the Transactions and preparing to operate the Business following the Closing.

(b)Notwithstanding anything in this Agreement to the contrary, and without limiting Seller’s obligations pursuant to Section 6.12, during the Pre-Closing Period,

i.(A) in no event shall Seller or its Subsidiaries be obligated to provide any (1) access or information in violation of any applicable Law, (2) information with respect to bids, the identity of any bidder, confidentiality or non-disclosure agreements, letters of intent, expressions of interest or other proposals received in connection with transactions comparable to those contemplated by this Agreement or any information or analysis relating to any such communications, (3) information the disclosure of which would jeopardize any applicable legal privilege (including the attorney-client privilege) available to Seller or any of its Subsidiaries relating to such information, (4) information the disclosure of which would cause Seller or any of its Subsidiaries to breach a confidentiality obligation to which it is bound (provided, in the case of clauses (1), (3) and (4), that (x) Seller shall use commercially reasonable efforts and work in good faith to develop substitute arrangements for providing information to Buyer that do not result in the loss of such privilege or the breach of such applicable Law or obligations, including by providing redacted information and using “clean room” arrangements to grant access to select Representatives of Buyer) or (5) consolidated Tax Return of Seller or any of its Subsidiaries (other than Tax Returns or any portions thereof that relate solely to the Transferred Entities) and (B) the investigation contemplated by Section 6.02(a) shall not unreasonably interfere with any of the businesses, personnel or operations of Seller or any of its Subsidiaries or require the creation or delivery of financial statements other than as required by other provisions of this Agreement;

ii.the auditors and accountants of any of Seller or any of its Subsidiaries shall not be obligated to make any work papers available to any Person except in accordance with such auditors’ and accountants’ normal disclosure procedures and then only after such Person has signed a customary agreement relating to such access to work papers in form and substance reasonably acceptable to such auditors or accountants;

iii.before the Closing, Buyer shall not conduct, without the prior written consent of Seller, which Seller may withhold for any reason, any intrusive environmental investigation at any property affiliated with the Business or with Seller or any of its Subsidiaries, including any sampling, testing or other intrusive indoor or outdoor investigation of soil, subsurface strata, surface water, groundwater, sediments or ambient air at or in connection with any property associated or affiliated in any way with the Business, Seller or any of its Subsidiaries;

iv.before the Closing, without the prior consent of Seller or its Representatives (which consent shall not be unreasonably delayed, conditioned or withheld solely in the case of contacts with employees) neither Buyer nor any of its Representatives shall contact any employees of, suppliers to, or customers of Seller or any of its Subsidiaries in connection with or with respect to this Agreement, any other Transaction Agreement or any Transaction, or to otherwise discuss the business or operations of any Transferred Entity or the Business; e

v.none of Seller nor any of its Subsidiaries shall be required, before the Closing, to disclose, or cause or seek to cause the disclosure of, to Buyer or its Affiliates or Representatives (or provide access to any properties, books or records of Seller or any of its Subsidiaries that would reasonably be expected to result in the disclosure to such persons or others of) any competitively sensitive confidential information relating to Trade Secrets, proprietary know-how,


processes, trademark applications, trade name applications, service mark applications, copyright applications or product development, or pricing and marketing plans, nor shall Seller or any of its Subsidiaries be required to permit or cause or seek to cause others to permit Buyer or its Affiliates or Representatives to have access to or to copy or remove from the properties of Seller or any of its Subsidiaries any documents, drawings or other materials that would reveal any such Confidential Information; provided that Seller shall use commercially reasonable efforts and work in good faith to develop substitute arrangements for providing such information to Buyer, including by providing redacted information and using “clean room” arrangements to grant access to select Representatives of Buyer.

(c)If so requested by Seller, Buyer shall enter into a customary joint defense agreement or common interest agreement with one or more of Seller or any of its Subsidiaries with respect to any information provided to Buyer, or to which Buyer gains access, pursuant to this Section 6.02 or otherwise.

Section 6.03. Confidentiality.

(a)The terms of the Confidentiality Agreement are incorporated into this Agreement by reference and shall continue in full force and effect (and all obligations thereunder shall be binding upon Buyer and its Representatives (as defined in the Confidentiality Agreement) as if parties thereto) until the Closing, at which time the obligations under the Confidentiality Agreement shall terminate; provided, however, that Buyer’s confidentiality obligations shall terminate only in respect of that portion of the Evaluation Materials (as defined in the Confidentiality Agreement) to the extent relating to the Transferred Entities or the Business, and for all other Evaluation Materials the Confidentiality Agreement shall continue in full force and effect in accordance with its terms. If for any reason the Closing does not occur, the Confidentiality Agreement shall continue in full force and effect in accordance with its terms.

(b)Following the Closing and for a period of seven (7) years thereafter (other than with respect to Trade Secrets, to which such limit shall not apply), except as required by Law, Seller shall not, and shall cause each Seller Party not to, disclose to any other Person or use in any manner (other than Seller’s compliance with any Transaction Agreement) any Confidential Information to the extent related to the Business or the Transferred Assets, except to the extent that such Confidential Information (i) was or becomes in the public domain other than as a result of a disclosure or other action (or failure to act) by Seller or any of its Affiliates in violation of this Section 6.03(b), (ii) is lawfully acquired by Seller or its Affiliates after the Closing on a non-confidential basis or (iii) relates to both the Business and the other businesses, assets or Liabilities of Seller or its Subsidiaries (it being understood that any portion of such Confidential Information relating solely to the Business shall not be excluded by this clause (iii)). If Seller undergoes an initial public offering of its healthcare division, or if Seller sells all or substantially all of its healthcare division to a third party, then the provisions of this Section 6.03(b) shall continue to apply to such resulting or sold entity as if such entity was Seller hereunder.  Seller shall, prior to any such transaction, secure from such transferred or sold entity an executed joinder agreement to the terms of this Section 6.03(b) that is directly enforceable by Buyer.

Section 6.04. Regulatory and Other Authorizations; Consents.

(a)Subject to the terms and conditions set forth in this Agreement, each of the Parties shall, and shall cause each of its Subsidiaries to, use its reasonable best efforts (subject to compliance with applicable Law) to promptly take, or cause to be taken, all actions, and to promptly do, or cause to be done, and to assist and cooperate with the other Party in doing, all things necessary, proper or advisable under applicable Laws to consummate and make effective the Transactions, including (i) promptly obtaining all authorizations, consents, Orders, approvals, licenses, Permits, and waivers of all Government Authorities and officials that may be or become necessary for the performance of its obligations pursuant to this Agreement (collectively, the “Government Approvals”), (ii) cooperating fully with the other Party in promptly seeking to obtain all such authorizations, consents, Orders, approvals, licenses, Permits and waivers, (iii) providing such other information to any Government Authority as such Government Authority may lawfully request in connection herewith and (iv) obtaining all consents, approvals or waivers from third parties that are (A) necessary to consummate the Transactions or (B) disclosed in the Disclosure Schedules; provided, that, notwithstanding the foregoing, none of Seller, any Subsidiary of Seller or Buyer or any Subsidiary of Buyer shall be required to make any payments or concessions in connection with the fulfillment of its obligations in this Section 6.04(a)(iv) and that neither Seller nor any of its Subsidiaries shall pay any consideration or make any agreements or commitments in connection with any such necessary consents, approvals or waivers without the prior written consent of Buyer. As promptly as Buyer deems advisable (after consulting with, and considering in good faith the views of Seller) following the Agreement Date, but no later than sixty (60) days after the Agreement Date, each Party shall make its respective filing, if necessary, pursuant to the HSR Act with respect to the Transactions and shall supply as promptly as reasonably practicable thereafter to the appropriate Government Authorities any additional information and documentary material that may be requested pursuant to the HSR Act. Each Party agrees to make as promptly as Buyer deems advisable (after consulting with, and considering in good faith the views of Seller) its respective filings and notifications, if any, under any other applicable


Regulatory Law, and to supply as promptly as reasonably practicable to the appropriate Government Authorities any additional information and documentary material that may be requested pursuant to the applicable Regulatory Law.

(b)Without limiting the generality of the undertaking of Buyer pursuant to Section 6.04(a), Buyer shall, and shall cause each of its Subsidiaries to, use its and their best efforts, and take any and all steps necessary to avoid or eliminate each and every impediment under any Regulatory Law that may be asserted by any Government Authority or any other Persons (“Regulatory Law Impediment” ) so as to enable the Parties to consummate the Transactions as promptly as practicable, and in any event prior to the Outside Date, including proposing, negotiating, committing to and effecting, by consent decree, hold separate orders, or otherwise, the sale, divestiture, license or other disposition of such of its and their assets, properties or businesses or of the assets, properties or businesses to be acquired by Buyer pursuant hereto, and entering into behavioral or conduct remedies and such other actions or arrangements, as are necessary or advisable in order to avoid any Regulatory Law Impediment, including the entry of, and the commencement of litigation seeking the entry of, or to effect the dissolution of, any injunction, temporary restraining order or other Order in any suit or proceeding by a Government Authority or any other person under Regulatory Laws that would otherwise have the effect of materially delaying or preventing the consummation of the Transactions; provided, that, notwithstanding the foregoing provisions of this Section 6.04(b) or any other provision of this Agreement, in no event shall Buyer or any of its Subsidiaries be required to agree to (nor shall Seller or any of its Subsidiaries be permitted to agree unless Buyer so directs them (and they shall, if Buyer so directs, agree to, so long as such agreements are limited to the Business and are conditioned upon the Closing)), any action, concession or undertaking, unless such action, concession or undertaking is conditioned on the Closing. In addition, Buyer shall defend through litigation on the merits any Claim asserted in court by any Government Authority or any other person under Regulatory Laws in order to avoid entry of, or to have vacated or terminated, any Order (whether temporary, preliminary or permanent) that would prevent the Closing prior to the Outside Date; provided, however, that such obligation to litigate in no way limits the obligation of Buyer to use, and cause each of its Subsidiaries to use, its and their best efforts, and to take any and all steps necessary to eliminate each and every impediment under any Regulatory Law to consummate the Transactions prior to the Outside Date.

(c)Each Party shall keep the other Party apprised of the content and status of any communications with, and communications from, any Government Authority with respect to the Transactions, including promptly notifying the other Party of any material communication it or any of its Affiliates receives from any Government Authority relating to any review or investigation of the Transactions under the HSR Act or any other applicable non-United States Regulatory Laws and shall permit the other Party to review in advance (and to consider any comments made by the other Party in relation to) any proposed substantive communication by such Party to any Government Authority relating to such matters. None of the Parties shall agree to participate in any substantive meeting, telephone call or discussion with any Government Authority in respect of any submissions, filings, investigation (including any settlement of the investigation), litigation or other inquiry relating to the matters that are the subject of this Agreement unless it consults with the other Party in advance and, to the extent permitted by such Government Authority, gives the other Party the opportunity to attend and participate at such meeting, telephone call or discussion. The Parties will coordinate and cooperate fully with each other in exchanging such information and providing such assistance as the other Party may reasonably request in connection with the foregoing and in seeking early termination of any applicable waiting periods, including under the HSR Act. The Parties shall provide each other with copies of all correspondence, filings or communications between them or any of their representatives, on the one hand, and any Government Authority or members of its staff, on the other hand, with respect to this Agreement and the transactions contemplated by this Agreement; provided, however, that materials may be redacted (i) to remove references concerning the valuation of the Business, (ii) as necessary to comply with contractual arrangements and (iii) as necessary to address reasonable attorney-client or other privilege or confidentiality concerns; provided, further, that each Party may reasonably designate materials, including materials submitted with that Party’s regulatory filings, as “Outside Counsel Only” or “Outside Advisors Only,” in which case access to such materials shall be restricted accordingly. Notwithstanding anything to the contrary contained in this Agreement, but subject to Seller’s consultation and participation rights described above, Buyer shall have the principal responsibility for devising and implementing the strategy for obtaining any necessary antitrust, competition or investment review clearances as promptly as practicable, and in any event prior to the Outside Date, including in connection with the determination of any actions to be taken under Section 6.04(b), and shall take the lead in all meetings and communications with any Government Authority in connection with obtaining any necessary antitrust, competition or investment review clearances; provided, however, that if by December 31, 2019 any Required Approval has not been obtained or agreed to in principle with the applicable Government Authority and such Required Approval has not been waived, Buyer will use its best efforts in its interactions with any such Government Authority to cause such Government Authority to offer a path or paths forward that would resolve such Government Authority’s concerns as promptly as practicable thereafter.

(d)Buyer shall not enter into any agreement, transaction or any agreement to effect any transaction (including any merger or acquisition) that would reasonably be expected to materially delay or materially and adversely affect Buyer’s ability to (i) obtain the timely expiration or termination of the waiting period under the HSR Act, or the authorizations, consents, Orders and approvals required under any other applicable Regulatory Law, applicable to the


transactions contemplated by this Agreement, (ii) avoid the entry of, the commencement of litigation seeking the entry of, or to effect the dissolution of, any injunction, temporary restraining order or other Order that would materially delay or prevent the consummation of the Transactions, or (iii) obtain all authorizations, consents, Orders and approvals of Government Authorities necessary for the consummation of the Transactions in accordance with the terms and conditions of this Agreement.

Section 6.05. Permits. Seller will use reasonable best efforts to provide Buyer with a list of all material Permits necessary for Buyer to own and operate the Business, the Transferred Entities or the Transferred Assets, as promptly as practicable following the Agreement Date. Seller and its Affiliates shall use its reasonable best efforts to assist Buyer in obtaining any Permits necessary (or that may become necessary) for Buyer to own or operate the Business, the Transferred Entities or the Transferred Assets. Notwithstanding anything to the contrary herein, no Seller Party, nor any of their Subsidiaries, shall be required to compensate any third party, commence or participate in any Action or offer or grant any accommodation (financial or otherwise, including any accommodation or arrangement to indemnify, remain secondarily liable or contingently liable for any Assumed Liability) to any third party in connection with the Seller Parties’ obligations under this Section 6.05, in each case other than payment obligations that are borne by Buyer. If any such Permit is not obtained prior to the Closing, Seller, its Affiliates and Buyer shall cooperate in good faith to enter into a reasonable transitional arrangement (to the extent permitted by the terms of the applicable Permit and applicable Law and at Buyer’s sole expense) under which Buyer shall obtain the benefit of such Permit in connection with the ownership or operation of the Business, the Transferred Entities or the Transferred Assets; provided that in the case of any such arrangement, without limiting the second sentence of this Section 6.05, Buyer shall use reasonable best efforts to obtain the applicable Permit as promptly as practicable after the Closing.

Section 6.06. Guarantees; Other Obligations.

(a)As promptly as practicable following the Agreement Date, Seller shall provide to Buyer a schedule listing all of the outstanding Seller Guarantees. At or before the Closing, Buyer shall use reasonable best efforts to (i) arrange for substitute letters of credit, Buyer guarantees and other obligations to replace any outstanding Seller Guarantees or (ii) to the extent permitted by applicable Law and the terms thereof, assume all obligations (solely to the extent constituting Assumed Liabilities) under each Seller Guarantee, and obtain from the creditor, beneficiary or other counterparty a full release (in a form satisfactory to Seller) of all parties liable, directly or indirectly, for reimbursement to the creditor or fulfillment of other obligations to a beneficiary or counterparty in connection with amounts drawn under the Seller Guarantees (solely to the extent relating to the Business). In furtherance and not in limitation of the foregoing, Seller shall reasonably cooperate with Buyer and have the primary responsibility to direct the process by which the Parties approach the beneficiaries or counterparties of such Seller Guarantees, including by taking the lead in all meetings, discussions and communications with beneficiaries or counterparties. To the extent the beneficiary or counterparty under any Seller Guarantees does not accept any such substitute letter of credit, Buyer guarantee or other obligation proffered by Buyer and Buyer is not permitted to assume or cause to be assumed any such Seller Guarantee in accordance with the foregoing clause (ii) from and after the Closing, Buyer shall (x) indemnify, defend and hold harmless Seller and its Subsidiaries against, and reimburse Seller and its Subsidiaries for, all amounts paid that are reasonably incurred, including reasonable and documented out-of-pocket costs or expenses in connection with such Seller Guarantees, including Seller’s and its Subsidiaries’ reasonable and documented out-of-pocket costs or expenses in maintaining such Seller Guarantees, whether or not any such Seller Guarantee is drawn upon or required to be performed, and shall in any event promptly reimburse Seller and its Subsidiaries to the extent any Seller Guarantee is drawn upon and Seller or any of its Subsidiaries makes any payment or reimburses the party issuing the Seller Guarantee and (y) not without Seller’s prior written consent, amend in any manner adverse to Seller or any of its Subsidiaries, or extend (or permit the extension of), any Seller Guarantee or any obligation supported by any Seller Guarantee.

(b)Except for those Intercompany Agreements specifically contemplated by this Agreement or the Transaction Agreements to survive the Closing or to the extent necessary to effectuate Section 6.07(b), Seller shall terminate or cause to be terminated all Intercompany Agreements, in each case without any Liability to Buyer, the Business or any of Buyer’s Affiliates (including the Transferred Entities).

(c)Prior to the Closing, the Seller Parties shall use commercially reasonable efforts, in consultation and cooperation with Buyer, to identify, pay off, discharge and satisfy in full, or cause the Transferred Entities and the JVs to identify, pay off, discharge and satisfy in full, all liabilities pursuant to any Related Party Financing (each such payment, a “Related Party Financing Payment”). The Parties agree that for purposes of this Agreement, (x) the Related Party Financing Payments, if any, shall be deemed to occur prior in time to the payment of the Purchase Price; (y) a Related Party Financing Payment shall be deemed to occur prior to Buyer or any Buyer Affiliate taking title to any equity interest in the applicable Transferred Entity or JV that is the obligor in respect of the applicable Related Party Financing Payment; and (z) Buyer and its respective Affiliates will take title to any equity interest of a Transferred Entity or JV only following the satisfaction of the Related Party Financing Payment in respect of which such Transferred Entity or JV is the obligor. If fewer than all the Related Party Financing Payments have been made by Closing, the Parties agree to treat the Transferred Entity or


JV that is the obligor in respect of any such Related Party Financing Payment that remains unpaid as of the Closing as a Deferred Business and the applicable Related Party Financing Payment as a Legal Restraint with the provisions of Section 2.05 applying mutatis mutandis to the transfer thereof, such that the interests in the applicable Transferred Entity or JV shall not be transferred to Buyer prior to the applicable Related Party Financing Payment.

Section 6.07. Cooperation.

(a)During the Pre-Closing Period, each of Seller and Buyer shall, and shall cause their respective Affiliates to, (i) except where greater efforts or outright non-efforts based obligations are expressly required by the terms of this Agreement, use reasonable best efforts to cause all Closing Conditions of the other Party to be met as promptly as practicable after the Agreement Date and in any event on or before the Outside Date and (ii) without limiting any other obligations set forth in this Agreement, keep the other Party reasonably apprised of the status of the matters relating to the completion of the Transactions, including with respect to the negotiations relating to the satisfaction of the Closing Conditions of the other Party. Questo Section 6.06(c) shall not apply with respect to Government Approvals, which are governed solely by Section 6.04.

(b)As soon as practicable after the Agreement Date, the Parties shall cooperate in good faith to develop a plan for separating the Business from the other businesses of Seller and its Affiliates (other than the Transferred Entities) so as to minimize the adverse impact of such separation on each Party’s business. Without limiting the foregoing, and as soon as practicable after the Agreement Date, Seller shall use reasonable best efforts to separate the data related to the Business from the data relating to the other businesses of Seller and its Affiliates (other than the Transferred Entities), including (i) the migration of employees unrelated to the Business to an information system separate from the Business Systems, (ii) the duplication for the Business of enterprise applications that are shared between the Business, on the one hand, and the other businesses of Seller and its Affiliates (other than the Transferred Entities), on the other hand, (iii) the separation of electronic data related to the Business from Seller’s systems and the transfer and integration of such electronic data to the Business Systems and (iv) the separation and removal of electronic data unrelated to the Business from the Business Systems.

Section 6.08. Shared Space Agreements. If, from and after the execution of this Agreement, until the date that is three (3) months after the Closing Date, either Party determines that (i) a portion of the business of Seller or its Subsidiaries (other than the Business) is being conducted at any Transferred Real Property or (ii) a portion of the Business is being conducted at any Retained Real Property, then each such property identified by Buyer or Seller, as the case may be, shall constitute a Shared Location. Upon identification of such Shared Location, Buyer and Seller shall work in good faith to determine the feasibility of separating the business operations of the parties at such Shared Location and/or relocating the operations to another property. If, notwithstanding such good-faith efforts, the parties are unable to agree on a mutually satisfactory plan for separating the business operations of the parties and/or relocating the operations, Buyer and Seller shall negotiate in good faith and cooperate to prepare, as soon as reasonably practicable, a Shared Space Agreement for each such Shared Location. Each such Shared Space Agreement shall take into account the specific use by each party of the applicable Shared Location and the other specific characteristics of such Shared Location. To the extent such Shared Space Agreement concerns any leased real property, such Shared Space Agreement shall take into consideration the terms of the applicable lease, sublease or license. To the extent such Shared Space Agreement concerns any owned real property, such Shared Space Agreement shall be on customary and market terms reflecting the characteristics and location of the applicable Shared Location (subject to terms reflecting the particular business plans and business needs of the parties and approved by the parties, each acting reasonably). Seller shall use reasonable best efforts to complete the separation of Shared Locations such that the Business Employees and the operations of the Business are segregated from the other employees and operations of the other businesses conducted by Seller at the Shared Locations prior to or at the Closing and all costs associated with such separations shall be borne by Seller.

Section 6.09. Subject Jurisdiction Put Options.

(a)Notwithstanding any other provision of this Agreement, this Agreement shall not constitute a binding agreement to sell or purchase any of the Subject Jurisdiction Businesses until the Subject Jurisdiction Put Option with respect to the applicable Business is exercised.

(b)In the event that the Subject Jurisdiction Put Option is exercised with respect to any Subject Jurisdiction Business on or prior to Closing, this Section 6.09 shall terminate and shall cease to have effect with respect to such applicable Subject Jurisdiction Business.

(c)In the event that the Subject Jurisdiction Put Option is not exercised on or prior to Closing with respect to any Subject Jurisdiction:


i.Section 2.01 e Article VIII (the “Disapplied Provisions”) shall not apply to such Subject Jurisdiction Business at the Closing;

ii.in respect of the Disapplied Provisions, (A) the term “Business” shall be deemed to exclude such Subject Jurisdiction Business, (B) the term “Transferred Entities” shall be deemed to exclude the applicable Subject Jurisdiction Transferred Entities, (C) the term “Transferred Assets” shall be deemed to exclude the applicable Subject Jurisdiction Transferred Assets, (D) the term “Assumed Liabilities” shall be deemed to exclude the applicable Subject Jurisdiction Assumed Liabilities and (E) the term “Business Employees” shall be deemed to exclude the applicable Subject Jurisdiction Employees;

iii.the parties shall negotiate in good faith to agree on any amendments to this Agreement, the Transition Services Agreement, the Local Transfer Agreements and the other Transaction Agreements as may be required in order to give effect to the principles set forth in this Section 6.09; e

iv.the Purchase Price shall be reduced as mutually agreed by Seller and Buyer.

Section 6.10. Subject Jurisdiction Put Option Terms.

i.Upon exercise by Seller of any Subject Jurisdiction Put Option, Buyer hereby promises and undertakes to purchase from the Seller Parties all (and not a portion) of the Subject Jurisdiction Transferred Equity Interests, Subject Jurisdiction Transferred Assets and Subject Jurisdiction Assumed Liabilities in accordance with and subject to the terms and conditions specified in this Agreement with respect to any Subject Jurisdiction (each, a “Subject Jurisdiction Put Option”), it being understood that, for the sake of clarity, if any Subject Jurisdiction Put Option is exercised prior to Closing, the Subject Jurisdiction Transferred Equity Interests, Subject Jurisdiction Transferred Assets and Subject Jurisdiction Assumed Liabilities with respect to the applicable Subject Jurisdiction shall be included in the Transferred Equity Interests, Transferred Assets and Assumed Liabilities and the purchase price for such Subject Jurisdiction Transferred Equity Interests, Subject Jurisdiction Transferred Equity Interests and Subject Jurisdiction Assumed Liabilities shall be included in the computation of the Purchase Price.

ii.Seller hereby accepts the benefit of the Subject Jurisdiction Put Option and may, at its own discretion and option, elect to exercise the Subject Jurisdiction Put Option in accordance with the procedures set forth herein, without having Seller being committed to sell to Buyer the Subject Jurisdiction Business. Seller shall only be entitled to exercise the Subject Jurisdiction Put Option for all (and not a portion) of the Subject Jurisdiction Transferred Equity Interests, Subject Jurisdiction Transferred Assets and Subject Jurisdiction Assumed Liabilities in each Subject Jurisdiction. Seller undertakes that the applicable Seller Party owns and will own all the issued and outstanding equity interests in the Subsidiaries in each Subject Jurisdiction until each Subject Jurisdiction Put Option is exercised or terminated.

iii.The Subject Jurisdiction Put Option will enter into force at the Agreement Date.

iv.The Subject Jurisdiction Put Option may be exercised by Seller at any time, after the date upon which all of the information and consultation processes of the applicable Works’ Council(s) have been completed in accordance with the applicable Laws, until the Expiry Date, by sending to Buyer a notice, in form set out under Schedule 6.10(iv) (the “Exercise Notice”).

v.If Seller has not exercised the Subject Jurisdiction Put Option with respect to any Subject Jurisdiction Business on or before the Expiry Date, then, the Subject Jurisdiction Put Option with respect to such Subject Jurisdiction Business shall automatically lapse, without any action on the part of either party.

vi.As soon as practicable, Seller will cause its relevant Subsidiaries (i) to initiate the information and consultation processes of the relevant employee representative bodies required under applicable Laws in the Subject Jurisdictions (collectively, the “Works Councils”) in connection with the sale of the Subject Jurisdiction Business and (ii) to use their reasonable best efforts to pursue diligently such procedures in accordance with applicable laws and regulations and to obtain the delivery of the Works Councils’ opinions as soon as possible.

vii.The Parties shall keep each other regularly informed of the status of each these processes, consult with each other in good faith in obtaining such opinions and provide to each other Party a copy of the opinions of the Works Councils (to the extent available) as soon as possible after obtaining such opinions.

viii.Each Subject Jurisdiction Put Option shall automatically terminate on the earlier of (a) the valid termination of this Agreement and (b) the date that is sixty (60) Business Days after Seller’s receipt of the final opinion from the Works Council in the applicable Subject Jurisdiction in connection with the Transaction or, in the absence of


any opinion, the date upon which the Works Council is deemed to have issued a negative opinion under applicable Law (the “Expiry Date”), unless the Subject Jurisdiction Put Option is exercised on or prior to such date.

Section 6.11. Factored Receivables; Trade Payables Program.

(a)The Factoring Entities do not own or hold any Transferred Assets other than the Factored Receivables and do not hold any Assumed Liabilities. None of the Factoring Entities shall be deemed to have any obligations hereunder, other than to transfer at the Effective Time the Factored Receivables. Prior to or at the Closing Date, Seller shall cause each Factoring Entity to enter into the Factored Receivables Bill of Sale, pursuant to which such Factoring Entity shall transfer to Buyer or any other Person designated by Buyer at Closing the Factored Receivables.

(b)Notwithstanding anything to the contrary set forth in this Agreement (including Section 6.01), Buyer and Seller have agreed that the Business may continue to sell and securitize its receivables to the Factoring Entities from the Agreement Date through the Closing in the ordinary course of Business (provided, that only Seller (including GE Capital) and Genpact on Seller’s behalf may interface with customers of the Business), and that Buyer shall purchase the Factored Receivables from each Factoring Entity at the Effective Time pursuant to and in accordance with the terms of this Agreement and the Factored Receivables Bill of Sale.

(c)From and after April 1, 2019, Seller shall discontinue new originations under the Trade Payables Program and discontinue the Trade Payables Program between the Agreement Date and the Closing Date through natural runoff.

(d)For the purpose of calculating the amount of the Closing Payment, the Estimated Purchase Price Adjustment and the Final Purchase Price Adjustment, in each case in U.S. dollars, under Article III hereof, (i) all non-U.S. dollar cash set forth on the applicable schedules of the Factored Receivables Bill of Sale entered into in connection with the consummation of the Transactions and (ii) any amounts of any local jurisdiction wires to be delivered at Closing that Buyer and Seller have mutually agreed pursuant to a Local Transfer Agreement shall be delivered in a foreign currency will, in the case of each of (i) and (ii), be converted to U.S. dollars using mid-rate (between the applicable local currency and U.S. dollars) as shown on the BFIX page on Bloomberg at 11:00 am GMT, on March 20, 2020 prior to the Closing Date (except for India, which shall be converted into U.S. dollars using such rate as shown on the BFIX page on Bloomberg at 11:00 am GMT on March 13, 2020).

Section 6.12. Financing Cooperation.

(a)Prior to the Closing, Seller will, and will cause its Subsidiaries to, and will use reasonable best efforts to cause its Representatives to, on a timely basis, provide to Buyer all cooperation reasonably requested by Buyer in connection with the arrangement, marketing, syndication and consummation of any financing deemed reasonably necessary or advisable by Buyer in connection with the Transactions (including any customary debt securities offering to be issued or incurred in lieu of all or a portion of any bridge facility, the “Financing”) (provided, however, that such requested cooperation does not unreasonably interfere with the ongoing operations of Seller or the Business, it being acknowledged that the required cooperation set forth in the clauses below shall not be deemed as unreasonable interference, and does not cause any covenant, representation or warranty to be breached or to fail to be satisfied or otherwise cause a breach of this Agreement), including:

i.making the senior officers of the Business available to the debt financing sources (including the Lender Related Parties) for a reasonable number of investor and lender meetings (including “road shows”), presentations and sessions with rating agencies at reasonable times upon reasonable advance notice;

ii.as promptly as reasonably practicable, using reasonable best efforts to provide all information reasonably requested by such debt financing sources (including the Lender Related Parties) in connection with such Financing, including to assist in the preparation of any pro forma financial statements required in connection therewith and/or under SEC rules applicable to Buyer, including with respect to the estimated impact of the application of acquisition accounting in accordance with GAAP to the Seller’s historical financial statements together with related footnote disclosures and supporting information to Buyer’s independent auditors to enable such auditors to provide customary comfort on such pro forma financial statements, it being agreed that Seller will not be required to provide any information relating to (A) the proposed aggregate amount of debt and equity financing (if any), together with assumed interest rates, dividends (if any) and fees and expenses relating to the incurrence of such debt or equity financing; (B) any post-Closing or pro forma cost savings, synergies, capitalization, ownership or other pro forma adjustments desired to be incorporated into any information used in connection with the Financing; or (C) any financial information related to Buyer or any of its Subsidiaries or any adjustments that are not directly related to the acquisition of the Business by Buyer;


iii.informing Buyer, as promptly as reasonably practicable, after Seller or its Subsidiaries have knowledge of any facts that would be reasonably expected to require the restatement of any financial statements of the Business in order for such financial statements to comply with GAAP;

iv.reasonably assisting Buyer with the preparation of materials for rating agency presentations, bank information memoranda, lender presentations, offering memoranda, private placement memoranda, prospectuses and similar marketing documents (including participation in a reasonable number of due diligence sessions, drafting session and sessions with ratings agencies);

v.executing and delivering as of (but not prior to) the Closing any guarantee, pledge and security documents, other definitive financing documents, customary closing certificates as may be required by the Financing or other certificates or documents as may be reasonably requested by Buyer and otherwise reasonably facilitating the making of guarantees, the pledging of collateral and the perfection of applicable security interests (including cooperation in connection with the pay-off of existing indebtedness to the extent contemplated by this Agreement and the release of related Liens and termination of security interests (including delivering prepayment or termination notices as required by the terms of any existing indebtedness and delivering termination agreements or UCC-3 or equivalent financing statements or notices)); provided, that (A) none of the documents or certificates shall be executed and/or delivered except in connection with the Closing (except for customary authorization letters, management representation letters and a “CFO certificate” with respect to due diligence items related to any offering memorandum, which shall be executed by a financial officer of Seller or the Business prior to Closing (in each case relating to the Business and its Subsidiaries)), (B) the effectiveness thereof shall be conditioned upon, or become operative after, the occurrence of the Closing, (C) neither Seller nor any of its Subsidiaries will be required to execute any document or instrument, or adopt any resolution or other corporate action in respect of financing arrangement of Buyer or its Subsidiaries (other than the Transferred Entities) and (D) no Liability shall be imposed on Seller or any of its Subsidiaries or any of their respective officers or employees;

vi.causing to be taken corporate and other actions by any Transferred Entity that are reasonably necessary to permit the consummation of the Financing on the Closing Date and to permit the proceeds thereof to be made available to Buyer as of the Closing; it being understood and agreed that (A) no such corporate or other action will take effect prior to the Closing and (B) any such corporate or other action will only be required of the directors, members, partners, managers or officers of the Transferred Entities who hold such positions as of the Closing and will act in a similar capacity after the Closing;

vii.providing, as promptly as reasonably practicable but no later than three (3) Business Days prior to the Closing, all documentation and other information about the Business and its Subsidiaries as is reasonably required under applicable “know your customer.” anti-money laundering rules and regulations including the USA PATRIOT Act and beneficial ownership regulations of 31 C.F.R. § 1010.230, in each case to the extent requested at least ten (10) Business Days in advance of the Closing;

viii.reasonably cooperating with financing sources’ (including the Lender Related Parties’) customary due diligence and marketing efforts, including access to documentation and “factual backup” support reasonably requested by such financing sources (including the Lender Related Parties) and their counsel; e

ix.using reasonable best efforts to cause independent auditors to provide, consistent with customary practice, consents to the use of their reports in any materials relating to the Financing or Current Reports on Form 8-K and other documents to be filed with the SEC and to deliver customary comfort letters (including customary negative assurance and change period comfort) to the financing sources (including the Lender Related Parties).

Notwithstanding the foregoing, nothing in this Agreement shall require Seller or any of its Subsidiaries or any of their respective Representatives (1) to take any action that would reasonably be expected to conflict with or violate any of the provisions of the certificate of incorporation or by-laws (or equivalent organizational documents) of Seller or any of its Subsidiaries or any Law, (2) to pay any commitment or similar fee, reimburse any third party expenses, provide any indemnities in connection with any such Financing (except to the extent Buyer promptly reimburses (in the case of out-of-pocket costs) or provides the funding (in all other cases) to Seller or any of its Subsidiaries therefor) or incur or assume any liability or obligation in connection with the Financing, (3) to provide any information that would violate any obligations of confidentiality or result in a violation of Law or loss of any legal privilege. Buyer shall promptly upon written request by Seller, reimburse Seller for all reasonable and documented out-of-pocket costs (including reasonable attorneys’ fees) incurred by Seller or any of its Subsidiaries in performing their obligations under this Section 6.12, and indemnify Seller for any and all liabilities, losses, damages, claims, costs, expenses, interest, awards, judgments and penalties suffered or incurred by Seller or any of its Subsidiaries arising therefrom, except to the extent such losses result from the gross negligence, willful misconduct or bad faith of Seller, its Subsidiaries or their respective Affiliates and Representatives in connection with the Financing. Tutti


non-public or other confidential information provided by Seller or any of its Representatives pursuant to this Section 6.12 shall be kept confidential in accordance with the Confidentiality Agreement, except that Buyer shall be permitted to disclose such information to potential financing sources (including the Lender Related Parties) and to ratings agencies and their respective counsel during the syndication and marketing of any Financing, subject to customary confidentiality undertakings by such potential financing sources.

(b)Seller hereby consents to the use of its logos in connection with the Financing; provided that Buyer shall ensure that such logos are used in connection with the Financing in a manner that is not intended to or reasonably likely to harm or disparage Seller or Seller’s reputation or goodwill and will comply with Seller’s usage requirements to the extent made available to Buyer prior to such use.

Section 6.13. Delivery of Financial Statements.

(a)Seller shall use reasonable best efforts to deliver true and complete copies of the Audited Financial Statements (which shall be compliant with Regulation S-X Rule 3-05) for the fiscal years ended December 31, 2018 and 2017 to Buyer within five (5) months following the Agreement Date and to cause the Audited Financial Statements to be accompanied by (i) a report and an unqualified opinion of KPMG, prepared in accordance with GAAP, (ii) a reconciliation explaining in reasonable detail the differences between the Unaudited Financial Statements and the Audited Financial Statements, and (iii) a copy of the customary management representation letter provided to KPMG by Seller (and Seller shall use reasonable best effort to facilitate any update or bring-down procedures related thereto) (clauses (i) and (iii), the “Accompanying Materials”). Seller shall use reasonable best efforts to deliver (x) true and complete copies of the Audited Financial Statements for each fiscal year subsequent to December 31, 2018 and ended at least 60 days prior to the Closing Date within two (2) months following such fiscal year end, accompanied by the Accompanying Materials and (y) unaudited consolidated financial statements (which shall be compliant with Regulation S-X Rule 3-05) of the Business and its Subsidiaries for the most recent fiscal quarter ending after the date of the last delivered Audited Financial Statements for the last fiscal year preceding the Closing and at least 30 Business Days prior to the Closing within 30 Business Days following such fiscal quarter end. Seller agrees as requested by Buyer from time to time after the Closing Date to assist Buyer in obtaining the consent of the Seller’s independent auditor to include the auditor’s report on the foregoing in any and all Buyer SEC filings, including Current Reports on Form 8-K.

(b)Until the Closing Date, Seller shall deliver, or cause to be delivered, to Buyer (i) within 10 Business Days after the end of each month the Monthly Operating Review Package (M1, M2 and M3 reports) and (ii) within 20 Business Days after the end of each fiscal quarter, the management-prepared unaudited interim consolidated balance sheets and income statements of the Business and its consolidated subsidiaries for such fiscal quarter subsequent to December 31, 2018 and ended prior to the Closing Date.

Section 6.14. Certain Agreements

(a)As promptly as practicable following the Agreement Date and in any event prior to the Closing, Seller and Buyer shall negotiate in good faith the terms and conditions of, and enter into, at the Closing, the Bill of Sale, Assignment and Assumption Agreement, the IP Assignment Agreement, the Lease Assignments and any other Transaction Agreements.

(b)As promptly as practicable following the Agreement Date and in any event prior to Closing, Seller and Buyer shall negotiate in good faith, and finalize the terms, conditions and content of, at the Closing, the Services Schedules, as defined in and in accordance with the principles set forth on Schedule A to the form of Transition Services Agreement attached hereto as Exhibit C. The Parties shall use reasonable best efforts to obtain as of the Closing Date all Consents (as defined in the Transition Services Agreement); provided that the costs of obtaining any such Consents shall be allocated between Buyer and Seller as set forth in Section 2.08 of the Transition Services Agreement. Seller (i) has, to Seller’s Knowledge and as of the Agreement Date, disclosed to Buyer its best currently practicably available information with respect to the scope, nature and internal allocation methodology of the services provided by Seller that are necessary for the operation of the Business, and (ii) will continue to cooperate with and provide such information to, as may be reasonably requested by Buyer with respect to the foregoing, the Service Schedules and the Transition Services Agreement.

(c)To the extent that, notwithstanding such good faith efforts, Buyer and Seller are unable to agree upon the Transition Service Schedules to be attached to the Transition Services Agreement prior to the earlier of (i) the end of the Negotiation Period (as defined in Schedule A to the form Transition Services Agreement attached hereto as Exhibit C) or (ii) the date this Agreement has been validly terminated pursuant to Article XI, such unresolved matters shall be referred for resolution to the chief financial officer of Buyer, on the one hand, and chief financial officer of Seller, on the other hand, who shall work together in good faith to reach final resolution within ten (10) days of such referral.


(d)As promptly as practical following the Agreement Date and in any event prior to the Closing, the Parties shall negotiate in good faith using reasonable best efforts the terms and conditions of, and enter into, effective as of the Closing, a manufacturing and supply agreement (the “Manufacturing and Supply Agreement”), pursuant to which Seller, or an applicable Subsidiary, shall manufacture and supply DE-52 Cellulose to Buyer or its designee(s) for a period of time no less than six (6) years following the Closing Date (provided that Buyer shall have the right to terminate for its convenience (without payment of any termination fees or the like) by providing six (6)-months notice).  The Manufacturing and Supply Agreement shall (i) contain reasonable terms and conditions consistent with the current business practices under which Seller (or its applicable Subsidiaries) have supplied such products to the Business during the twelve (12) month period prior to the Agreement Date, (ii) provide that pricing for the products shall be calculated as direct costs (materials plus labor costs) for the first three (3) years following the Closing Date and as direct costs (materials plus labor costs) plus 10% margin for the remainder of the term; (iii) provided that, upon the expiration or early termination of the Manufacturing and Supply Agreement in accordance with its terms, Buyer may elect, at its sole option, to either (A) require Seller (or its applicable Subsidiaries) to (1) provide technology transfer to Buyer or its designees as reasonably required to enable the transition of manufacturing and supply of the products to Buyer’s or its designees’ facilities and (2) promptly deliver all equipment, tooling and machinery used by Seller for the manufacturing of DE-52 Cellulose following the termination of the Manufacturing and Supply Agreement (provided that all costs of such technology transfer and delivery incurred in connection with this clause (A) shall be shared 50% by Seller and 50% by Buyer) or (B) extend the term of the Manufacturing and Supply Agreement on the same commercial and pricing terms in effect during the last three (3) years of the initial term.

Section 6.15. Ownership of the Business Subsidiaries. In the event that Seller becomes aware that the representation and warranty set forth in Section 4.03(c) is breached in any material respect, or upon Buyer’s notification to Seller of any such breach, Seller shall (a) prior to the Closing, use its reasonable best efforts to remedy such breach and (b) following the Closing, remedy such breach as soon as practicable.

Section 6.16. Commingled Entities.

(a)Promptly following the Agreement Date, Seller and Buyer shall discuss in good faith the manner in which the portion of the business of Wipro GE Healthcare Private Ltd (“Wipro”) Related to the Business (and the assets of Wipro Related to the Business) (collectively, the “Wipro Business”) shall be separated from Wipro and delivered to Buyer. All costs, expenses and Liabilities (other than Transfer Taxes which shall be treated in accordance with Section 9.07) associated with such separation shall be borne by Seller (except that Buyer shall be solely responsible for any migration costs associated with relocating to a new facility, including costs of relocating personnel or assets and the costs of establishing or licensing facilities or entities, as well as any licensing fees necessary to effect the separation (collectively, “Transition Costs”)). Any Liabilities assumed or otherwise incurred by Buyer or its Affiliates in connection with or as a result of such separation (other than Transition Costs) shall be deemed Excluded Liabilities for all purposes of this Agreement. In connection with (and without limiting) the foregoing, if requested by Buyer, Seller shall, prior to Closing, facilitate customer and distributor introductions and cooperate in negotiating substitute commercial arrangements with respect to the activities of Wipro.

(b)If, as of the Closing, Seller cannot deliver the Wipro Business to Buyer, and/or cannot cause, as of the Closing, Wipro to provide Services under the Transition Services Agreement, (i) Buyer may elect to treat the Wipro Business as a Deferred Business or (ii) Buyer may elect to enter into a transitional arrangement with Seller pursuant to which (A) Buyer shall be entitled to receive all products and services the Business currently receives from Wipro, for a period of up to 24 months following Closing (or such shorter period as may be required by applicable Law) on terms and conditions that are at least as favorable to Buyer and its Affiliates as compared to Seller and its Affiliates prior to the Agreement Date and (B) the cost to Buyer of the continued provision of services to the Business by Wipro shall not exceed the commissions charged to Business for the sale of the Business’ products under the commission structure in effect on the Agreement Date between Seller and Wipro.

(c)If the Business is conducted through a joint venture or comparable vehicle (other than the Transferred Entities or Wipro) with an unaffiliated Person (each, a “Commingled Entity”) then, except as otherwise agreed to by the Parties, the Parties shall treat each such Commingled Entity in the same manner as Wipro described above.

Section 6.17. Capex Budget. Within seven Business Days of the Agreement Date, Seller shall deliver to Buyer a capital expenditure budget for each fiscal quarter of 2019 that shall (a) in the aggregate be equal to the annual Capex Budget set forth on Schedule 6.01(a)(xii), (b) reflect Seller’s good faith estimate of the quarterly capital expenditure spending of the Business for the applicable quarter and (c) be prepared consistent with past practice and derived from the latest 2019 quarterly capital expenditure analysis as of the Agreement Date, if any exists.


Section 6.18.    Digital Twin Framework. Exhibit B to the Intellectual Property Cross License Agreement is hereby amended to add the Seller Licensed DTF Items (as defined in Schedule 6.18) as Exclusively Licensed IP. Seller shall, prior to or as of the Closing Date, deliver to Buyer the Digital Twin Framework (as defined in Schedule 6.18) and the GitHub repository in which the source code for the Digital Twin Framework (as defined in Schedule 6.18) is stored as of immediately prior to the Closing, which repository shall include the items set forth in Schedule 6.18 (the “GitHub Repository”). To the extent that anything set forth in Schedule 6.18 is not included in the GitHub Repository, Seller shall, and shall cause its Affiliates to, promptly provide to Buyer and its Affiliates such missing items in a format reasonably requested by and acceptable to Buyer.

ARTICLE VII

POST-CLOSING COVENANTS

Section 7.01. Accesso.

(a)For a period of six (6) years from and after the Closing Date, to the extent necessary in connection with Seller’s or its Subsidiaries’ preparation or amendment of Tax Returns, claims or obligations relating to Excluded Liabilities, in each case, other than any Claims arising from disputes with respect to any Transaction Agreement or by or against any Buyer Indemnified Party, preparation of financial statements, U.S. Securities and Exchange Commission or bank regulatory reporting obligations, or the determination of any matter relating to the rights or obligations of Seller or any of its Subsidiaries in relation to a third party, upon reasonable prior notice, and except as otherwise provided in this Agreement and to the extent necessary to (i) ensure compliance with any applicable Law, (ii) preserve any applicable legal privilege (including the attorney-client privilege) or (iii) comply with any contractual confidentiality obligations, Buyer shall, and shall cause each of the Transferred Entities to (A) afford each Seller Party and its Representatives and their respective Affiliates reasonable access, during normal business hours, to the books and records of the Business in respect of the Transferred Entities and the Business, the Transferred Assets and the Assumed Liabilities and (B) furnish to each Seller Party and its Representatives and their respective Affiliates such additional existing financial and other existing information regarding the Transferred Entities, their respective Affiliates, the Business, the Transferred Assets and the Assumed Liabilities as any Seller Party or its Representatives may from time to time reasonably request, in each case of clauses (A) and (B), to the extent such books, records and information relate to the Pre-Closing Period; provided, however, that, in each case of clauses (A) and (B), such access shall not unreasonably interfere with the business or operations of Buyer or any of its Affiliates; e provided, further, that the auditors and accountants of Buyer or its Affiliates shall not be obligated to make any work papers available to any Person except in accordance with such auditors’ and accountants’ normal disclosure procedures and then only after such Person has signed a customary agreement relating to such access to work papers in form and substance reasonably acceptable to such auditors or accountants; e provided, further that nothing in this Agreement shall limit or expand Seller’s or any of its Subsidiaries’ rights of discovery.

(b)If so requested by Buyer, Seller or one of its Affiliates, as the case may be, shall enter into a customary joint defense agreement or common interest agreement with Buyer and its Affiliates with respect to any information to be provided to Seller or its Subsidiaries pursuant to Section 7.01(a).

(c)Subject to Section 6.03(a), Buyer agrees that it shall preserve and keep all books and records in respect of the Business in the possession or control of Buyer or its Affiliates for a period of six (6) years from the Closing Date.

(d)For a period of six (6) years from and after the Closing Date, to the extent necessary in connection with a Party’s or its Subsidiaries’ preparation or amendment of Tax Returns, claims or obligations relating to Assumed Liabilities or Excluded Liabilities, as applicable, in each case, other than any Claims arising from disputes with respect to any Transaction Agreement or by or against any Buyer Indemnified Party, in the case of Seller, or any Seller Indemnified Party, in the case of Buyer, preparation of financial statements, U.S. Securities and Exchange Commission or bank regulatory reporting obligations, or the determination of any matter relating to the rights or obligations of a Party or any of its Subsidiaries in relation to a third party, each Party will make available to the other Party and its Representatives and their respective Affiliates those employees of the providing Party or its Subsidiaries whose assistance, expertise, testimony, notes or recollections or presence are reasonably necessary to assist such receiving Party, its Representatives or their respective Affiliates in connection with its inquiries for any purpose referred to above, including, subject to payment of reasonable and customary per diems, the presence of such persons for interviews and depositions and as witnesses in hearings or trials for such purposes.


Section 7.02. Rights to Seller Names and Seller Marks.

(a)With respect to the licensing of the Seller Names and Seller Marks, the parties shall enter into the Transitional Trademark License Agreement. Except as otherwise provided in this Section 7.02 or the Transitional Trademark License Agreement, Buyer and its Affiliates (which, for the purposes of this Section 7.02, shall include the Transferred Entities) shall cease and discontinue all uses of the Seller Names and Seller Marks immediately upon the Closing. Buyer, for itself and its Affiliates, agrees that the rights of the Transferred Entities and their respective Affiliates to the Seller Names and Seller Marks pursuant to the terms of any trademark agreements or otherwise between Seller or any of its Subsidiaries, on the one hand, and the Transferred Entities or their respective Affiliates, on the other, shall terminate on the Closing Date and be replaced by such rights as are provided by the Transitional Trademark License Agreement.

(b)Buyer and its Affiliates shall (i) subject to and in accordance with the Transitional Trademark License Agreement, (A) cease all use of any of the Seller Names and Seller Marks on or in connection with all stationery, business cards, purchase orders, lease agreements, warranties, indemnifications, invoices and other similar correspondence and other documents of a contractual nature as promptly as reasonably practicable, and, in any event, prior to expiration of the periods expressly provided therefor in the Transitional Trademark License Agreement and (B) complete the removal of the Seller Names and Seller Marks from all product, services and technical information promotional brochures prior to expiration of the Transitional Trademark License Agreement and (ii) with respect to Transferred Assets bearing any Seller Names and Seller Marks, use their commercially reasonable efforts to relabel such Transferred Assets or remove such Seller Names and Seller Marks from such Transferred Assets as promptly as reasonably practicable, and, in any event, prior to the expiration of the periods expressly provided therefor in the Transitional Trademark License Agreement.

(c)Buyer, for itself and its Affiliates, agrees that after the Closing Date Buyer and its Affiliates (i) will not expressly, or by implication, do business as or represent themselves as Seller or its Subsidiaries and (ii) will cooperate with Seller or any of its Affiliates in terminating any contract or agreements pursuant to which Seller or its Subsidiaries license any Seller Names and Seller Marks to customers. Buyer and its Affiliates shall take all necessary action to ensure that other users of any Seller Names and Seller Marks, whose rights terminate upon the Closing pursuant to this Section 7.02, shall cease use of the Seller Names and Seller Marks, except as expressly authorized thereafter by Seller or under the Transitional Trademark License Agreement.

(d)Promptly after the Closing Date, but in any event no later than the expiration of the periods expressly provided therefor in the Transitional Trademark License Agreement, Buyer and its Affiliates shall make all filings with any and all offices, agencies and bodies and take all other actions necessary to adopt new corporate names, registered names and registered fictitious names of the Transferred Entities and their respective Affiliates that do not consist in whole or in part of, and are not dilutive of or confusingly similar to, the Seller Names and Seller Marks (“New Corporate Names”) in accordance with the terms of the Transitional Trademark License. Upon receipt of confirmation from the appropriate registry that such name changes have been effected, Buyer shall provide Seller with written notice that such name changes have been effected.

(e)Buyer, for itself and its Affiliates, acknowledges and agrees that, except to the extent expressly provided in this Section 7.02 or in the Transitional Trademark License Agreement, neither Buyer nor any of its Affiliates shall have any rights in any of the Seller Names and Seller Marks and neither Buyer nor any of its Affiliates shall contest the ownership or validity of any rights of Seller or any of its Subsidiaries in or to any of the Seller Names and Seller Marks.

Section 7.03. Directors’ and Officers’ Indemnification.

(a)From and after the Closing, Buyer shall cause each Transferred Entity to (i) indemnify, defend and hold harmless, all of their respective past and present directors and officers (in all of their capacities) (collectively, the “D&O Indemnified Parties”) against any and all Losses incurred in connection with any Action, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that such D&O Indemnified Party is or was a director or officer of any Transferred Entity or is or was serving at the request of any Transferred Entity as a director or officer of any other Person at or prior to Closing whether asserted or claimed before, at or after the Closing (including with respect to acts or omissions occurring in connection with the Transaction Agreements and the consummation of the Transactions), and provide advancement of expenses to the D&O Indemnified Parties (within 10 days of receipt by Buyer or any Transferred Entity from a D&O Indemnified Party of a request therefor), in all such cases to the greatest extent that such Persons are indemnified or have the right to advancement of expenses before the Closing by a Transferred Entity pursuant to its certificate of incorporation, bylaws, other comparable organizational documents and indemnification agreements, if any, in existence before the Agreement Date and made available to Buyer and (ii) without limitation of clause (i), to the fullest extent permitted by applicable Law, include and cause to be maintained in effect the provisions regarding elimination of liability of directors, and indemnification


of and advancement of expenses to directors and officers contained in the certificate of incorporation, bylaws and other comparable organizational documents of the Transferred Entities, in each case in existence before the Agreement Date and made available to Buyer.

(b)The obligations of Buyer, and each Transferred Entity under this Section 7.03 shall not be terminated, amended or modified in any manner so as to adversely affect any D&O Indemnified Party (including such Person’s successors, heirs and legal representatives) to whom this Section 7.03 applies without the written consent of such affected D&O Indemnified Party (it being expressly agreed that, from and after the Closing, the D&O Indemnified Parties to whom this Section 7.03 applies shall be third party beneficiaries of this Section 7.03, and this Section 7.03 shall be enforceable by such D&O Indemnified Parties and their respective successors, heirs and legal representatives and shall be binding on all successors and assigns of Buyer and each Transferred Entity).

(c)If Buyer or, following the Closing, any Transferred Entity, or any of their respective successors or assigns, (i) shall consolidate with or merge into any other corporation or entity and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii) shall transfer all or substantially all of its properties and assets to any Person, then, and in each such case, proper provisions shall be made so that the successors and assigns of Buyer or such Transferred Entity or any of their respective successors or assigns, as the case may be, shall assume all of the obligations set forth in this Section 7.03.

(d)The rights of the D&O Indemnified Parties under this Section 7.03 shall be in addition to any rights such D&O Indemnified Parties may have under the certificates of incorporation or bylaws or other comparable organizational documents of the Transferred Entities, or under any applicable contracts or Laws, in each case in existence before the Agreement Date and made available to Buyer (in the case of such rights under applicable contracts, before the Closing), and from and after the Closing, Buyer shall cause each Transferred Entity to, honor and perform under all indemnification agreements entered into by such Transferred Entity, as applicable, as in effect on the Agreement Date and made available to Buyer (in the case of indemnification agreements, before the Closing).

(e)Notwithstanding anything to the contrary, nothing in this Section 7.03 (i) requires Buyer or any Transferred Entity to be liable for any Excluded Liabilities or (ii) limits, modifies or in any way affects the subrogation rights of, or rights to any insurance proceeds received by, Buyer or any Transferred Entity pursuant to Section 12.06 e Section 12.08.

Section 7.04. Insurance.

(a)After the Closing Date, the Transferred Entities and the Business shall cease to be in any manner insured by, entitled to any benefits or coverage under or entitled to seek benefits or coverage from or under any Insurance Policies other than (i) any Insurance Policy issued in the name and for the benefit of any Transferred Entity, the Business or any D&O Indemnified Party; (ii) with respect to any matters covered by an Insurance Policy that are properly reported to the relevant insurer(s) prior to April 1, 2020; or (iii) for Claims brought within a three-year period concluding on the third anniversary of April 1, 2020, solely under the Available Insurance Policies, for any losses or Claims arising from or based on any fact, circumstance, occurrence, act or omission that occurred or existed prior to April 1, 2020, in each case of clauses (i) through (iii), subject to the terms and conditions of the relevant Insurance Policies and this Agreement, except to the extent otherwise mandated by Law. “Available Insurance Policies” means Insurance Policies maintained by Seller or any of its Subsidiaries prior to or as of the Closing Date that by their terms cover Losses, acts and omissions of the Business, the Transferred Entities or any D&O Indemnified Party occurring prior to April 1, 2020 and permit the applicable Claims as contemplated by this Section 7.04. The Transferred Entities shall, and Seller shall reasonably assist Buyer and the Transferred Entities to, procure all contractual and statutorily obligated insurance at Closing.

(b)The rights of the Business, the Transferred Entities or any D&O Indemnified Party under subparagraphs (a)(ii) and (a)(iii) (collectively, “Available Insurance Claims”) are subject to and conditioned upon the following:

i.The Transferred Entities shall be solely responsible for notifying any and all insurance companies of such Claims and complying with all policy terms and conditions for pursuit and collection of such Claims; provided that Seller shall promptly forward to Buyer or the applicable Transferred Entity any communication from an insurer in respect of such Claims and, to the extent applicable, reasonably assist Buyer’s or the applicable Transferred Entity’s communications with an insurer. The Transferred Entities shall not, without the written consent of Seller, amend, modify or waive any rights of Seller or other insureds (other than any Transferred Entity or the Business) under any such insurance policies and programs. The Transferred Entities and the Business shall exclusively bear and be liable (and Seller shall have no obligation to repay or reimburse the Transferred Entities or the Business) for all uninsured, uncovered, unavailable or uncollectible amounts relating to or associated with all such Claims; e


ii.With respect to Claims or requests for benefits asserted by the Transferred Entities under the Available Insurance Policies, subject to the proviso in the first sentence of Section 7.04(b)(i), Seller shall have the right but not the duty to monitor and/or associate with such Claims. The Transferred Entities shall be liable for any out-of-pocket fees, costs and expenses incurred by Seller directly, or indirectly through the insurers or reinsurers of the Available Insurance Policies, relating to any unsuccessful coverage Claims. The Transferred Entities shall not assign any Available Insurance Policies or any rights or Claims under the Available Insurance Policies.

(c)Notwithstanding anything contained in this Agreement, (i) nothing in this Agreement shall limit, waive or abrogate in any manner any rights of Seller to insurance coverage for any matter and (ii) Seller shall retain the exclusive right to control its Insurance Policies, including the right to exhaust, settle, release, commute, buy-back or otherwise resolve disputes with respect to any of its Insurance Policies and to amend, modify or waive any rights under any such Insurance Policies as long as such action is not taken with the primary purpose to reduce the insurance coverage for Liabilities or losses as to which any Transferred Entity or the Business has made, or could in the future make, a Claim for coverage; provided, that the Transferred Entities and Seller shall cooperate with respect to coverage Claims and requests for benefits and sharing such information as is reasonably necessary in order to permit (x) Buyer and the Transferred Entities to seek the Available Insurance Claims and (y) Seller to manage and conduct its insurance matters.

(d)Nothing in this Section 7.04 shall limit, modify or in any way affect the rights and obligations of the Parties under Article VIII or Buyer’s right to acquire the Transferred Assets in accordance with the terms of this Agreement; provided, however, that any insurance proceeds actually collected with respect to a particular Loss shall be taken into account in accordance with and to the extent required by Section 12.06. No payments due under this Section 7.04 shall affect, be affected by, or be subject to set off against, any adjustment to the Purchase Price. Whenever this Section 7.04 requires any Transferred Entity to take any action after the Closing, such requirement shall be deemed to constitute an undertaking on the part of Buyer to take such action or to cause such Transferred Entity to take such action. If Seller or any of its Subsidiaries receives insurance proceeds in connection with any Available Insurance Claim to which Buyer is entitled pursuant to the rights set forth in Section 7.04(a) e (b), Seller shall cause such proceeds to which Buyer is entitled to be promptly delivered to the applicable Transferred Entity or another Person designated by Buyer.

Section 7.05. Intellectual Property Matters. From and after the Closing Date, Seller shall, and shall cause its Subsidiaries and Affiliates to, at Seller’s sole cost and at the reasonable direction of Buyer, use its and their respective commercially reasonable efforts to remedy any title breaks or other deficiencies of record arising on or before Closing in any registrations or applications for registration of any Company Intellectual Property that constitutes Registrable IP (including those listed on Schedule 7.05 hereto), including making all necessary filings, or entering into or obtaining all necessary assignment agreements and other instruments (whether among Seller’s Subsidiaries and Affiliates internally, or between Seller’s Subsidiaries and Affiliates, on the one hand, and Buyer and its Subsidiaries and Affiliates (including the Transferred Entities) or third parties (including inventors), on the other hand, or among third parties (including inventors)), excluding in such cases only formal or procedural actions (e.g., filings) that can be made by the Transferred Entities on their own or by obtaining assignments from inventors employed by the Transferred Entities as of the Closing Date. Without limiting the foregoing, except as not permitted under applicable Law or otherwise not commercially reasonable due to requirements of a particular jurisdiction, Seller shall take such further action within a reasonable amount of time after the Closing Date (including the execution and delivery of such instruments and documents) not to exceed one (1) year. Questo Section 7.05 shall survive the Closing until it is fully performed.

Section 7.06. Further Assurances. From time to time following the Closing, Buyer and Seller shall, and shall cause their respective Affiliates to, execute, acknowledge and deliver all reasonable further conveyances, notices, assumptions, releases and acquittances and such instruments, and shall take such reasonable actions as may be reasonably necessary or appropriate to make effective the transactions contemplated hereby as may be reasonably requested by the other Party (including (i) transferring back to Seller or its designated Subsidiary (and having Seller or its designated Subsidiary assume) (A) each Excluded Asset and each Excluded Liability transferred by a Seller Party to Buyer (directly or as an asset or Liability of any Transferred Entity) at the Closing and (B) any Excluded Asset that is transferred or paid to Buyer or its Affiliates by a third party after the Closing and (ii) transferring to Buyer or its designated Subsidiary (and having Buyer or its designated Subsidiary assume) (A) each Transferred Asset and each Assumed Liability that was not transferred by a Seller Party to Buyer (directly or as an asset or Liability of any Transferred Entity) at the Closing and (B) any Transferred Asset that is transferred or paid to Seller or its Affiliates by a third party after the Closing); provided, however, that except for Buyer’s obligations to discharge an Assumed Liability and Seller’s obligations to discharge an Excluded Liability, nothing in this Section 7.06 shall require either Party or its Affiliates to pay money to, commence or participate in any Action with respect to, or offer or grant any accommodation (financial or otherwise) to, any third party following the Closing.


Section 7.07. Further Action Regarding Intellectual Property and Technology.

(a)If, after the Closing Date, Seller or Buyer identifies any item of Company Intellectual Property or Company Technology that inadvertently was not previously transferred by a Seller Party to Buyer, then, Seller shall (or shall cause a Seller party to) promptly transfer such Company Intellectual Property or Company Technology to Buyer for no additional consideration. Until such time that Seller Party transfers such Company Intellectual Property or Company Technology to Buyer, such Seller Party, on behalf of itself and its Affiliates, hereby grants to Buyer and its Subsidiaries (i) a non-exclusive, royalty-free, fully paid-up, worldwide, irrevocable, sub-licensable and transferable right and license (or sub-license, as the case may be) to fully use, practice and otherwise exploit such Company Intellectual Property or Company Technology Controlled (as such term is defined in the Intellectual Property Cross License Agreement) by the Seller Party and its Affiliates and (ii) a covenant not to sue with respect to the foregoing activities, in each case under clauses (i) and (ii), effective as of the Closing Date.

(b)If, after the Closing Date, Seller or Buyer identifies any item of Seller Intellectual Property or Seller Technology that was (i) transferred by a Seller Party or (ii) owned by any Transferred Entity prior to the Closing Date and that was not transferred to Seller or any Subsidiary of Seller prior to the Closing Date, Buyer shall, or shall cause the applicable Transferred Entity to, promptly transfer such Seller Intellectual Property or Seller Technology to Seller or its designated Subsidiary for no additional consideration. Until such time that Buyer transfers such Seller Intellectual Property or Seller Technology to Seller, Buyer hereby grants to Seller and its Subsidiaries (i) a non-exclusive, royalty-free, fully paid-up, worldwide, irrevocable, sub-licensable and transferable right and license (or sub-license, as the case may be) to fully use, practice and otherwise exploit such Seller Intellectual Property or Seller Technology Controlled (as such term is defined in the Intellectual Property Cross License Agreement) by Buyer and (ii) a covenant not to sue with respect to the foregoing activities, in each case under clauses (i) and (ii), effective as of the Closing Date.

(c)Without limiting the foregoing, if, prior to the Closing Date, Seller or Buyer identifies any item of Seller Intellectual Property, Seller Technology, Company Intellectual Property or Company Technology that inadvertently was listed or omitted on a Schedule of Company Intellectual Property or Company Technology, then such Schedule shall be deemed amended to remove or add such item, as applicable.

Section 7.08. Local Transfer Agreements.

(a)The parties do not intend this Agreement to transfer title to any Transferred Equity Interests or Transferred Assets, or to constitute the assumption of any Assumed Liabilities, in any jurisdiction in which such transfer or assumption is required by applicable Law to be made pursuant to a Local Transfer Agreement, and any such Transferred Equity Interests or Transferred Assets or Assumed Liabilities, as applicable, shall only be transferred or assumed by the applicable Local Transfer Agreement (which transfers and assumptions shall, except as otherwise expressly set forth herein, be on an “as-is”, “where-is” basis, without representation or warranty of any kind or nature). The Local Transfer Agreements shall serve purely to effect the legal transfer of the applicable Transferred Equity Interests or Transferred Assets, or the assumption of any Assumed Liabilities in the applicable jurisdictions, and, for the avoidance of doubt, the Local Transfer Agreements shall not have any effect on the value being given or received by the Seller Parties or Buyer, including the allocation of assets and Liabilities as between them, all of which shall be determined solely in accordance with this Agreement; in any such case except as expressly agreed in writing by Buyer and Seller (and not any Affiliates thereof).

(b)Without limiting the generality of Section 7.08(a), to the extent that the provisions of a Local Transfer Agreement are inconsistent with, or (except to the extent they implement a transfer in accordance with this Agreement) additional to, the provisions of this Agreement (or do not fully give effect to the provisions of this Agreement with respect to the transfer of the Transferred Equity Interests, Transferred Assets or the assumption of Assumed Liabilities): (i) the provisions of this Agreement shall prevail; and (ii) so far as permissible under applicable Law of the relevant jurisdiction, the Seller Parties and Buyer shall cause the provisions of the relevant Local Transfer Agreement to be adjusted, to the extent necessary to give effect to the provisions of this Agreement.

(c)Each party hereto shall not, and shall cause its respective Affiliates not to, bring any Claim (including for breach of any warranty, representation, undertaking, covenant or indemnity relating to the Transactions) against the other party or any of its Affiliates in respect of or based upon any of the Local Transfer Agreements, except to the extent necessary to enforce any transfer of the Transferred Equity Interests, Transferred Assets or the assumption of Assumed Liabilities sold or assigned to Buyer hereunder in a manner consistent with the terms of this Agreement. All such Claims (except as referred to above) shall be brought in accordance with, and be subject to the provisions, rights and limitations set out in, this Agreement, and no party shall be entitled to recover damages or obtain payment, reimbursement, restitution or indemnity under or pursuant to any of the Local Transfer Agreements (but without prejudice to the establishment of the existence of the Claim hereunder) to the extent inconsistent with this Agreement.


Section 7.09. Non-Competition. With respect to non-competition matters, Buyer and Seller have made the agreements and covenants set forth in Exhibit D to this Agreement, which is hereby incorporated into this Agreement.

ARTICLE VIII

EMPLOYEE MATTERS

With respect to employee matters, the Parties have made the agreements and covenants set forth in Exhibit E to this Agreement, which is hereby incorporated into this Agreement.

ARTICLE IX

TAX MATTERS

Section 9.01. Filing of Tax Returns by Seller.

(a)Seller shall, at Seller’s cost and expense, (i) timely prepare and file (or cause to be timely prepared and filed) all Tax Returns that are required to be filed by or with respect to each Transferred Entity on an affiliated, consolidated, combined or unitary basis with Seller or with at least one Subsidiary of Seller that is not a Transferred Entity for Tax years or periods beginning on or before the Closing Date and (ii) timely prepare and file (or cause to be timely prepared and filed) all other Tax Returns required to be filed by any Transferred Entity with a due date (taking into account extensions to file such returns) on or before the Closing Date.

(b)Any Tax Return prepared by Seller pursuant to Section 9.01(a) (i) that includes the Closing Date shall reflect a deduction for the Transaction Deductions (unless otherwise reflected on a corresponding Tax Return of Seller or any of its Subsidiaries other than a Transferred Entity) and (ii) shall, to the extent that such Tax Return shows a net operating loss of any Transferred Entity, carry back such net operating loss to previous Tax periods to the maximum extent permitted by applicable Law.

(c)With respect to each Tax Return prepared and filed by Seller pursuant to Section 9.01(a), Seller shall timely remit (or cause to be timely remitted) any and all Taxes shown as due on such Tax Returns to the extent that Taxes are required to be remitted upon filing such Tax Returns, except to the extent such Taxes were taken into account in the calculation of Purchase Price (as finalized pursuant to Section 3.04), which Taxes shall be remitted by Buyer (or its applicable Affiliate) to Seller within five (5) Business Days of filing such Tax Return. In the event that the amount of Taxes taken into account in calculating Purchase Price (as finalized pursuant to Section 3.04) exceeds the actual Tax liability reflected on such Tax Return, Buyer (or its applicable Affiliate) shall remit such excess to Seller within five (5) Business Days of filing such Tax Return.

Section 9.02. Filing of Tax Returns by Buyer.

(a)Except for the Tax Returns described in Section 9.01(a), Buyer shall, at Buyer’s cost and expense, timely prepare and file (or cause to be timely prepared and filed) all Tax Returns of the Transferred Entities. If such Tax Returns or, in the case of clause (ii), Tax Returns of a JV reflect (i) any Taxes for which indemnification may be claimed from Seller pursuant to Article XII or (ii) Taxes with respect to which a Transferred Entity or a JV is treated as a pass-through entity and which Taxes flow through to Seller or any of its Affiliates (other than a Transferred Entity or JV), then: (A) subject to Section 9.02(b), Buyer shall prepare (or cause to be prepared) such Tax Returns in accordance with past practices of the Business to the extent that there is at least a “more likely than not” basis for such past practices under applicable Tax Law, (B) completed drafts of such Tax Returns, and, in the case of any Tax Return for a Straddle Period, a pro forma Tax Return for the portion of the Straddle Period ending on the Closing Date, shall be submitted to Seller for Seller’s review not later than 30 days before the due date for filing such Tax Returns (or, if such due date is within 45 days following the Closing Date, as promptly as practicable following the Closing Date), (C) Seller shall have the right to review and approve (such approval not to be unreasonably withheld, conditioned or delayed) each such Tax Return delivered to it before the filing thereof and (D) to the extent relating to the matters described in either clause (i) or clause (ii) of this Section 9.02(a), Buyer shall make any changes to such Tax Returns reasonably requested by Seller at least fifteen (15) days prior to the prior to the due date of such Tax Return and provide such amended Tax Return to the Seller at least ten (10) days before the Tax Return is due. Seller shall, at least two (2) days before any Tax Return that Buyer is obligated to file under this Section 9.02(a) is due, pay Buyer (or its Subsidiary) the amount of Taxes shown as due thereon to the extent Seller is liable for such Taxes pursuant to Article XII, except to the extent such Taxes were taken into account in the calculation of Purchase Price (as finalized pursuant to Section 3.04). In the event that the amount of Taxes taken into account in calculating Purchase Price (as finalized pursuant to Section 3.04) exceeds the portion of the actual Tax liability reflected on such Tax Return for which Seller is liable pursuant to Article XII, Buyer (or its applicable Affiliate) shall remit such excess to Seller within five (5) Business Days of filing such Tax Return.


(b)Any income Tax Return prepared by Buyer pursuant to Section 9.02(a) (i) that includes the Closing Date shall reflect a deduction for the Transaction Deductions (unless otherwise reflected on a corresponding Tax Return of Seller or any of its Affiliates other than a Transferred Entity) and (ii) shall, to the extent that such Tax Return shows a net operating loss of any Transferred Entity, carry back such net operating loss to previous Tax periods to the maximum extent permitted by applicable Law.

(c)Except upon Seller’s request pursuant to Section 9.05, neither Buyer nor any Affiliate of Buyer shall (or shall cause or permit any Transferred Entity to) amend, refile or otherwise modify (or grant an extension of any statute of limitation with respect to) any Tax Return relating in whole or in part to any Transferred Entity (or a group the parent of which is a Transferred Entity) with respect to any taxable year or period (or portion thereof) ending on or before the Closing Date (or with respect to any Straddle Period) without the prior written consent of Seller, not to be unreasonably withheld, conditioned or delayed.

Section 9.03. Straddle Periods. To the extent possible under applicable Law, the parties shall take such actions as shall be necessary or appropriate to cause the taxable year of each Transferred Entity and JV to end on the Closing Date. For all purposes under this Agreement, including, for the avoidance of doubt, Section 2.01, in the case of any Tax period that includes but does not end on the Closing Date (a “Straddle Period”), the portion of Taxes (or any Tax refund or amount credited against any Tax) that are allocable to the portion of the Straddle Period ending at the end of the Closing Date will be: (i) in the case of property Taxes and other Taxes imposed on a periodic basis without regard to income, gross receipts, payroll, sales or any specific transaction or event deemed to be the amount of such Taxes (or Tax refund or amount credited against Tax) for the entire Straddle Period multiplied by a fraction, the numerator of which is the number of calendar days in the portion of such Straddle Period ending at the end of the Closing Date and the denominator of which is the number of calendar days in the entire Straddle Period and (ii) in the case of all other Taxes, including Taxes attributable to the ownership of JV interest or any Transferred Entity treated for U.S. federal income tax purposes as a “pass-through” entity or “controlled foreign corporation” (within the meaning of Section 957(a) of the Code or any comparable state, local or non-U.S. Applicable Law), determined as though the taxable year terminated at the end of the Closing Date. Any Transaction Deductions shall be reflected in the portion of any Straddle Period ending at the end of the Closing Date.

Section 9.04. Tax Proceedings.

(a)Buyer shall promptly notify Seller in writing upon receipt by Buyer or any of its Affiliates (including, following the Closing and for the avoidance of doubt, any Transferred Entity) of any written communication from a Taxing Authority concerning any pending or threatened audit, Claim, demand, proposed adjustment or deficiency, assessment or administrative or judicial proceeding (a “Tax Claim”) described in clause (A), (B) or (C) of Section 9.04(b) and to the extent known, describing in reasonable detail the facts and circumstances with respect to the subject matter of such Tax Claim; provided, however, that the failure of Buyer to provide such notice shall not release Seller from any of its obligations under this Agreement except to the extent Seller is actually prejudiced by such failure.

(b)Subject to Section 9.06(b), Seller shall have the exclusive right to (i) prepare (or cause to be prepared) any amended Tax Returns and (ii) control any Tax Claim, in each case to the extent that any such Tax Return or Tax Claim (A) relates to any taxable year or period ending on or before the Closing Date, (B) could reasonably be expected to result in any Tax Liability with respect to which Seller has agreed to provide indemnification under this Agreement or (C) relates to Taxes with respect to which a Transferred Entity or JV is treated as a pass-through entity and which Taxes flow through to Seller or any of its Affiliates (other than a Transferred Entity or JV). Subject to the immediately succeeding sentence, upon Seller’s request, Buyer shall file (or shall cause to be filed) any amended Tax Return described in the immediately preceding sentence and shall execute any powers of attorney or similar documents that may be required to effectuate the intent of this Section 9.04(b). Except for Taxes paid on an affiliated, consolidated, combined or unitary basis with Seller or its Affiliates, Seller shall not settle any Tax Claim or file (or cause to be filed) any amended Tax Return pursuant to this Section 9.04(b) without Buyer’s consent, not to be unreasonably withheld, conditioned or delayed. In the case of any Tax Claim or amended Tax Return controlled by Seller pursuant to this Section 9.04(a), Seller shall (x) notify Buyer of any material development with respect to any such Tax Claim or amended Tax Return, (y) provide Buyer with copies of any material documents submitted in connection with such Tax Claim or amended Tax Return and (z) notify Buyer regarding any material action to be taken by Seller with respect to such Tax Claim or amended Tax Return.

Section 9.05. Refunds. Buyer shall pay (or cause to be paid) to Seller any Tax refunds that are actually received by any Transferred Entity (or Buyer or any Affiliate of Buyer on any Transferred Entity’s behalf), and any amounts credited against Tax to which any Transferred Entity (or Buyer or any Affiliate of Buyer on any Transferred Entity’s behalf) becomes entitled, in each case, (i) that relate to Tax periods (or portions of a Straddle Period) ending on or before the Closing Date, (ii) except to the extent any such refund (x) arises as a result of carryback of loss or other Tax Benefit from a period beginning after the Closing Date or (y) was taken into account in the calculation of Purchase Price (as finalized pursuant to


Section 3.04), and (iii) net of costs and expenses incurred by the Buyer and its Subsidiaries, including Taxes, with respect to such refunds of Taxes. Buyer shall file (or cause to be filed), at the cost and expense of the Seller Parties, all Tax Returns (including amended Tax Returns) claiming any refunds, including through the carryback of any net operating losses that are attributable to a Tax period ending on or before the Closing Date, to which Seller is entitled pursuant to the immediately preceding sentence. Any payments required to be made under this Section 9.05 shall be made in immediately available funds, to an account or accounts as directed by Seller, within five days of the receipt of the refund or the application of any such refunds as a credit against Tax for which Seller has not otherwise agreed to provide indemnification under this Agreement. For purposes of this Section 9.05, Buyer or any Affiliate of Buyer shall be treated as becoming entitled to a credit in lieu of cash Taxes only if, when and to the extent that such credit is actually utilized on a Tax Return filed by the Buyer or an Affiliate of Buyer after the Closing. Notwithstanding anything to the contrary in this Section 9.05, any refunds or credits of Creditable VAT which is the responsibility of the Buyer pursuant to Section 9.07 shall be for the benefit of the Buyer.

Section 9.06. Post-Closing Actions.

(a)Except as otherwise required by applicable law, Buyer shall not, and shall not permit any of its Affiliates (including, after the Closing for the avoidance of doubt, the Transferred Entities) to (i) voluntarily approach any Taxing Authority regarding any Taxes or Tax Returns of any Transferred Entity relating to any Tax period (or portions of a Straddle Period) ending on or before the Closing Date, (ii) take any action relating to Taxes, or that could create a Tax Liability, on the Closing Date after the Closing that is outside the ordinary course of business (other than as expressly contemplated by this Agreement) or (iii) except as provided by Section 9.02(a) or upon Seller’s request pursuant to Section 9.05, carryback any net operating losses from any Tax period (or portion thereof) ending after the Closing Date to any Tax period (or portion thereof) ending on or before the Closing Date, in each case without the prior written consent of Seller.

(b)Notwithstanding anything herein to the contrary, Seller shall not, and shall not permit any of its Affiliates to, amend any Tax Return of a Person other than a Transferred Entity to the extent that such amendment could materially adversely affect the Tax liability of any Transferred Entity in a taxable period (or portion thereof) beginning after the Closing Date (including, for the avoidance of doubt, through the utilization of any net operating loss, tax credit, or other similar tax attribute of a Transferred Entity), in each case without the prior written consent of Buyer, which consent will not be unreasonably withheld, conditioned or delayed.

Section 9.07. Transfer Taxes. Notwithstanding anything to the contrary in this Agreement, Transfer Taxes imposed or arising with respect to the sale and purchase hereunder of Transferred Assets and Transferred Equity Interests (including any Transfer Taxes imposed or arising in connection with transactions contemplated by Schedule 2.06 or otherwise in connection with Section 2.06, but excluding any Pre-Closing Restructuring Taxes), shall be borne 50% by the Seller Parties and 50% by the Buyer, except for any Creditable VAT, which shall be borne 100% by the Buyer and except for any VAT incurred in connection with the transfer of assets pursuant to the Business Transfer Agreement, dated January 1, 2020, between GE Medical Systems Trade and development (Shanghai) Co., Ltd. an Global Life Sciences Technologies (Shanghai) Co., Ltd. (the “Lingang VAT”), which shall be borne 100% by the Seller Parties (and for the avoidance of doubt, in no event shall the Seller Parties be entitled to reimbursement or other payment from the Buyer at or following the Closing with respect to the Lingang VAT). The Party required by Law to file a Tax Return with respect to such Transfer Taxes shall timely prepare, with the other Party’s cooperation, file such Tax Return and pay all Taxes reflected on every Tax Return, and the other Party shall promptly reimburse the Party required by Law to file such tax return for its share of any Transfer Taxes paid by it in connection with the filing of such Tax Return; provided, however, that for the first 180 days following the Closing Date, three (3) Business Days following the end of every calendar month following the Closing Date, (i) the reimbursement payments owed by the Seller Parties to the Buyer with respect to Transfer Taxes paid by the Buyer in accordance with this Section 9.07 during such calendar month shall be aggregated, (ii) the reimbursement payments owed by the Buyer to the Seller Parties with respect to Transfer Taxes paid by the Seller Parties in accordance with this Section 9.07 shall be aggregated, and (iii) (A) if the amount determined pursuant to clause (i) is greater than the amount determined pursuant to clause (ii), the Seller Parties shall promptly reimburse the Buyer for the amount of such excess, and only for the amount of such excess, and the Buyer shall make no reimbursement payment to the Seller Parties in respect of such calendar month, (B) if the amount determined pursuant to clause (ii) is greater than the amount determined pursuant to clause (i), the Buyer shall promptly reimburse the Seller Parties for the amount of such excess, and only for the amount of such excess, and the Seller Parties shall make no reimbursement payment to the Buyer in respect of such calendar month or (C) if the amount determined pursuant to clause (i) is equal to the amount determined pursuant to clause (ii) neither Party shall make a reimbursement payment to the other Party; provided further, that on the Closing Date reimbursement payments with respect to any Transfer Taxes paid prior to the Closing Date shall be made in accordance with the previous proviso on the Closing Date.  For the avoidance of doubt, any Transfer Taxes not incurred prior to or within 180 days of the Closing Date or not otherwise covered pursuant to the provisos to the immediately preceding sentence shall remain subject to the indemnification provisions of Article XII, and, in particular, Sections 12.02(a)(iii)(E) and 12.03(a)(iii)(C). Buyer and Seller each agree to timely sign and deliver (or to cause to be timely signed and delivered) such certificates or forms as may be necessary or appropriate and otherwise to cooperate to establish any available exemption from


(or otherwise reduce) any such Transfer Taxes (which shall include cooperating to treat the sale and purchase of Transferred Assets as the transfer of a going concern for value added tax purposes where such treatment is possible and agreeing to take all reasonably necessary steps for such treatment to apply).

Section 9.08. Tax Sharing Agreements. To the extent relating to a Transferred Entity, Seller shall terminate (or cause to be terminated) on or before the Closing Date all Tax sharing agreements or arrangements (other than this Agreement) among the Transferred Entities, on the one hand, and Seller or any of its Subsidiaries (other than the Transferred Entities), on the other hand, such that neither Seller nor any such Subsidiary, on the one hand, or any of the Transferred Entities, on the other hand, will have any Liability or entitlement to any right thereunder to each other on or after the Closing Date.

Section 9.09. Tax Cooperation. Without limiting the obligations set forth in Sections 6.02 e 7.01, the Parties shall furnish or cause to be furnished to each other, upon request, as promptly as practicable, such information and assistance relating to the Transferred Entities, their respective assets or businesses and the Transferred Assets (including access to books and records) as is reasonably necessary for the filing of all Tax Returns, the making of any election related to Taxes, the preparation for, or the prosecution or defense of, any Tax Claim. The Parties shall cooperate with each other in the conduct of any audit or other proceeding related to Taxes and all other Tax matters relating to the Transferred Entities or their respective assets or businesses and each shall execute and deliver such powers of attorney and other documents and shall make employees available on a mutually convenient basis to provide additional information or explanation of any material provided hereunder or to testify at related Tax Claim proceedings as are necessary to carry out the intent of this Article IX. Each of the Parties agrees that it shall preserve and keep, or cause to be preserved and kept, all original books and records in respect of the Business relating to any Taxes with respect to Taxable years or periods (in whole or in part) ending on or before the Closing Date and in the possession of such Party or any of its Affiliates in accordance with Section 7.01. Notwithstanding anything to the contrary herein, nothing in this Agreement shall permit or be deemed to permit a Party or any of its Affiliates or representatives to review or otherwise have access to any affiliated, consolidated, combined or unitary Tax Return that includes the other Party or any of its Affiliates (other than Tax Returns that relate solely to the Transferred Entities).

Section 9.10. Section 338 Elections. Subject to Section 2.06, Buyer shall not make (or permit to be made) an election under Section 338(g) of the Code (or any comparable applicable provision of state, local or foreign Law) with respect to the acquisition of any Transferred Entity.

Section 9.11. Section 754 Elections. Seller Parties shall use commercially reasonable efforts to cause each of the Transferred Entities and JVs that are treated as a partnership for U.S. federal income tax purposes to have an effective election under Section 754 of the Code (or any comparable applicable provision of state, local or foreign law) in effect for the taxable year that includes the Closing Date.

Section 9.12. Swedish Tax Matters. Notwithstanding anything herein to the contrary, in no event shall the Seller Parties or their respective Affiliates (i) utilize any net operating loss, tax credit or other tax attribute of any Swedish Transferred Entity to reduce, offset or eliminate any Tax of any person other than a Swedish Transferred Entity, (ii) following the Agreement Date, utilize any net operating loss, tax credit or other tax attribute of any Swedish Transferred Entity to reduce, offset or eliminate any Tax of any Person in connection with any Tax Claim (including, for the avoidance of doubt, any Tax of any Swedish Transferred Entity), or (iii) assign, transfer, or otherwise convey any taxable income, tax liability or other similar tax item to a Swedish Transferred Entity from a Seller Party or any other Person that is not a Swedish Transferred Entity.

Section 9.13. Survival. The indemnity and payment obligations set forth in this Article IX o Article XII with respect to Taxes shall survive until the date that is 30 days following the expiration of the applicable statute of limitations.

ARTICLE X

CONDITIONS TO CLOSING

Section 10.01. Conditions to Obligations of Seller. The obligation of Seller to consummate the transactions contemplated by this Agreement shall be subject to the satisfaction or Seller’s waiver (to the extent permitted by applicable Law) in its sole discretion, at or before the Closing, of each of the following conditions:

(a)Representations and Warranties; Covenants. (i) The representations and warranties of Buyer contained in this Agreement shall be true and correct as of the Closing as if made on the Closing Date (other than representations and warranties that are made as of a specific date, which representations and warranties shall have been true and correct as of such date), except for breaches or inaccuracies, as the case may be, as to matters that, individually or in the aggregate, would not reasonably be expected to materially impair or delay the ability of Buyer to consummate the Buyer Transactions or otherwise perform its obligations under the Buyer Transaction Agreements; provided, however, that for


purposes of determining the satisfaction of the condition in this clause (i), no effect shall be given to the exceptions of “material” in such representations and warranties, (ii) the covenants contained in this Agreement required to be complied with by Buyer on or before the Closing shall have been complied with in all material respects, (iii) Seller shall have received a certificate signed by an authorized officer of Buyer, dated as of the Closing Date, with respect to the matters set forth in the foregoing clauses (i) and (ii).

(b)Governmental Approvals. All (i) Required Approvals shall have been obtained and (ii) waiting periods necessary for the consummation of the Transactions imposed by any Government Authority in any jurisdiction where a Required Approval is required shall have expired or shall have been terminated.

(c)No Legal Restraint. There shall be no Legal Restraint in effect in a jurisdiction where a Required Approval is required.

Section 10.02. Conditions to Obligations of Buyer. The obligations of Buyer to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment or Buyer’s waiver (to the extent permitted by applicable Law) in its sole discretion, at or before the Closing, of each of the following conditions:

(a)Representations and Warranties; Covenants. (i) The representations and warranties of Seller made in Sections 4.01(a), 4.02, 4.03(a), 4.03(b), 4.04, 4.17, 4.18(b) e 4.20(a) shall be true and correct in all material respects as of the Closing as if made on the Closing Date (other than representations and warranties that are made as of a specific date, which representations and warranties shall have been true and correct in all material respects as of such date), (ii) the representations and warranties made in Section 4.08(b) shall be true and correct in all respects as of the Closing Date as if made on the Closing Date, (iii) all other representations and warranties of Seller contained in this Agreement shall be true and correct as of the Closing as if made on the Closing Date (other than representations and warranties that are made as of a specific date, which representations and warranties shall have been true and correct as of such date), except for breaches or inaccuracies, as the case may be, as to matters that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect; provided, however, that for purposes of determining the satisfaction of the condition in this clause (iii), no effect shall be given to the exceptions of “material” or “Material Adverse Effect” in such representations and warranties, (iv) the covenants contained in this Agreement required to be complied with by Seller on or before the Closing shall have been complied with in all material respects, and (v) Buyer shall have received a certificate signed by an authorized officer of Seller, dated as of the Closing Date, with respect to the matters set forth in the foregoing clauses (i) through (iv).

(b)Governmental Approvals. All (i) Required Approvals shall have been obtained and (ii) waiting periods necessary for the consummation of the Transactions imposed by any Government Authority in any jurisdiction where a Required Approval is required shall have expired or shall have been terminated.

(c)No Legal Restraint. There shall be no Legal Restraint in effect in a jurisdiction where a Required Approval is required.

ARTICLE XI

TERMINATION

Section 11.01. Termination. Notwithstanding anything in this Agreement to the contrary, this Agreement may be terminated before the Closing:

(a)by the mutual written consent of Seller and Buyer;

(b)by Seller, if Buyer shall have breached any representation or warranty or failed to comply with any covenant or agreement applicable to Buyer that would cause any Closing Condition set forth in Section 10.01(a) not to be satisfied, and such Closing Condition is incapable of being satisfied by the Outside Date or such breach has not been cured within sixty (60) days after delivery by Seller to Buyer of a written notice of such breach; provided, however, that, at the time of termination, Seller is not then in material breach of this Agreement;

(c)by Buyer, if Seller shall have breached any representation or warranty or failed to comply with any covenant or agreement applicable to Seller that would cause any Closing Condition set forth in Section 10.02(a) not to be satisfied, and such Closing Condition is incapable of being satisfied by the Outside Date or such breach has not been cured within sixty (60) days after delivery by Buyer to Seller of a written notice of such breach; provided, however, that, at the time of termination, Buyer is not then in material breach of this Agreement;

(d)by either Seller or Buyer if the Closing shall not have occurred by August 25, 2020 (the “Outside Date”); provided, however, that the right to terminate this Agreement under this Section 11.01(d) shall not be


available to either Party whose breach or failure to fulfill any obligations under this Agreement (including Section 6.04) has been the principal cause of, or resulted in, the failure of the Closing to occur before such date; o

(e)by either Seller or Buyer in the event that any Government Authority of competent jurisdiction shall have issued or enacted a Legal Restraint in effect in any jurisdiction where a Required Approval is required that permanently enjoins or prohibits the consummation of the purchase or sale of the Transferred Equity Interests or the Transferred Assets or the other Transactions and such Legal Restraint shall have become final and non-appealable; provided, however, that the right to terminate this Agreement under this Section 11.01(e) shall not be available to any Party whose breach or failure to fulfill any obligations under this Agreement has been the principal cause of, or resulted in, the issuance or enactment of any such Legal Restraint.

Section 11.02. Notice of Termination. Either Party desiring to terminate this Agreement pursuant to Section 11.01 shall give written notice of such termination to the other Party.

Section 11.03. Effect of Termination. In the event this Agreement is terminated pursuant to Section 11.01, this Agreement shall thereupon become null and void and of no further force and effect, except for the provisions of (i) Section 6.03(a), (ii) the last paragraph of Section 6.12(a), (iii) Section 11.01 and this Section 11.03 and (iv) Article XIII and, subject to such foregoing sections and the following sentence, there shall be no Liability on the part of either Party. Nothing in this Section 11.03 shall be deemed to release any Party from any Liability for Fraud or any knowing and material breach by such Party of any term of this Agreement (which shall include, for the avoidance of doubt, the knowing and material breach of Section 6.04 by either Party or impair the right of any Party (prior to the termination of this Agreement) to compel specific performance by any other Party of its obligations under this Agreement pursuant to Section 13.15).

ARTICLE XII

INDEMNIFICATION

Section 12.01. Survival. The representations and warranties of Seller and Buyer contained in or made pursuant to this Agreement shall terminate and not survive and be of no further force and effect from and after the Closing Date, and no party to this Agreement shall have any Liability with respect thereto from and after the Closing. The covenants in this Agreement that by their terms apply or are to be performed in whole or in part prior to the Closing shall survive in full force and effect until the date that is one year after the Closing Date, at which time they shall terminate and no claims shall be made for indemnification with respect thereto under Section 12.02 o 12.03 thereafter. The covenants in this Agreement that contemplate performance at or following the Effective Time shall survive in accordance with their terms, after which such covenants shall terminate and no claims shall be made for indemnification with respect thereto under Section 12.02 o Section 12.03 thereafter. For the avoidance of doubt, if notice of any covenant breach has been given to an Indemnifying Party prior to the time that such covenant would otherwise terminate hereunder, such claim shall survive until it is finally resolved.

Section 12.02. Indemnification by Seller.

(a)From and after the Closing, and subject to the terms of this Agreement, Seller shall indemnify and hold harmless Buyer and its Affiliates (collectively, the “Buyer Indemnified Parties”) against, and reimburse any Buyer Indemnified Party for, all Losses that such Buyer Indemnified Party may suffer or incur, or become subject to, without duplication as a result of:

i.prior to their expiration in accordance with Section 12.01 (to the extent applicable), any breach or failure by Seller to perform any of its covenants or agreements contained in this Agreement;

ii.any Excluded Liability; o

iii.(A) any Taxes (other than Transfer Taxes) imposed on any Transferred Entity solely as a result of such Transferred Entity being, or ceasing to be, a member of any affiliated, consolidated, combined or unitary Tax group (other than any such group that consists only of Transferred Entities) at any time on or prior to the Closing Date pursuant to Treasury Regulation Section 1.1502-6(a) (or under any similar provision of Law), (B) any Taxes (other than Transfer Taxes) imposed on a Transferred Entity, including Taxes of any Person (other than the Transferred Entities) imposed on a Transferred Entity as a transferee or successor, by contract or pursuant to any Law, for taxable years or periods ending on or before the Closing Date, (C) in the case of any Straddle Period, any Taxes (other than Transfer Taxes) imposed on a Transferred Entity, including Taxes of any Person (other than the Transferred Entities) imposed on a Transferred Entity as a transferee or successor, by contract or pursuant to any Law, for the portion of such Straddle Period ending on and including the Closing Date (D) any Pre-Closing Restructuring Taxes and (E) Transfer Taxes for which Seller is responsible pursuant to Section 9.07 (collectively, “Pre-Closing Taxes”); provided that for purposes of this Article XII, Pre-Closing Taxes shall be


calculated without taking into account any net operating loss, tax credit or other tax attribute of the Swedish Transferred Entities otherwise available to reduce, offset or eliminate such Pre-Closing Tax.

(b)Notwithstanding anything in this Agreement to the contrary:

i.the cumulative indemnification obligation of Seller under Article XII (other than Section 12.02(a)(ii)) shall in no event exceed 100% of the Purchase Price;

ii.Seller shall not be required to indemnify or hold harmless any Buyer Indemnified Party for any Losses reflected in the Final Closing Statement;

iii.the Buyer Indemnified Parties shall not have any right to indemnification under this Agreement with respect to, or based on, Taxes to the extent such Taxes (A) are attributable to Tax periods (or portions thereof) beginning after the Closing Date, (B) result from transactions or actions taken by Buyer or any of its Affiliates (including, for the avoidance of doubt, the Transferred Entities) outside the ordinary course of business on the Closing Date after the Closing except to the extent such transactions or actions are specifically contemplated by this Agreement or are required by applicable Law or (C) were taken into account in calculating the Purchase Price (as finalized pursuant to Section 3.04), as adjusted for payments from Buyer (or its applicable Affiliate) to Seller pursuant to Section 9.01(c) or the final sentence of Section 9.02(a); e

iv.Without limiting the rights and remedies of the applicable Buyer Indemnified Parties with respect to their Losses arising from, as a result of or related to the JVs, (A) none of the JVs shall be Buyer Indemnified Parties and (B) to the extent that any Claim is made pursuant to Section 12.02(a)(iii)(A) that arises out of or relates to Taxes imposed on a JV, Seller’s Liability hereunder for any Losses resulting therefrom shall be limited to the Buyer Indemnified Parties’ proportionate share of such Losses based on Buyer’s percentage ownership interest in such JV, as applicable, represented by the JV Interests in such JV, as applicable, sold to Buyer pursuant to Section 2.01(a) o Section 2.06, as applicable.

Section 12.03. Indemnification by Buyer.

(a)From and after the Closing, and subject to the terms of this Agreement, Buyer shall indemnify and hold harmless Seller and its Affiliates (collectively, the “Seller Indemnified Parties”) against, and reimburse any Seller Indemnified Party for, all Losses that such Seller Indemnified Party may suffer or incur, or become subject to as a result of:

i.prior to their expiration in accordance with Section 12.01 (to the extent applicable), any breach or failure by Buyer to perform any of its covenants or agreements contained in this Agreement;

ii.any Assumed Liability; o

iii.(A) any Taxes that such Seller Indemnified Party may be liable for or incur, or become subject to, as a result of any Taxes imposed in respect of a Transferred Entity, or with respect to the Business, with respect to any Tax period (or portion thereof) beginning after the Closing Date and (B) any Taxes that result from transactions or actions taken by Buyer or any of its Affiliates (including, for the avoidance of doubt, the Transferred Entities) outside the ordinary course of business on the Closing Date after the Closing except to the extent such transactions or actions are specifically contemplated by this Agreement or are required by applicable Law and (C) any Taxes for which Buyer is liable pursuant to Section 9.07, Section 9.01(c) o Section 9.02(a).

(b)Notwithstanding anything in this Agreement to the contrary, the cumulative indemnification obligation of Buyer under Article XII (other than Section 12.03(a)(ii)) shall in no event exceed 100% of the Purchase Price.

Section 12.04. Notification of Claims.

(a)Except as otherwise provided in this Agreement, a Person that may be entitled to be indemnified under this Agreement (the “Indemnified Party”), shall promptly notify the Party liable for such indemnification (the “Indemnifying Party”) in writing of any pending or threatened Claim, demand or circumstance that the Indemnified Party has determined has given or would reasonably be expected to give rise to a right of indemnification under this Agreement (including a pending or threatened Claim or demand asserted by a third party against the Indemnified Party, such Claim being a “Third Party Claim”), describing in reasonable detail the facts and circumstances with respect to the subject matter of such Claim, demand or circumstance; provided, however, that the failure to provide such notice shall not release the Indemnifying Party from any of its obligations under this Article XII except to the extent the Indemnifying Party is prejudiced by such failure.


(b)Upon receipt of a notice of a Claim for indemnity from an Indemnified Party pursuant to Section 12.04(a) with respect to any Third Party Claim, the Indemnifying Party shall have the right (but not the obligation) to assume the defense and control of any Third Party Claim and, in the event that the Indemnifying Party shall assume the defense of such Claim, it shall allow the Indemnified Party a reasonable opportunity to participate in the defense of such Third Party Claim with its own counsel and at its own expense; provided that, notwithstanding anything to the contrary in this Section 12.04, the Indemnifying Party shall not be entitled to assume the defense of any Third Party Claim (and, to the extent the Indemnifying Party has assumed the defense, shall transfer control of such defense to the Indemnified Party) if (i) such Third Party Claim seeks equitable relief or involves a criminal Action or (ii) the Indemnifying Party shall not have assumed the defense of such Third Party Claim within thirty (30) days of receipt of a notice of such Claim for indemnity. If the Indemnifying Party shall assume the defense of any such Third Party Claim, (x) the Indemnifying Party shall select, at the Indemnifying Party’s sole cost and expense, counsel, contractors and consultants of recognized standing and competence after consultation with the Indemnified Party (and in each case subject to approval by the Indemnified Party, which shall not be unreasonably withheld) and shall take all steps reasonably necessary in the defense or, to the extent permitted by Section 12.04(c), settlement of such Third Party Claim and (y) the Indemnified Party may retain separate co-counsel at its sole cost and expense and participate in the defense of such Third Party Claim; provided that the fees, costs and expenses of one such counsel shall be at the expense of the Indemnifying Party if the Indemnifying Party and the Indemnified Party are both named parties to the proceedings and the Indemnified Party shall have reasonably concluded that representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them.

(c)If the Indemnifying Party assumes the defense of any Third Party Claim, the Indemnified Party shall, and shall cause each of its Affiliates and Representatives to, cooperate fully with the Indemnifying Party, at the Indemnifying Party’s sole cost and expense, in the defense of any Third Party Claim. The Indemnifying Party shall not consent to a settlement of, or the entry of any judgment arising from, any Third Party Claim, without the consent of any Indemnified Party (which consent shall not be unreasonably withheld), provided, that the Indemnifying Party may agree to the settlement of, or the entry of any judgment arising from, any Third Party Claim without the Indemnified Party’s consent if it (i) does not include an injunction or other equitable remedy adversely affecting or encumbering any material assets of the Indemnified Parties, their respective Affiliates or the Business, (ii) does not involve criminal liability or any admission of wrongdoing, (iii) involves only the payment of monetary damages and the Indemnifying Party pays all amounts arising out of such settlement or judgment (subject to Section 12.02(b), if applicable) and (iv) includes, as a condition of such settlement or judgment, a complete release of any Indemnified Party potentially affected by such Third Party Claim.

(d)Notwithstanding anything in this Agreement to the contrary, no direct Claim may be made by any Buyer Indemnified Party for Taxes pursuant to this Agreement, and in the event of a conflict between this Section 12.04 e Section 9.04 with respect to the procedures governing a Claim for indemnification involving Taxes, the procedures set forth in Section 9.04 will control.

Section 12.05. Exclusive Remedies. Except as otherwise expressly set forth in this Agreement and without limiting any right or obligation under any other Transaction Agreements, including Section 3.04 e Section 13.15, following the Effective Time, the indemnification provisions of this Article XII (and, in the case of any Buyer Indemnified Party, the R&W Policy) shall be the sole and exclusive remedies of any Seller Indemnified Party and any Buyer Indemnified Party, respectively, for any Losses (including any Losses from Claims for breach of contract, warranty, tortious conduct (including negligence) or otherwise and whether predicated on common law, statute, strict Liability or otherwise) that it may at any time suffer or incur, or become subject to, as a result of, or in connection with, this Agreement or the Transactions, except in the case of Fraud. Without limiting the generality of the foregoing, the Parties hereby irrevocably waive any right of rescission they may otherwise have or to which they may become entitled.

Section 12.06. Additional Indemnification Provisions.

(a)With respect to each indemnification obligation contained in this Agreement: (i)  each such obligation shall be reduced by any Tax benefit actually realized in cash by the Indemnified Party during the taxable period in which such Loss arises or any of the three succeeding taxable periods (excluding, for the avoidance of doubt, any Tax benefit that represents only an acceleration of the timing with respect to which a loss, deduction, or other tax attribute is taken into account rather than a Tax benefit that results in permanent reduction in Tax Liability), (ii) all Losses shall be net of any amounts (less Recovery Expenses) that have been recovered by the Indemnified Party pursuant to any indemnification by, or indemnification agreement with, any third party or any insurance policy or other cash receipts or sources of reimbursement in respect of such Loss, (ii) all Losses shall be net of any amounts (less Recovery Expenses) that have been recovered by the Indemnified Party pursuant to any indemnification by, or indemnification agreement with, any third party or any insurance policy or other cash receipts or sources of reimbursement in respect of such Loss, (iii) all Losses will be determined after deducting therefrom the amount of any reserve with respect to such matter on the Final Closing Statement and (iv) Seller shall not be liable for any Losses to the extent that such Losses suffered by any Buyer Indemnified Party (A) result from the failure


of such Buyer Indemnified Party to take reasonable action to mitigate such Losses, (B) are taken into account in the calculation of Final Working Capital, or (C) are caused by or result from any action taken at the request of Buyer.

(b)If an Indemnifying Party makes any payment for any Losses suffered or incurred by an Indemnified Party pursuant to the provisions of this Article XII, such Indemnifying Party shall be subrogated, to the extent of such payment, to all rights and remedies of the Indemnified Party to any insurance benefits or other Claims of the Indemnified Party with respect to such Losses and with respect to the Claim giving rise to such Losses, in each case, to the extent permitted by the applicable insurance policies.

Section 12.07. Mitigation. Each Party shall, and shall cause its applicable Affiliates (including the Transferred Entities) and Representatives to, take reasonable steps to mitigate their respective Losses upon and after becoming aware of any fact, event, circumstance or condition that has given rise to or would reasonably be expected to give rise to, any Losses for which it would have the right to seek indemnification hereunder.

Section 12.08. Third Party Remedies. If any Buyer Indemnified Party or any of its Affiliates is at any time entitled (whether by reason of a contractual right, a right to take or bring an Action, availability of insurance, or a right to require a payment discount or otherwise) to recover from another Person any amount in respect of any matter giving rise to a Loss that is indemnifiable hereunder (whether before or after Seller has made a payment to any Buyer Indemnified Party hereunder and in respect thereof), in each case other than with respect to the R&W Policy, Buyer shall (and shall cause its applicable Affiliates (including the Transferred Entities) and Representatives to) (a) promptly notify Seller and provide such information as Seller may require relating to such right of recovery and the steps taken or to be taken by Buyer in connection therewith, (b) if so required by Seller (subject to Buyer being indemnified to its reasonable satisfaction by Seller against all reasonable out-of-pocket costs and expenses inc urred by Buyer in respect thereof) and before being entitled to recover any amount from Seller under this Agreement, first take such reasonable steps (whether by making a claim against its insurers, commencement of an Action or otherwise) as Seller may reasonably require to pursue such recovery and (c) keep Seller fully informed of the progress of any action taken in respect thereof. Thereafter, any claim against Seller shall be limited (in addition to the other limitations on Seller’s Liability referred to in this Agreement) to the amount by which the Losses suffered by Buyer Indemnified Party exceed the amounts so recovered by Buyer Indemnified Party or any such Affiliate, net of Recovery Expenses. If Buyer Indemnified Parties recover any amounts in respect of Losses from any third party at any time after Seller has paid all or a portion of such Losses to Buyer Indemnified Parties pursuant to the provisions of this Article XII, Buyer shall, or shall cause such Buyer Indemnified Parties to, promptly (and in any event within five (5) Business Days after receipt) pay over to Seller the amount so received (to the extent previously paid by Seller) net of Recovery Expenses, provided that no Buyer Indemnified Party shall be required to first seek recovery from an insurer or any other Person prior to seeking and obtaining recovery from the Indemnifying Party. The provisions of this Section 12.08 shall apply mutatis mutandis to claims of a Seller Indemnified Party.

Section 12.09. Limitation on Liability. Notwithstanding anything in this Agreement or in any other Transaction Agreement to the contrary, in no event shall either Party have any Liability under any Transaction Agreement (including under this Article XII) for any punitive damages (except to the extent actually awarded and payable to any third party).

Section 12.10. Tax Treatment of Payments. Seller and Buyer shall treat any adjustments or indemnity payments made pursuant to this Agreement as adjustments to the Purchase Price for income Tax purposes unless applicable Tax Law causes such payment not to be so treated.

Section 12.11. Representation and Warranty Insurance. If Buyer or any of its Affiliates procures a representation and warranty insurance policy (or other similar policy) (a “R&W Policy”), then (i) such R&W Policy shall be at Buyer’s sole expense and (ii) Buyer shall cause such R&W Policy to expressly include a waiver by the insurer of any and all subrogation rights against Seller and its Affiliates and their respective officers, directors and employees (other than arising from Fraud). Buyer shall cause each insured party under any such R&W Policy not to waive, amend, modify or otherwise revise such subrogation provision, or allow such provision to be waived, amended, modified or otherwise revised in a manner that is adverse to Seller without the prior written consent of Seller. Seller shall reasonably cooperate with Buyer with respect to Buyer’s procurement of any such R&W Policy.


ARTICLE XIII

MISCELLANEOUS

Section 13.01. Rules of Construction. The following rules of construction shall govern the interpretation of this Agreement:

(a)references to “applicable” Law or Laws with respect to a particular Person, thing or matter means only such Law or Laws as to which the Government Authority that enacted or promulgated such Law or Laws has jurisdiction over such Person, thing or matter; references to any statute, rule, regulation or form (including in the definition thereof) shall be deemed to include references to such statute, rule, regulation or form as amended, modified, supplemented or replaced from time to time (and, in the case of any statute, include any rules and regulations promulgated under such statute), and all references to any section of any statute, rule, regulation or form include any successor to such section;

(b)an item arising with respect to a specific representation or warranty shall be deemed to be “reflected on” or “set forth in” a balance sheet or financial statements (other than any Closing Statements) to the extent (i) there is a reserve, accrual or other similar item underlying a number on such balance sheet or financial statement that is related to the subject matter of such representation, (ii) such item is otherwise specifically set forth on the balance sheet or financial statement or (iii) such item is reflected on the balance sheet or financial statement and is specifically referred to in the notes thereto;

(c)when calculating the period of time before which, within which or following which any act is to be done or step taken pursuant to this Agreement, the date that is referenced in beginning the calculation of such period will be excluded (for example, if an action is to be taken within two days after a triggering event and such event occurs on a Tuesday, then the action must be taken by Thursday); if the last day of such period is a non-Business Day, the period in question will end on the next succeeding Business Day;

(d)whenever the context requires, words in the singular shall be held to include the plural and vice versa, and words of one gender shall be held to include the other gender as the context requires;

(e)(i) the provision of a table of contents, the division into Articles, Sections and other subdivisions and the insertion of headings are for convenience of reference only and shall not affect or be utilized in construing or interpreting this Agreement and (ii) references to the terms “Article,” “Section,” “subsection,” “subclause,” “clause,” “Schedule” and “Exhibit” are references to the Articles, Sections, subsections, subclauses, clauses, Schedules and Exhibits to this Agreement unless otherwise specified;

(f)(i) the terms “hereof,” “herein,” “hereby,” “hereto” and derivative or similar words refer to this entire Agreement, including the Schedules and Exhibits hereto, (ii) the terms “include,” “includes,” “including” and words of similar import when used in this Agreement mean “including, without limitation” unless otherwise specified, (iii) the term “any” means “any and all,” (iv) the term “or” shall not be exclusive and shall mean “and/or,” and (v) “extent” in the term “to the extent” means the degree to which a subject or other thing extends, and such term does not mean simply “if”;

(g)(i) references to “days” means calendar days unless Business Days are expressly specified, (ii) references to “written” or “in writing” include in electronic form to the extent in compliance with Section 13.03, (iii) references to “$” mean U.S. dollars and (iv) references to a date or time shall be deemed to be references to such date or time in the City of Boston, Massachusetts, U.S.A., unless otherwise specified;

(h)references to any Person includes such Person’s successors and permitted assigns;

(i)where any information, document or material is described as “delivered” or “made available” to Buyer prior to the Agreement Date, it shall mean that such information, document or material has been posted to the Data Room established by Seller by 7:00 p.m. New York time on February 24, 2019;

(j)the term “in the ordinary course of business” means in the ordinary course of business consistent with past practice;

(k)the term “knowing and material breach” means a deliberate act or failure to act, which act or failure to act the breaching Party knows (or should reasonably have known) constitutes, or would reasonably be expected to constitute, in and of itself a material breach of this Agreement;


(l)whenever this Agreement requires any Seller Party to take any action, such requirement shall be deemed to involve an undertaking on the part of Seller to take such action or to cause such Seller Party to take such action; e

(m)each Party has participated in the negotiation and drafting of this Agreement and if an ambiguity or question of interpretation should arise, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or burdening either Party by virtue of the authorship of any provision in this Agreement; the language used herein will be deemed to be the language chosen by the Parties to express their mutual intent, and no rule of strict construction will be applied against either Party. Further, prior drafts of this Agreement or any ancillary agreements hereto or the fact that any clauses have been added, deleted or otherwise modified from any prior drafts of this Agreement or any ancillary agreements hereto or emails exchanged between the Parties or their Representatives shall not be used as an aide of construction or otherwise constitute evidence of the intent of the Parties; and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of such prior drafts or communications.

Section 13.02. Expenses. Except as otherwise specified in the Transaction Agreements, each Party will pay its own costs and expenses, including legal, consulting, financial advisor and accounting fees and expenses, incurred in connection with the Transaction Agreements and the Transactions, irrespective of when incurred or whether or not the Closing occurs.

Section 13.03 Notices. All notices and other communications under or by reason of the Transaction Agreements shall be in writing and shall be deemed to have been duly given or made (a) when personally delivered, (b) when delivered by e-mail transmission with receipt confirmed (followed by delivery of an original by another delivery method provided for in this Section 13.03) or (c) upon delivery by overnight courier service, in each case to the addresses and attention parties indicated below (or such other address, e-mail address or attention party as the recipient party has specified by prior notice given to the sending party in accordance with this Section 13.03):

If to Seller, to:

General Electric Company

41 Farnsworth Street

Boston, Massachusetts 02210

Attention:

Michael Buckner

Jessica Wenzell

E-mail:

michael.buckner@ge.com

jessica.wenzell@ge.com

with a copy (which will not constitute notice) to:

Paul, Weiss, Rifkind, Wharton & Garrison LLP

1285 Avenue of the Americas

New York, New York 10019

Attention:

Scott A. Barshay

Steven J. Williams

E-mail:

sbarshay@paulweiss.com

swilliams@paulweiss.com


If to Buyer, to:

Danaher Corporation

2200 Pennsylvania Ave., NW

Suite 800W

Washington D.C. 20037

Attention:

Attila Bodi

Jeffrey Szekeres

Angela Lin

E-mail:

attila.bodi@danaher.com

jeff.szekeres@danaher.com

angela.lin@danaher.com

with a copy (which will not constitute notice) to:

Kirkland & Ellis LLP

601 Lexington Avenue

New York, New York 10022

Attention:

Daniel E. Wolf, P.C.

Michael P. Brueck, P.C.

James Hu

E-mail:

daniel.wolf@kirkland.com

michael.brueck@kirkland.com

james.hu@kirkland.com

Section 13.04. Public Announcements. The initial press release with respect to the execution of this Agreement of each Party shall be reasonably agreed upon by the other Party. Neither Party or any Affiliate or Representative of either Party shall issue or cause the publication of any press release or public announcement or otherwise communicate with any news media in respect of the Transaction Agreements or the Transactions without the prior written consent of the other Party (which consent shall not be unreasonably withheld, conditioned or delayed), except (a) as a Party believes in good faith and based on reasonable advice of counsel is required by applicable Law or by applicable rules of any stock exchange or quotation system on which such Party or its Affiliates lists or trades securities (in which case the disclosing Party will use its commercially reasonable efforts to (i) advise the other Party before making such disclosure and (ii) provide such other Party a reasonable opportunity to review and comment on such release or announcement and consider in good faith any comments with respect thereto) or (b) a Party may make such public disclosures that a re consistent with prior disclosures made in compliance with this Section 13.04 or any communication plan or strategy previously agreed to by the Parties.

Section 13.05 Severability. If any term or provision of this Agreement is held invalid, illegal or unenforceable in any respect under any applicable Law, as a matter of public policy or on any other grounds, the validity, legality and enforceability of all other terms and provisions of this Agreement will not in any way be affected or impaired. If the final judgment of a court of competent jurisdiction or other Government Authority declares that any term or provision hereof is invalid, illegal or unenforceable, the Parties agree that the court making such determination will have the power to reduce the scope, duration, area or applicability of the term or provision, to delete specific words or phrases, or to replace any invalid, illegal or unenforceable term or provision with a term or provision that is valid, legal and enforceable and that comes closest to expressing the intention of the invalid, illegal or unenforceable term or provision.

Section 13.06 Assignment. This Agreement will be binding upon and inure to the benefit of and be enforceable by the respective successors and permitted assigns of the Parties. Neither Party may assign (whether by operation of Law or otherwise) this Agreement or any rights, interests or obligations provided by this Agreement without the prior written consent of the other Party; provided, however, that either Party may assign this Agreement and any or all rights and obligations under this Agreement to any of its Affiliates upon prior written notice to the other Party; provided, further, that no such assignment shall release either Party from any Liability under this Agreement. Any attempted assignment in violation of this Section 13.06 shall be void ab initio.

Section 13.07 No Third-Party Beneficiaries. This Agreement and the other Transaction Agreements are for the sole benefit of the Parties and their respective successors and permitted assigns, and, except with respect to Buyer


Indemnified Parties and Seller Indemnified Parties pursuant to Article XII and the D&O Indemnified Parties pursuant to Section 7.03, or as expressly set forth in the applicable Transaction Agreement, nothing in the Transaction Agreements shall create or be deemed to create any third-party beneficiary rights in any Person not a party to the Transaction Agreements, including any Affiliates of any Party.

Section 13.08 Entire Agreement. This Agreement (including the Disclosure Schedules), the other Transaction Agreements (and all exhibits and schedules hereto and thereto) and the Confidentiality Agreement collectively constitute and contain the entire agreement and understanding of the Parties with respect to the subject matter hereof and thereof and supersede all prior negotiations, correspondence, understandings, contracts and agreements, whether written or oral, among the Parties respecting the subject matter hereof and thereof. In the event that the provisions of the Transitional Trademark License Agreement, Intellectual Property Cross License Agreement or the Transition Services Agreement conflict with the provisions of this Agreement, the provisions of such other Transaction Agreement shall govern with respect to the subject matter addressed thereby to the extent of such conflict.

Section 13.09. Amendments. The Transaction Agreements (including all exhibits and schedules thereto) may be amended, restated supplemented or otherwise modified, only by written agreement making specific reference to the applicable Transaction Agreement to be amended, restated, supplemented or otherwise modified, in each case duly executed by each party to such Transaction Agreement. No Consent from any Indemnified Party under Article XIII (in each case other than the Parties) shall be required to amend this Agreement.

Section 13.10. Waiver. At any time before the Closing, either Seller or Buyer may (a) extend the time for the performance of any obligation or other acts of the other Person, (b) waive any breaches or inaccuracies in the representations and warranties of the other Person contained in this Agreement or in any document delivered pursuant to this Agreement or (c) waive compliance with any covenant, agreement or condition contained in this Agreement but such waiver of compliance with any such covenant, agreement or condition shall not operate as a waiver of, or estoppel with respect to, any subsequent or other failure. Any such waiver shall be in a written instrument duly executed by the waiving Party. No failure on the part of either Party to exercise, and no delay in exercising, any right, power or remedy under any Transaction Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such Party preclude any other or further exercise thereof or the exercise of any other right, power or remedy.

Section 13.11 Governing Law. The Transaction Agreements, and any Action that may be based upon, arise out of or relate or be incidental to any Transaction, any Transaction Agreement, the negotiation, execution, performance or consummation of any of the foregoing or the inducement of any Party to enter into any of the foregoing, whether for breach of contract, tortious conduct or otherwise, and whether now existing or hereafter arising (each, a “Transaction Dispute”), will be exclusively governed by and construed and enforced in accordance with the internal Laws of the State of Delaware, without giving effect to any Law or rule that would cause the Laws of any jurisdiction other than the State of Delaware to be applied. The Parties expressly acknowledge and agree that (a) the requirements of 6 Del. C § 2708 are satisfied by the provisions of this Agreement and that such statute mandates the application of Laws of the State of Delaware to this Agreement, the relationship of the Parties, the Transactions and the interpretation and enforcement of the rights and duties of the Parties hereunder and (b) the Parties have a reasonable basis for the application of the Laws of the State of Delaware to this Agreement, the relationship of the Parties, the Transactions and the interpretation and enforcement of the rights and duties of the Parties hereunder. Seller shall cause the Seller Indemnified Parties, and Buyer shall cause the Buyer Indemnified Parties, to comply with the foregoing as though such Indemnified Parties were a Party to this Agreement.

Section 13.12. Dispute Resolution; Consent to Jurisdiction.

(a)Except as otherwise provided in Section 3.04, any Transaction Dispute will exclusively be brought and resolved in the Court of Chancery of the State of Delaware (or, only if such court declines to accept jurisdiction over a particular matter, then in the United States District Court for the District of Delaware or, if jurisdiction is not then available in the United States District Court for the District of Delaware (but only in such event), then in any Delaware state court sitting in New Castle County) and any appellate court from any of such courts. In that context, and without limiting the generality of the foregoing, each Party irrevocably and unconditionally:

i.submits for itself and its property to the exclusive jurisdiction of such courts with respect to any Transaction Dispute and for recognition and enforcement of any judgment in respect thereof, and agrees that all Claims in respect of any Transaction Dispute shall be heard and determined in such courts;

ii.agrees that venue would be proper in such courts, and waives any objection that it may now or hereafter have that any such court is an improper or inconvenient forum for the resolution of any Transaction Dispute; e


iii.agrees that the mailing by certified or registered mail, return receipt requested, to the Persons listed in Section 13.03 of any process required by any such court, will be effective service of process; provided, however, that nothing herein will be deemed to prevent a Party from making service of process by any means authorized by the Laws of the State of Delaware.

(b)The foregoing consent to jurisdiction will not constitute submission to jurisdiction or general consent to service of process in the State of Delaware for any purpose except with respect to any Transaction Dispute.

Section 13.13. Waiver of Jury Trial. To the maximum extent permitted by Law, each Party irrevocably and unconditionally waives any right to trial by jury in any forum in respect of any Transaction Dispute and covenants that neither it nor any of its Affiliates or Representatives will assert (whether as plaintiff, defendant or otherwise) any right to such trial by jury. Each Party certifies and acknowledges that (a) such Party has considered the implications of this waiver, (b) such Party makes this waiver voluntarily and (c) such waiver constitutes a material inducement upon which such Party is relying and will rely in entering into the Transaction Agreements. Each Party may file an original counterpart or a copy of this Section 13.13 with any court as written evidence of the consent of each Party to the waiver of its right to trial by jury.

Section 13.14. Admissibility into Evidence. All offers of compromise or settlement among the Parties or their Representatives in connection with the attempted resolution of any Transaction Dispute (a) shall be deemed to have been delivered in furtherance of a Transaction Dispute settlement, (b) shall be exempt from discovery and production and (c) shall not be admissible into evidence (whether as an admission or otherwise) in any proceeding for the resolution of the Transaction Dispute.

Section 13.15. Remedies; Specific Performance.

(a)Except to the extent set forth otherwise in this Agreement (including in Section 12.05), all remedies under this Agreement expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy.

(b)Each Party acknowledges and agrees that irreparable damage (for which monetary relief, even if available, would not be an adequate remedy) would occur and the Parties would not have an adequate remedy at law if any provision of this Agreement is not performed in accordance with its specific terms or is otherwise breached, including if any Party fails to take such actions as are required of it hereunder to consummate the Transactions or to enable the Transactions to be consummated. Accordingly, each Party agrees that, unless this Agreement is validly terminated, the other Party will be entitled to injunctive relief at any time from time to time in respect of breaches (or threatened breaches) of the provisions of this Agreement and to enforce specifically the terms and provisions of this Agreement, in each case (i) without the requirement of posting any bond or other indemnity and (ii) in addition to any other remedy to which it may be entitled, at law or in equity. Furthermore, each Party agrees (x) not to raise any objections (whether on the basis that a remedy of monetary damages would provide an adequate remedy for any such breach or otherwise) to the availability of the equitable remedy of specific performance to restrain breaches or threatened breaches of this Agreement, and to specifically enforce the terms of this Agreement to prevent breaches or threatened breaches of, or to enforce compliance with, the covenants and obligations of such Party under this Agreement and (y) that the right to specific performance is an integral part of the Transactions and without such right neither Seller nor Buyer would have entered into this Agreement. Each Party expressly disclaims that it is owed any duty not expressly set forth in this Agreement.

(c)The Parties further agree that (i) by seeking the remedies provided for in this Section 13.15, a Party shall not in any respect waive its right to seek any other form of relief that may be available to a Party under this Agreement in the event that this Agreement has been terminated or in the event that the remedies provided for in this Section 13.15 are not available or otherwise are not granted, and (ii) nothing set forth in this Section 13.15 shall require any Party to institute any proceeding for (or limit any Party’s right to institute any proceeding for) specific performance under this Section 13.15 prior to or as a condition to exercising any termination right under Article XI (and pursuing damages after such termination), nor shall the commencement of any legal proceeding pursuant to this Section 13.15 or anything set forth in this Section 13.15 restrict or limit any Party’s right to pursue any other remedies under this Agreement that may be available then or thereafter. In the event that a party initiates a proceeding seeking equitable relief pursuant to this Section 13.15, the Outside Date shall automatically be extended until such proceeding is finally resolved.

Section 13.16. Non-Recourse. All Claims, obligations, Liabilities or causes of action (whether in contract or in tort, in law or in equity, or granted by statute) that may be based upon, in respect of, arise under, out or by reason of, be connected with, or relate in any manner to the Transaction Agreements, or the negotiation, execution, or performance of the Transaction Agreements (including any representation or warranty made in, in connection with, or as an inducement to, the Transaction Agreements), may be made only against (and are expressly limited to) the entities that are expressly identified as


parties in the preamble to this Agreement or the other Transaction Agreements, as applicable (“Contracting Parties”). No Person who is not a Contracting Party, including any past, present or future director, officer, employee, incorporator, member, partner, manager, stockholder, Affiliate, agent, attorney, or representative of, and any financial advisor or lender to, any Contracting Party, or any director, officer, employee, incorporator, member, partner, manager, stockholder, Affiliate, agent, attorney, or representative of, and any financial advisor or lender to, any of the foregoing (“Nonparty Affiliates”), shall have any Liability (whether in contract or in tort, in law or in equity, or granted by statute) for any claims, causes of action, obligations or Liabilities arising under, out of, in connection with, or related in any manner to the Transaction Agreements or based on, in respect of, or by reason of the Transaction Agreements or their negotiation, execution, performance or breach; and, to the maximum extent permitted by law, each Contracting Party hereby waives and releases all such Liabilities, claims, causes of action and obligations against any such Nonparty Affiliates.

Section 13.17. Interest. If any payment expressly required to be made to a Party under this Agreement is made after the date on which such payment is due, interest shall accrue on such amount from (but not including) the due date of the payment to (and including) the date such payment is actually made at the Interest Rate. All computations of interest pursuant to this Agreement shall be made on the basis of a year of 365 days, in each case, for the actual number of days from (but not including) the first day to (and including) the last day occurring in the period for which such interest is payable.

Section 13.18. Disclosure Schedules and Exhibits. The Disclosure Schedules, Schedules and Exhibits attached to this Agreement shall be construed with and as an integral part of this Agreement to the same extent as if the same had been set forth verbatim herein. Any capitalized terms used in any Exhibit or Schedule or in the Disclosure Schedules but not otherwise defined therein shall be defined as set forth in this Agreement. The representations and warranties of Seller set forth in this Agreement are made and given subject to the disclosures contained in the Disclosure Schedules, and neither Seller nor any of its Affiliates shall be, or deemed to be, in breach of any such representations and warranties (and no claim shall lie in respect thereof) in respect of any such matter so disclosed in the Disclosure Schedules. Where only brief particulars of a matter are set out or referred to in the Disclosure Schedules or a reference is made only to a particular part of a disclosed document, full particulars of the matter and the full contents of the document are deemed to be disclosed to the extent such full particulars or full contents can be reasonably understood from the disclosures set forth in the Disclosure Schedules together with such documents as have been made available to Buyer. Inclusion of information in the Disclosure Schedules will not be construed as an admission that such information is material to the business, operations or condition (financial or otherwise) of the Business. The Disclosure Schedules have been arranged for purposes of convenience in separately titled Schedules corresponding to the Sections of this Agreement, however, each Schedule (other than Schedule 4.08(b)) of the Disclosure Schedules shall be deemed to incorporate by reference all information disclosed in any other Schedule of the Disclosure Schedules to the extent it is reasonably apparent that the disclosure of such matter is applicable to such Schedule of the Disclosure Schedules.

Section 13.19. Provision Respecting Legal Representation. Each Party to this Agreement agrees, on its own behalf and on behalf of its Affiliates and Representatives, that Paul, Weiss, Rifkind, Wharton & Garrison LLP may serve as counsel to Seller or any of its Subsidiaries, on the one hand, and any Transferred Entity, on the other hand, in connection with the negotiation, preparation, execution and delivery of the Transaction Agreements and the consummation of the Transactions, and that, following consummation of the Transactions, Paul, Weiss, Rifkind, Wharton & Garrison LLP may serve as counsel to Seller or any of its Subsidiaries or any Representative of any such party, in connection with any litigation, claim or obligation arising out of or relating to the Transactions and the Transaction Agreements notwithstanding such prior representation of any Transferred Entity and each Party consents thereto and waives any conflict of interest arising therefrom, and each Party shall cause its Affiliates and Representatives to consent to waive any con flict of interest arising from such representation.

Section 13.20. Privilege. Buyer, for itself and its Affiliates, and its and its Affiliates’ respective successors and assigns, hereby irrevocably and unconditionally acknowledges and agrees that, other than in the case of Fraud, all attorney-client privileged communications between any Seller, any of its Subsidiaries (including any Transferred Entity), any JV and their respective current or former Affiliates or Representatives and their counsel, including Paul, Weiss, Rifkind, Wharton & Garrison LLP, made before the consummation of the Closing in connection with the negotiation, preparation, execution, delivery and Closing under any Transaction Agreement or any Transaction Dispute shall continue after the Closing to be privileged communications with such counsel and neither Buyer nor any of its former or current Affiliates or Representatives nor any Person purporting to act on behalf of or through Buyer or any of its current or former Affiliates or Representatives, shall seek to obtain the same by any process on the grounds that the privilege attaching to such communications belongs to Buyer, any Transferred Entity or the Business or on any other grounds.

Section 13.21. Counterparts. Each Transaction Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which when taken together shall constitute one and the same instrument. Facsimiles, e-mail transmission of .pdf signatures or other electronic copies of signatures shall be deemed to be originals.


Section 13.22. Debt Financing Sources. Notwithstanding anything to the contrary contained in this Agreement, each Party: (a) agrees that it will not bring any action, suit, proceeding, cause of action, claim, cross-claim or third-party claim of any kind or description, whether in law or in equity, whether in contract or in tort or otherwise, against any of the debt financing sources (or any Lender Related Party) in any way relating to this Agreement or any of the Transactions, including any dispute arising out of or relating in any way to the Financing, in any forum other than the federal and New York State courts located in the Borough of Manhattan of the City of New York; (b) agrees that all claims or causes of action (whether in law, in equity, in contract, in tort or otherwise) against any of the debt financing sources (or any Lender Related Party) in any way relating to the Financing, shall be exclusively governed by, and construed in accordance with, the Laws of the State of New York; and (c) hereby irrevocably and unconditionally waives any right such party may have to a trial by jury in respect of any litigation (whether in law or in equity; whether in contract or in tort or otherwise) directly or indirectly arising out of or relating in any way to the Financing. Notwithstanding anything to the contrary contained this Agreement, (i) the Seller, the Company and their respective Subsidiaries and their respective Representatives, Affiliates, directors, officers, employees, agents, partners, managers, members or stockholders shall not have any rights or Claims against any debt financing source (or any Lender Related Party) in any way relating to this Agreement or any of the Transactions, or in respect of any oral representations made or alleged to have been made in connection herewith or therewith, including any dispute arising out of or relating in any way to the Financing, whether at law or equity, in contract, in tort or otherwise and (ii) no debt financing source (and no Lender Related Party) shall have any Liability (whether in contract, in tort or otherwise) to the Seller, its Subsidiaries, their respective Representatives and their respective Affiliates, directors, officers, employees, agents, partners, managers, members or stockholders for any obligations or Liabilities of any Party hereto under this Agreement or for any Claim based on, in respect of, or by reason of, the Transactions or in respect of any oral representations made or alleged to have been made in connection herewith or therewith, including any dispute arising out of or relating in any way to the Financing, whether at law or equity, in contract, in tort or otherwise. Notwithstanding anything to the contrary contained in this Agreement, the debt financing sources (and the Lender Related Parties) are intended third-party beneficiaries of, and shall be entitled to the protections of this provision (it being understood that the foregoing provisions may not be amended in a manner adverse to the debt financing sources (or the Lender Related Parties) in any material respect without their prior written consent).

Section 13.23. Release. Effective as of the Closing and except as otherwise expressly set forth in this Agreement or any Transaction Agreement, (a) Seller, on behalf of itself, its Affiliates, its Subsidiaries (excluding the Transferred Entities) and all of their respective successors and assigns (each, a “Seller Releasing Party”), irrevocably waives, releases and discharges Buyer, its Affiliates, its Subsidiaries (including the Transferred Entities) and all of their respective successors and assigns (each, a “Seller Released Party”) from and against any and all Claims, Actions, obligations or Liabilities of any nature whatsoever, whether now known or unknown, suspected or unsuspected, primary or secondary, direct or indirect, absolute or contingent (collectively, the “Seller Claims”), that any Seller Releasing Party now has, or at any time had, or shall or may have in the future, in connection with any Seller Releasing Party’s direct or indirect ownership or operation of the Business or any Transferred Assets, or as a counterparty to any contract or agreement with any Transferred Entity or otherwise, in each case arising with respect to any matter occurring at or prior to the Closing; provided, that the foregoing waiver, release and discharge shall not apply to (i) any Seller Claim arising out of or relating to this Agreement or any other Transaction Agreement, (ii) any Seller Claim unrelated to the Business or the Transferred Assets or (iii) any Intercompany Agreement set forth on Schedule 4.20, and (b) Buyer, on behalf of itself, its Affiliates, its Subsidiaries (including the Transferred Entities) and all of their respective successors and assigns (each, a “Buyer Releasing Party”), irrevocably waives, releases and discharges Seller, its Affiliates, its Subsidiaries (excluding the Transferred Entities) and all of their respective successors and assigns (each, a “Buyer Released Party”) from and against any and all Claims, Actions, obligations or Liabilities of any nature whatsoever, whether now known or unknown, suspected or unsuspected, primary or secondary, direct or indirect, absolute or contingent (collectively, the “Buyer Claims”), that any Buyer Releasing Party now has, or at any time had, or shall or may have in the future, in connection with any Buyer Releasing Party’s direct or indirect ownership or operation of the Business or any Transferred Assets, or as a counterparty to any contract or agreement with any Transferred Entity or otherwise, in each case arising with respect to any matter occurring at or prior to the Closing; provided, that the foregoing waiver, release and discharge shall not apply to (i) any Buyer Claim arising out of or relating to this Agreement or any other Transaction Agreement, (ii) any Buyer Claim unrelated to the Business or the Transferred Assets or (iii) any Intercompany Agreement set forth on Schedule 4.20.

(REMAINDER OF PAGE INTENTIONALLY LEFT BLANK;

SIGNATURE PAGE FOLLOWS)


IN WITNESS WHEREOF, Seller and Buyer have caused this Agreement to be executed on the date first written above by their respective duly authorized officers.

SELLER:

GENERAL ELECTRIC COMPANY

By:

/s/John Godsman

Name:

John Godsman

Title:

Vice President, Business Development

BUYER:

DANAHER CORPORATION

By:

/s/Frank T. McFaden

Name:

Frank T. McFaden

Title:

Vice President & Treasurer

(Signature Page to Equity and Asset Purchase Agreement)


EXHIBIT A

DEFINITIONS

2018 Audited Balance Sheet” means the audited balance sheet of the Business as of December 31, 2018.

2018 EBITDA” means the earnings before interest, income taxes, depreciation expense, amortization expense, and any charge related to the impairment of goodwill of the Business for the fiscal year ended December 31, 2018 derived from the Audited Financial Statements for the fiscal year ended December 31, 2018, as calculated in accordance with Annex A.

2018 Unaudited Balance Sheet” means the management-prepared unaudited balance sheet of the Business as of December 31, 2018.

Accrued Income Taxes” means an amount (not less than zero) equal to the aggregate current Income Tax Liabilities of the Transferred Entities (which shall not be less than zero in any jurisdiction) for all taxable periods (or portions thereof) ending on or before the Closing Date for which final Tax Returns have not been filed. The calculation of Accrued Income Taxes shall (i) exclude any deferred Tax Liabilities or deferred Tax assets and any amounts in respect of speculative or contingent Liabilities for Tax, (ii) include estimated (or other prepaid) Income Tax payments only to the extent that such payments have the effect of reducing (not below zero) the particular current Income Tax Liability in respect of which such payments were made, (iii) include Income Tax deductions or Tax refunds (including for overpayments of estimated Taxes), in each case, only to the extent such deductions or Tax refunds have the effect of reducing (not below zero) a particular current Income Tax Liability to which they are relevant, (iv) be prepared in accordance with the past practice (including reporting positions and accounting methods) of the applicable Transferred Entity in preparing Tax Returns for Income Taxes and (v) in the case of a Straddle Period, be determined in accordance with Section 9.03.

Action” means any action, suit, charge, complaint, audit, investigation, arbitration or proceeding by or before any Government Authority.

Active Participants” means Transferred Employees who are accruing a benefit as of the Effective Time under one of the Specified Pension Plans.

Affiliate” means, with respect to any specified Person, any other Person that, at the time of determination, directly or indirectly through one or more intermediaries, Controls, is Controlled by or is under common Control with such specified Person; provided, however, that for the purposes of this Agreement (a) Seller shall not be deemed an Affiliate of Buyer, nor, after the Closing, of any Transferred Entity and (b) after the Closing, Buyer shall be deemed an Affiliate of each of the Transferred Entities (and vice versa). For the avoidance of doubt, prior to the Closing, the Transferred Entities shall be deemed Affiliates of Seller.

Agreement” means this Equity and Asset Purchase Agreement, dated as of February 25, 2019, by and between Seller and Buyer, including the Disclosure Schedules and the Exhibits (as amended and restated as of March 31, 2020), and all amendments to such agreement made in accordance with Section 13.09.

Anti-Corruption Laws” means all applicable U.S. and non-U.S. Laws for the prevention of public or commercial corruption and bribery, including, without limitation, the U.S. Foreign Corrupt Practices Act of 1977, as amended.

Audited Financial Statements” means the audited balance sheet, income statement and cash flow statement of the Business for (i) the fiscal years ended December 31, 2018 and 2017 and (ii) each fiscal year subsequent to December 31, 2018 and ended at least 60 days prior to the Closing Date.

Bankruptcy and Equity Exception” means the effect on enforceability of (a) any applicable Law relating to bankruptcy, reorganization, insolvency, moratorium, fraudulent conveyance or preferential transfers, or similar Law relating to or affecting creditors’ rights generally and (b) general principles of equity (regardless of whether enforceability is considered in a proceeding in equity or at law).

BP Entity” means each Transferred Entity, each JV, and any other Person in which any Transferred Entity, a JV, or their respective Subsidiaries is a shareholder, a member or a partner.

Attività commerciale” means the Biopharma division of the Life Sciences Business Unit (excluding, for the avoidance of doubt, the PDx business).


Business Day” means any day that is not a Saturday, a Sunday or other day on which commercial banks in the City of New York, New York are required or authorized by Law to be closed.

Business Employee” means:

(i) each employee of the Healthcare Business Unit, Life Sciences Business Unit, or Biopharma division of the Life Sciences Business Unit who (A) during 2018, dedicated at least 80% of his or her working time for Seller and its Subsidiaries to or on behalf of the Business and (B) as of the Agreement Date is employed in a substantially similar manner (such employees described in this clause (i), the “Dedicated Employees”);

(ii) each employee of Seller or any of its Subsidiaries in the Life Sciences Business Unit listed on Schedule A-1;

(iii) (A) (1) each Oracle Center of Excellence (CofE) technical and functional Oracle employee who supports the Oracle 12 instance for the Biopharma division of the Life Sciences Business Unit and (2) each employee who supports the eCommerce/Hybris environment in connection with the Business, and (B) each employee of the Healthcare Business Unit or Life Sciences Business Unit who (1) supports the Oracle 12 instance for the Biopharma division of the Life Sciences Business Unit and (2) has been selected by Buyer and Seller acting reasonably and in good faith between the Agreement Date and the Closing Date to be included as a Business Employee;

(iv) each employee of Seller or any of its Subsidiaries in the Healthcare Business Unit or Life Sciences Business Unit who (A) is not a Dedicated Employee, (B) during 2018, dedicated a substantial portion of his or her working time on behalf of Seller or its Subsidiaries to or on behalf of the Business, (C) as of the Agreement Date is employed in a substantially similar manner, and (D) has been selected by Buyer and Seller acting reasonably and in good faith between the Agreement Date and the Closing Date to be included as a Business Employee;

(v) each employee of Seller and its Subsidiaries (not otherwise covered by clause (i), (ii), (iii) or (iv)), who (A) is in Seller’s Global Operations Shared Services or IT group that currently supports the Healthcare Business Unit and who, during 2018, dedicated at least 80% of his or her working time for Seller and its Subsidiaries to or on behalf of the Business and (B) as of the Agreement Date is employed in substantially similar manner;

(vi) each Automatically Transferring Business Employee (as defined in Exhibit E hereto) who is not covered by clause (i), (ii), (iii), (iv) or (v) above; e

(vii) in the case of each person who qualifies under any of the foregoing prongs and whose employment terminates following the Agreement Date, each employee who is hired or transferred into a position to replace such terminated employee shall be a Business Employee hereunder.

For the avoidance of doubt, the employees referenced in file 8.3 in the Data Room (which includes the employees of Wipro GE Healthcare Private Limited who work on behalf of the Business) are Business Employees.

Business Employee Recordsshall mean (a) the following current employment and current personnel information with respect to each Transferred Employee, in each case, to the extent permitted by applicable Law: salary, job function, job band, variable compensation targets, social security number (or similar identification number), gender, marital status, hire or service date, full-time or part-time status, work e-mail and business mailing addresses and telephone numbers and (b) Forms I-9 for Transferred Employees working in the United States.

Business Plans” means the U.S. Business Plans and the International Business Plans, collectively.

Business Systems” means all Software, Technology, computer hardware (whether general or special purpose), electronic data processing, information, record keeping, communications, telecommunications, networks, interfaces, platforms, servers, peripherals, and computer systems, including any outsourced systems and processes, that are owned or used by Seller or any of its Subsidiaries exclusively in the conduct of the Business.

Buyer Transaction Agreements” means this Agreement and each other Transaction Agreement to which Buyer or an Affiliate thereof is named as a party on the signature pages thereto.

Buyer Transactions” means the transactions contemplated by the Buyer Transaction Agreements.


Cardiff Liability” means any Liabilities to the extent arising from or relating to radioactive waste (including the presence, storage, generation and Release of, and contamination by, radioactive waste) on, at, under or from the facility where the operations of the Business are or have been conducted located in Cardiff, United Kingdom, including such waste associated with former operations of the Cardiff, United Kingdom facility.

Cellulose Adjustment Amount” means the amount of $11,850,000.

Cellulose Termination Amount” means the amount of: (i) if the Manufacturing and Supply Agreement is terminated by GEHC in accordance therewith at any time on or before December 31, 2020, $10,370,000; (ii) if the Manufacturing and Supply Agreement is terminated by GEHC in accordance therewith at any time on or after January 1, 2021 and on or before December 31, 2021, $8,400,000; (iii) if the Manufacturing and Supply Agreement is terminated by GEHC in accordance therewith at any time on or after January 1, 2022 and on or before December 31, 2022, $6,360,000; (iv) if the Manufacturing and Supply Agreement is terminated by GEHC in accordance therewith at any time on or after January 1, 2023 and on or before December 31, 2023, $4,290,000; or (v) if the Manufacturing and Supply Agreement is terminated by GEHC in accordance therewith at any time on or after January 1, 2024 and on or before December 31, 2024, $2,200,000.”

Claim” means, collectively, all rights, claims, cross claims, counterclaims and causes of action, whether class, individual or otherwise in nature, under contract or in law or in equity, known or unknown, contingent or matured, liquidated or unliquidated and all rights and remedies with respect thereto.

Closing Cash” means, as of the Effective Time, any cash and cash equivalents of the Transferred Entities, excluding (a) any insurance proceeds referred to in Section 2.01(a)(v), and (b) any cash and cash equivalents used to pay any Transaction Expenses, dividends or distributions, or repurchase any securities of the Transferred Entities, in each case of clause (b), after the Effective Time and prior to the Closing and (c) any Restricted Cash or deposits.

Closing Conditions” means conditions to the respective obligations of the Parties to consummate the transactions contemplated by this Agreement, as set forth in Article X.

Closing Debt” means, as of the Effective Time, the Debt of the Transferred Entities or otherwise constituting Assumed Liabilities.

Closing Notice” means a notice prepared and delivered by Seller to Buyer that contains the amount of the Closing Payment and the account or accounts to which Buyer shall pay the Closing Payment pursuant to Section 3.02(b)(i).

Closing Statements” means, collectively, the Estimated Closing Statement, the Proposed Final Closing Statement and the Final Closing Statement.

Code” means the U.S. Internal Revenue Code of 1986, as amended.

Company Intellectual Property” means all of the following owned by Seller or any of its Subsidiaries: (a) all Registrable IP that is Used primarily in the Business, (b) all Software that is Used primarily in the Business, and (c) all other Intellectual Property (excluding for the avoidance of doubt the Seller Names and Seller Marks), other than Registrable IP and Software, that is Used primarily in the Business.

Company Technology” means all of the following owned by Seller or any of its Subsidiaries: (a) all Technology that is Used primarily in the Business and (b) all Data that is Used primarily in the Business.

Confidential Information” means all Trade Secrets and other confidential and proprietary information of a Person, whether in written, oral or other form, including such information derived from reports, investigations, research, work in progress, codes, marketing and sales programs, financial projections, cost summaries, pricing formulae, contract analyses, financial information, projections, confidential filings with any Government Authority, and all other confidential concepts, methods of doing business, ideas, materials or information prepared or performed for, by or on behalf of such Person by its employees, officers, directors, agents or Representatives.

Confidentiality Agreement means the Confidentiality Agreement dated November 22, 2018, by and between Buyer and Seller, as the same may be amended from time to time in accordance with its terms.

Consent” means any consent, approval, clearance or authorization.


contracts or agreements” means any written or oral legally binding contract, agreement, obligation, promise, understanding, arrangement, commitment or undertaking of any nature.

Control” means, as to any Person, the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contracts or agreements or otherwise. The terms “Controlled by,” “Controlled,” “under common Control with” and “Controlling” shall have correlative meanings.

Creditable VAT” means value added tax that the relevant Buyer or Buyer Affiliate can reasonably be expected to successfully reclaim as recoverable input value added tax under the laws of the relevant jurisdiction prior to the second anniversary of the Closing Date.

Data” means databases and compilations, including all data and collections of data, whether machine readable or otherwise.

Data Room” means the virtual data room established by Seller and maintained by Intralinks, Inc. with respect to the Business, having Exchange ID 6371855.

Data Security Requirements” means, collectively, all of the following to the extent relating to Data treatment or otherwise relating to privacy, security, or security breach notification requirements and applicable to the conduct of the Business, or to any of the Business Systems or any Company Technology: (a) the Business’ own rules, policies, and procedures, and (b) all applicable Laws including, to the extent applicable, the General Data Protection Regulation (GDPR) (EU) 2016/679).

Debt” means, with respect to any Person, (a) indebtedness for borrowed money (including the principal amount thereof and the amount of accrued and unpaid interest thereon), whether or not evidenced by bonds, debentures, notes or other similar instruments, for the repayment of money borrowed, including any pre-payment penalties, premiums or breakage costs; (b) all obligations under a lease of real or personal property which is required by GAAP to be classified as a capital lease on the books and records of such Person (which, for the avoidance of doubt, does not include any right of use lease liability that will be required to be recorded upon the adoption of ASC 842); (c) all obligations for the reimbursement of draws under outstanding letters of credit, performance bonds or similar instruments (but only to the extent actually drawn or called); (d) all obligations arising out of any Hedging Contracts, in each case including any amounts payable to terminate such arrangements; (e) any deferred purchase price of business or asset, conditional sale obligations, obligations under any title retention agreement (including any earnout, purchase price adjustment or holdbacks) and any amount required to be contributed to any JVs pursuant to the Governing Documents of such JVs (to the extent such amounts are due and payable); and (f) such items as are set forth on Schedule A-2. For the avoidance of doubt, no amounts payable under the put or call arrangements pursuant to (i) the Subscription and Shareholders Agreement relating to GE Healthcare CTH Holding Limited, dated 2017, by and among GE Healthcare UK Limited, GE Healthcare CTH Holding Limited and the persons set out on Schedule 1 attached thereto, or (ii) each Put and Call Option Deed, dated November 24, 2017, by and between GE Healthcare UK Limited and each Participating Seller (as defined in such Put and Call Option Deed) shall constitute Debt hereunder.

Dedicated Pension Plans” means those Business Plans listed on Schedule 4.14(a) that are “defined benefit pension plans” and that are specifically labeled as a “Designated Pension Plan” on such schedule.

Disclosure Schedules” means the disclosure schedules dated as of the Agreement Date delivered by Seller to Buyer, and which form a part of this Agreement.

Employee Plans” means (a) all “employee benefit plans” (within the meaning of Section 3(3) of ERISA, whether or not subject to ERISA), (b) all retirement, welfare benefit, bonus, commission, equity or equity-based, stock option, stock purchase, restricted stock, incentive, supplemental retirement, deferred compensation, retiree health, life insurance, severance, Code Section 125 flexible benefit, or vacation or other benefit or compensation plans, programs, policies, contracts, arrangements or agreements and (c) all individual employment, retention, termination, severance or other similar agreements, in each case that any of the Transferred Entities sponsor or contribute to or have any Liability with respect to, or that Seller or any of its Affiliates sponsor or contribute to for the benefit of any Business Employee or any other current or former employee, officer, director or individual service provider of the Business, other than such plans or arrangements that are solely maintained by a Government Authority.

Environmental Law” means any Law relating to human health or safety (with respect to exposure to Hazardous Materials), pollution, or protection of the environment, including the use, handling, transportation, treatment, storage, disposal, release or threat of release or discharge of, or exposure of any Person to, Hazardous Materials.


Environmental Permit” means any Permit that is required or issued by a Government Authority under any Environmental Law for the operation of the Business.

ERISA” means the Employee Retirement Income Security Act of 1974, and the rules and regulations promulgated thereunder.

Estimated 2018 EBITDA” means the Seller’s good faith estimate of 2018 EBITDA.

Estimated Closing Cash” means Seller’s good faith estimate of Closing Cash as of the Effective Time.

Estimated Closing Debt” means Seller’s good faith estimate of Closing Debt as of the Effective Time.

Estimated Closing Statement” means a written statement setting forth (i) the Estimated Working Capital Increase or Estimated Working Capital Decrease, (ii) the amount of any Estimated Closing Cash, (iii) the amount of any Estimated Closing Debt, (iv) the amount of any Estimated Transaction Expenses, (v) the amount of Estimated 2018 EBITDA and (vi) the amount to be paid by Buyer to Seller (for the benefit of the Seller Parties) at Closing, prepared in accordance with Section 3.03.

Estimated EBITDA-Based Reduction” means Seller’s good faith estimate of the EBITDA-Based Reduction.

Estimated Purchase Price Adjustment” means the amount equal to the Estimated Closing Cash, if any, più the Estimated Working Capital Increase, if any, meno the Estimated Working Capital Decrease, if any, meno the Estimated Closing Debt, meno the Estimated Transaction Expenses, if any, meno the Estimated EBITDA-Based Reduction, if any.

Estimated Target Working Capital” means Seller’s good faith estimate of Target Working Capital as of the Effective Time.

Estimated Transaction Expenses” means Seller’s good faith estimate of Transaction Expenses as of the Effective Time.

Estimated Working Capital” means Seller’s good faith estimate of Net Working Capital as of the Effective Time.

Estimated Working Capital Decrease” means Seller’s good faith estimate of the amount, if any, by which Estimated Target Working Capital exceeds Estimated Working Capital set forth on the Estimated Closing Statement.

Estimated Working Capital Increase” means Seller’s good faith estimate of the amount, if any, by which Estimated Working Capital set forth on the Estimated Closing Statement exceeds Estimated Target Working Capital.

Ex-Im Laws” means all applicable U.S. and non-U.S. Laws relating to export, reexport, transfer, and import controls, including, without limitation, the Export Administration Regulations, the International Traffic in Arms Regulations, the customs and import Laws administered by U.S. Customs and Border Protection, and the EU Dual Use Regulation.

Factored Receivables” means receivables sold by the Business to the Factoring Entities prior to the Closing and that are uncollected and not written off in the ordinary course of business consistent with past practice as of the Closing.

Factored Receivables Bill of Sale” means a bill of sale for the Factored Receivables in a form reasonably acceptable to Buyer and Seller.

Factoring Entity” means the applicable Affiliates of Seller to which the Business sells receivables pursuant to an account receivables factoring arrangement.

Final 2018 EBITDA” means the amount of 2018 EBITDA as finally determined pursuant to Section 3.04.

Final Closing Cash” means the amount of Closing Cash as finally determined pursuant to Section 3.04.

Final Closing Debt” means the amount of Closing Debt as finally determined pursuant to Section 3.04.

Final Closing Statement” means a written statement setting forth (i) the Final Working Capital Increase or Final Working Capital Decrease, as applicable, (ii) the amount of any Final Closing Cash, (iii) the amount of any Final Closing Debt,


(iv) the amount of any Final Transaction Expenses, (v) the Final 2018 EBITDA and (vi) the Final Purchase Price Adjustment and the Post-Closing Adjustment, each as finally determined pursuant to Section 3.04.

Final EBITDA-Based Reduction” means the amount of EBITDA-Based Reduction as finally determined pursuant to Section 3.04.

Final Purchase Price Adjustment” means the amount equal to the Final Closing Cash, if any, plus the Final Working Capital Increase, if any, minus the Final Working Capital Decrease, if any, minus the Final Closing Debt, if any, minus the Final Transaction Expenses, if any, minus the Final EBITDA-Based Reduction, if any.

Final Target Working Capital” means the amount of Target Working Capital as finally determined pursuant to Section 3.04.

Final Transaction Expenses” means the amount of Transaction Expenses as finally determined pursuant to Section 3.04.

Final Working Capital” means the calculation of Net Working Capital as of the Effective Time as finally determined pursuant to Section 3.04.

Final Working Capital Decrease” means the amount (if any) by which Final Target Working Capital exceeds Final Working Capital.

Final Working Capital Increase” means the amount (if any) by which Final Working Capital exceeds Final Target Working Capital.

Financial Statements” means the Unaudited Financial Statements, the Audited Financial Statements and any other financial statements delivered pursuant to Section 6.13.

Fraud” means, with respect to any party to this Agreement, an actual and intentional fraud with respect to the making of any of the representations and warranties contained in this Agreement and not with respect to any other matters; provided, that such actual and intentional fraud of such party hereto specifically excludes any statement, representation or omission made negligently or recklessly, or any constructive fraud or equitable fraud.

GAAP” means U.S. generally accepted accounting principles.

Governing Documents” means, with respect to any particular Person: the articles or certificate of incorporation and the bylaws, the limited partnership agreement and the certificate of limited partnership, the articles or certificate of organization or formation and the operating agreement, or any other charter or similar document adopted or filed in connection with the creation, formation or organization of a Person, including any amendment, modification or supplement thereto.

Government Authority” means any U.S. federal, state or local or any supra-national or non-U.S. government, political subdivision, governmental, regulatory or administrative authority, instrumentality, agency, body or commission, self-regulatory organization or any court, tribunal, or judicial or arbitral body (public or private), including any stock exchange.

Hazardous Materials” means any substance, material or waste that is defined or regulated as “hazardous,” “toxic,” “dangerous,” a “pollutant,” a “contaminant” or words of similar effect, or for which Liability or standards of conduct may be imposed, under any applicable Environmental Law, including asbestos, polychlorinated biphenyls, per- and polyfluoroalkyl substances, radioactive materials, lead, petroleum and petroleum by-products and distillates.

Healthcare Business Unit” means the Healthcare segment of the Seller as described in the Annual Report on Form 10-K for the period ended December 31, 2017 filed by the Seller, and as operated and conducted since December 31, 2017.

Hedging Contracts” means any and all interest rate contracts, foreign exchange contracts, currency swap or option agreements, forward contracts, commodity swap, purchase or option agreements, other commodity price hedging arrangements and all other similar agreements or arrangements designed to alter the risks of Seller or its Subsidiaries arising from fluctuations in interest rates, currency values or commodity prices, in each case, with respect to the Business.

HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976.


Intellectual Property” means all of the following intellectual property and similar rights, title, or interest in or arising under the Laws of the U.S. or any other country: (a) patents, patent applications, and patent rights, including any such rights granted upon any reissue, reexamination, division, extension, provisional, continuation, or continuation-in-part applications, (b) copyrights, moral rights, mask work rights, database rights and design rights, in each case, whether or not registered, and registrations and applications for registration thereof, and all rights therein provided by international treaties or conventions, (c) Trademarks and (d) Trade Secrets, in each case, including for clarity, any of the foregoing rights in Software, Technology or Data.

Interest Rate” means the prevailing prime lending rate as published in Il giornale di Wall Street at the time that a payment expressly required by this Agreement is due.

International Business Plan means each Employee Plan (i) sponsored or maintained by a Transferred Entity or (ii) substantially covering current Business Employees who are employed in the Business, employed outside the United States.

IRS” means the U.S. Internal Revenue Service.

Japan Pension Liability Amount” means the amount of $3,543,157.00.

JV” means the joint ventures set forth on Schedule A-3.

JV Interests” means the equity interests in the JVs held by any of the Seller Parties, Companies or Business Subsidiaries (excluding interests in the JVs held by GE Ventures).

Knowledge of Seller” means the actual knowledge (after due inquiry of Persons that are aware of the Transactions) of the Persons set forth on Schedule A-4 as of the Agreement Date.

KUBio Contract” means, collectively, any one or a series of related Contracts related to the construction of KUBio manufacturing facilities or similar facilities or any bio park or biopharmaceutical manufacturing campus.

Legge” means any U.S. federal, state, local or non-U.S. statute, law, act, ordinance, regulation, rule, code, Order or other requirement or rule of law (including common law) promulgated by a Government Authority.

Legacy Liability” means any environmental Liabilities to the extent arising from or relating to any business, line of business, facility or other real property disposed of, or formerly owned, operated, or leased, by the Business or any Transferred Entity prior to the Effective Time, including under any agreement providing for the sale of any such business, line of business, facility or real property.

Legal Restraint” means any Law or Order that has the effect of prohibiting or making illegal the consummation of any of the Transactions contemplated by the Transaction Agreements.

Lender Related Parties” means any Financing sources, together with their respective Affiliates, and the respective officers, directors, employees, partners, trustees, shareholders, controlling persons, agents and representatives of the foregoing, and their respective successors and assigns.

Liabilities” means any liability, debt, guarantee, claim, demand, expense, commitment or obligation (whether direct or indirect, absolute or contingent, accrued or unaccrued, liquidated or unliquidated, or due or to become due) of every kind and description, including all costs and expenses related thereto.

Lien” means any mortgage, deed of trust, pledge, hypothecation, security interest, encumbrance, claim, lien, charge or any other encumbrance of any kind (other than transfer restrictions under applicable securities Laws).

Life Sciences Business Unit” means the Life Sciences sub-segment of the Seller as described in the Annual Report on Form 10-K for the period ended December 31, 2017 filed by the Seller, and as operated and conducted since December 31, 2017.

Local Transfer Agreement” means any agreement or instrument of conveyance or assumption entered into or delivered in connection with the transfer of the Transferred Equity Interests or the Transferred Assets to Buyer or for Buyer to assume the Assumed Liabilities, in any jurisdiction where the Business is organized or operates (including, with respect to each


Transferred Owned Real Property, a quitclaim deed (or local equivalent) in customary form and substance reasonably satisfactory to Seller and Buyer).

Losses” means all losses, damages, fines, penalties, costs, expenses, and Liabilities actually suffered or incurred and paid (including reasonable attorneys’ fees and out-of-pocket costs).

Material Adverse Effect” means any change, event, circumstance, development, occurrence or effect (a) having, or that would reasonably be expected to have, individually or in the aggregate with all other changes, events, circumstances, developments, occurrences or effects, a material adverse effect on the business, assets, financial condition or results of operations of the Business, taken as a whole or (b) that would reasonably be expected to materially impair or delay the ability of a Seller Party to consummate the Seller Transactions or otherwise perform its obligations under the Seller Transaction Agreements to which such Seller Party is a party; provided, however, that, with respect to clause (a), any adverse effect to the extent arising out of, resulting from or attributable to (i) an event or circumstances or series of events or circumstances affecting (A) the U.S. (or any other country or jurisdiction) or the global economy generally or capital, financial, banking, credit or securities markets generally, including changes in interest or exchange rates, (B) political conditions generally of the U.S. or any other country or jurisdiction in which the Business operates or (C) any industry generally in which the Business thereof operates, (ii) the announcement or pendency of the Transactions, including adverse effects related to the identity of Buyer or its Affiliates, and any adverse effect to the extent proximately caused by (A) shortfalls or declines in revenue, margins or profitability, (B) threatened or actual loss of, or disruption in, any customer, supplier, vendor, licensor, employee or landlord relationships or (C) loss of any personnel, in each case of clauses (A) through (C), as a result of the announcement or pendency of the Transactions; provided, that this clause (ii) shall not be given effect when determining whether Section 4.05(c) has been breached, (iii) any changes in applicable Law or GAAP, or accounting principles, practices or policies that any of Seller or its Subsidiaries is required by Law to adopt, or the enforcement or interpretation thereof, in each case with respect to the Business, (iv) actions specifically required to be taken or omitted pursuant to this Agreement or actions taken or omitted to be taken at the request of Buyer, (v) the effect of any action taken by Buyer or its Affiliates, (vi) any acts of God, including any earthquakes, hurricanes, tornadoes, floods, tsunami, or other natural disasters, (vii) any acts of war (whether or not declared), terrorism or military actions, or any escalation or worsening of any such act of war, terrorism or military actions, or (viii) any failure to meet internal or published projections, estimates or forecasts of revenues, earnings, or other measures of financial or operating performance for any period (provided, that the underlying causes of such failures (subject to the other provisions of this definition) shall not be excluded) shall not, in any such case, constitute or be deemed to contribute to a Material Adverse Effect, and otherwise shall not be taken into account in determining whether a Material Adverse Effect has occurred or would be reasonably likely to occur; provided, that any adverse effect arising out of, resulting from or attributable to the foregoing clauses (i), (iii), (vi) and (vii) may be taken into account in determining whether a Material Adverse Effect has occurred or would be reasonably likely to occur to the extent such adverse effect has a disproportionate impact on the Business, taken as a whole, relative to other similarly situated businesses in the same industry.

Material Permits” means Permits required for Seller and its Subsidiaries to conduct the Business in all material respects as conducted on the Agreement Date.

Minority-Owned JV” means any JV that is not a Subsidiary.

Multiplier” means 17.

Net Working Capital” means (a) the current assets of the Business minus (b) the current Liabilities of the Business, in each case determined in accordance with the Transaction Accounting Principles; provided that in no event shall Net Working Capital include any assets or Liabilities related or attributable to Income Taxes (including any deferred Tax assets or Liabilities).

OFAC” means the U.S. Department of Treasury, Office of Foreign Assets Control.

Order” means any order, writ, judgment, injunction, ruling, temporary restraining order, decree, stipulation, determination or award entered by or with any Government Authority.

Parent Plans means each Employee Plan which is not a Business Plan.

Permits” means all permits, licenses, Consents, registrations, concessions, grants, franchises, certificates, identification numbers exemptions, waivers, and filings issued or required by any Government Authority under applicable Law.


Permitted Liens” means the following Liens: (a) Liens for Taxes, assessments or other governmental charges or levies that are not yet due or payable or that are being contested in good faith by appropriate proceedings and for which appropriate reserves have been established in the Financial Statements in accordance with GAAP, (b) statutory Liens of landlords and Liens of carriers imposed by Law in the ordinary course of business, (c) warehousemen, mechanics, materialmen, workmen, repairmen and other Liens imposed by Law in the ordinary course of business which are not yet due and payable or that are being contested in good faith by appropriate proceedings and for which appropriate reserves have been established in the Financial Statements in accordance with GAAP, (d) Liens incurred or deposits made in the ordinary course of business in connection with workers’ compensation, unemployment insurance or other types of social security, (e) defects or imperfections of title, easements, covenants, rights of way, restrictions and other similar charges, defects or encumbrances affecting title to the Transferred Real Properties which do not or would not reasonably be expected to materially interfere with the occupancy of such Transferred Real Properties or the conduct of the Business as currently conducted thereon, (f) zoning, entitlement, building and other generally applicable land use and environmental restrictions by a Government Authority, which are not violated by the current use or occupancy of the Transferred Real Properties or the operation of the Business thereon, (g) Liens not created by Seller or any of its Subsidiaries that affect the underlying fee interest or any other superior interest in any Transferred Leased Real Property or real property over which Seller or any if its Subsidiaries (with respect to the Business) have easement or other property rights, (h) Liens created by or through, or resulting from any facts or circumstances relating to, Buyer or its Affiliates, (i) Liens arising out of, under or in connection with this Agreement or the other Transaction Agreements, (j) rights, terms or conditions of any Transferred Real Property Leases made available to Buyer and (k) in the case of Intellectual Property, Software, Data and Technology, licenses.

Person” means any natural person, general or limited partnership, corporation, company, trust, limited liability company, limited liability partnership, firm, association or organization or other legal entity.

Personally Identifiable Information” means any information that specifically identifies, or which, when combined with other information, could be reasonably be used to identify, any individual who has provided information to any Seller Party or Transferred Entity in connection with the conduct of the Business, whether a living or dead individual person, including (i) any personally-identifiable information, such as addresses, telephone numbers, health information, drivers’ license numbers, and government issued identification numbers and (ii) any non-public personally identifiable financial information.

Post-Closing Adjustment” means the amount obtained by subtracting the Estimated Purchase Price Adjustment from the Final Purchase Price Adjustment.

Pre-Closing Period” means the period beginning on the Agreement Date and ending on the later of the Closing and the Effective Time; provided, that if this Agreement is terminated in accordance with its terms, the Pre-Closing Period shall end upon the termination of this Agreement.

Pre-Closing Restructuring Taxes” means Transfer Taxes imposed or arising in connection with the transactions effected pursuant to Section 2.06(e) to the extent attributable to the transfer of any asset or entity interest that is not a Transferred Asset or Transferred Equity Interest other than any transfer undertaken at the request of Buyer in accordance with Section 2.06(e).

Proposed Final Closing Cash” means Buyer’s good faith estimate of Closing Cash as of the Effective Time.

Proposed Final Closing Debt” means Buyer’s good faith estimate of Closing Debt as of the Effective Time.

Proposed Final Closing Statement” means (a) a written statement setting forth Proposed Final Purchase Price Adjustment, describing in reasonable detail any proposed changes to the Estimated Closing Statement and attaching supporting schedules, working papers and other reasonable details to enable a review by Seller thereof or (b) a written statement that Buyer proposed no changes to the Estimated Closing Statement, as applicable.

Proposed Final Purchase Price Adjustment” means the amount equal to the Proposed Final Closing Cash, if any, più the Proposed Final Working Capital Increase, if any, meno the Proposed Final Working Capital Decrease, if any, meno the Proposed Final Closing Debt, if any, meno the Proposed Final Transaction Expenses, if any, meno the EBITDA-Based Reduction, if any.

Proposed Final Transaction Expenses” means Buyer’s good faith estimate of Transaction Expenses as of the Effective Time.


Proposed Final Working Capital Decrease” means Buyer’s good faith estimate of the amount (if any) by which Target Working Capital exceeds Final Working Capital.

Proposed Final Working Capital Increase” means Buyer’s good faith estimate of the amount (if any) by which Final Working Capital exceeds Target Working Capital.

Recovery Expenses” means (a) any deductibles paid by the Indemnified Party or its Affiliates to obtain insurance coverage, (b) any direct increase in the premiums payable in order to obtain such insurance coverage and (c) any reasonable and documented out-of-pocket costs and expenses incurred by the Indemnified Party or its Affiliates in investigating, prosecuting, defending and collecting amounts recovered under any such insurance coverage.

Registrable IP” means patents, patent applications, statutory invention and design registrations, registered Trademarks, Trademark applications, copyright registrations and copyright applications.

Regulation S-X” means Regulation S-X promulgated under the Securities Act of 1933 as from time to time in effect and all official rulings and interpretations thereunder or thereof.

Regulatory Laws” means the HSR Act, the Sherman Antitrust Act of 1890, the Clayton Antitrust Act of 1914, the Federal Trade Commission Act of 1914, Council Regulation No. 139/2004 of the European Union and all other national, multinational, federal or state, domestic or foreign, statutes, rules, regulations, orders, decrees, administrative and judicial doctrines and other Laws applicable to the Business, Buyer, any Seller Party or any Transferred Entity that are designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade, that relate to antitrust, competition or market conditions through merger, acquisition or other transaction, that affect foreign investment, national security or national interest of any jurisdiction or that otherwise are applicable to the Transactions.

Related Party” means (i) a Person who owns directly or indirectly at least 25% of the equity, partnership or membership interests of a BP Entity, but cannot be fully consolidated in any Seller Entity’s reporting group under local country accounting principles or International Financial Reporting Standards (such person, a “JV Partner”), or (ii) a person related to a JV Partner within the meaning of Sec. 1 para. 2 German Foreign Tax Act – AStG, including any person that has a direct or indirect equity, partnership or membership interest of more than 25% in a JV Partner or has dominating influence over a JV Partner.

Related Party Financing” shall mean any interest bearing indebtedness for borrowed money (whether or not evidenced by a written instrument) owed by any BP Entity to a Related Party or any guarantee received by any BP Entity from a Related Party in respect of any such interest bearing indebtedness, or the assumption of any BP Entity’s interest bearing indebtedness by a Related Party.

Related to the Business” means (a) except as set forth on Schedule A-5, for (i) manufacturing facilities, (ii) warehouse facilities, (iii) research and development facilities (in each case of clauses (i) through (iii), including all equipment, machinery, hardware, electronic devices, furniture, fixtures, vehicles, tools, repair and replacement parts, supplies, materials, consumables, dies, molds and all other personal property or personal property leases therein), (iv) inventory, (v) Strategic Sourcing Contracts, and (vi) contracts with Material Customers, (x) used in or (y) arising, directly or indirectly, out of, the operation or conduct of, the Business as conducted by Seller and its Subsidiaries, (b) for all Intellectual Property, Software, Technology and Data, Used primarily in the Business, and (c) for all other categories of assets other than those set forth in clauses (a) and (b) above, (x) used primarily in or (y) arising directly or indirectly, primarily out of or primarily relating to, the operation or conduct of, the Business as conducted by Seller and its Subsidiaries.

Release” means any release, spill, emission, leaking, pumping, pouring, injection, escaping, deposit, disposal, discharge, dispersal, dumping, leaching, movement, or migration of any Hazardous Material into or through the environment.

Representative” of a Person means the directors, officers, employees, advisors, agents, consultants, attorneys, accountants, investment bankers or other representatives of such Person.

Required Approvals” means each of the Government Approvals set forth on Schedule A-6.

Restricted Cash” means cash to the extent that it is not freely usable by the Business because of any restrictions or limitations on use or distribution by Law, contract or otherwise. For the avoidance of doubt, none of the following shall constitute Restricted Cash: (i) any amount held by GE BioTechnology (China) Co., Ltd. in connection with the “Lonza project” contemplated by that certain Site Delivery Agreement by and among GE BioTechnology (China) Co., Ltd., Lonza Guangzhou


Nansha Ltd. and GE (China) Finance Leasing Co., Ltd., dated December 9, 2018, including, but not limited to a payment in the amount of $12,978,156.84 in December, 2019 by GE (China) Co., Ltd., and (ii) any amount of cash held by GE Healthcare Bioscience Holding Limited or GE Healthcare CTH Holding Limited.

Retained Real Property” means all real property owned, leased, subleased or licensed by Seller or its Subsidiaries, other than the Transferred Leased Real Property and the Transferred Owned Real Property.

Sanctioned Country” means any country or region that is, or was at the relevant time, the subject or target of a comprehensive embargo under Sanctions Laws (including Cuba, Iran, North Korea, Sudan, Syria, and the Crimea region of Ukraine).

Sanctioned Person” means any individual or entity that is the subject or target of sanctions or restrictions under Sanctions Laws or Ex-Im Laws, including: (i) any individual or entity listed on any applicable U.S. or non-U.S. sanctions- or export-related restricted party list, including, without limitation, OFAC’s Specially Designated Nationals and Blocked Persons List and the EU Consolidated List; (ii) any entity that is, in the aggregate, fifty percent (50%) or greater owned, directly or indirectly, or otherwise controlled by a person or persons described in clause (i); or (iii) any national of a Sanctioned Country.

Sanctions Laws” means all applicable U.S. and non-U.S. Laws relating to economic or trade sanctions, including, without limitation, the Laws administered or enforced by the United States (including by OFAC or the U.S. Department of State), the United Nations Security Council, and the European Union.

SEC” means the U.S. Securities and Exchange Commission.

Section 75 Liability” means any amount that is or could become due by virtue of Section 75 or Section 75A of the Pensions Act 1995 as amended by subsequent regulations with respect to Seller’s or its Affiliates’ United Kingdom defined benefit pension plan.

Securities Act” means the Securities Act of 1933.

Seller Designee” means any Affiliate of Seller designated by Seller as a “Seller Party” hereunder.

Seller Guarantees” means, collectively, all letters of credit, guarantees, surety bonds, performance bonds and other financial assurance obligations issued or entered into by or on behalf of (or for the account of) Seller or any of its Subsidiaries (other than exclusively by the Transferred Entities) in connection with the Business.

Seller Intellectual Property” means all Intellectual Property and/or Software that is owned by Seller or any of its Subsidiaries other than the Company Intellectual Property.

Seller Names and Seller Marks” means the names or marks of General Electric Company, a New York corporation, or any other Subsidiary of Seller, that in each case use or contain “GE” (in block letters or otherwise), the GE monogram, “General Electric Company,” “General Electric” or any translation or derivation thereof, either alone or in combination with other words and all marks, trade dress, logos, monograms, domain name registrations and other source identifiers confusingly similar to or embodying any of the foregoing either alone or in combination with other words.

Seller Technology” means all Technology and Data that is owned by any of Seller or any of its Subsidiaries other than the Company Technology.

Seller Transaction Agreements” means this Agreement and each other Transaction Agreement to which any Seller Party is named as a party on the signature pages thereto.

Seller Transactions” means the transactions contemplated by the Seller Transaction Agreements.

Shared Contracts” means all contracts or agreements to which Seller or any of its Subsidiaries, on the one hand, and one or more third parties, on the other hand, are party, that relate in part, but not exclusively, to the Business; provided that contracts with Material Customers and Strategic Sourcing Contracts shall not constitute Shared Contracts.

Shared Locations” mean, collectively, (i) any Real Property a portion of which is used in the business of Seller or any of its Subsidiaries (other than the Business) and (ii) any Retained Real Property a portion of which is used in the Business, each of which are to be subject to the Shared Space Agreements.


Shared Space Agreements” mean, collectively, the lease, sublease, license or other space sharing agreement pursuant to which, after the Closing, (i) Seller or any of its Subsidiaries will occupy the Shared Locations described in clause (i) of the definition of “Shared Locations” and (ii) Buyer or its Affiliates will occupy the Shared Locations described in clause (ii) of the definitions of “Shared Locations”.

Software” means all (a) computer programs, including all software implementation of algorithms, models and methodologies, whether in source code, object code, human readable form or other form, (b) descriptions, flow charts and other work products used to design, plan, organize and develop any of the foregoing, screens, user interfaces, report formats, firmware, development tools, templates, menus, buttons and icons and (c) all documentation including user manuals and other training documentation relating to any of the foregoing, in each case (a)-(c), excluding Data.

Specified Adjustment Amount” means the sum of the Cellulose Adjustment Amount, più the Japan Pension Liability Amount, più the Taiwan Pension Liability Amount, più $6,000,000.

Specified Pension Plans” means LB_4036 Whatman GmbH Pension, including GEWA 4-VO2010, LB 5807Whatman Limited, 12_GE Common Plan (GEHJC – for YMS Employees), Taiwan Labor Standards Act Retirement Plan and Taiwan Supplementary Pension Plan.

Strategic Sourcing Contracts” means contracts for the supply of materials and other products or services that are critical to the Business, and for which (i) there are a limited number of suppliers and (ii) there are not readily available alternative products or services that could be used in the Business for the equivalent purpose (including any contract with any Material Supplier set forth in Schedule 4.13(a)(i)).

Subject Jurisdiction” means those countries listed on Schedule A-7.

Subject Jurisdiction Assumed Liabilities” means all of the Assumed Liabilities to the extent related to the applicable Subject Jurisdiction Business.

Subject Jurisdiction Business” means the portion of the Business conducted in the applicable Subject Jurisdiction.

Subject Jurisdiction Employees” means the Business Employees that are exclusively located in the applicable Subject Jurisdiction.

Subject Jurisdiction Transferred Assets” means all of the Transferred Assets exclusively used in the applicable Subject Jurisdiction Business.

Subject Jurisdiction Transferred Entities” means the Transferred Entities that exclusively conduct business in the applicable Subject Jurisdiction.

Subject Jurisdiction Transferred Equity Interests” means all of the issued and outstanding equity interests in the Transferred Entities that exclusively conduct business in the applicable Subject Jurisdiction.

Subsidiary” of any specified Person means any other Person of which such first Person owns (either directly or through one or more other Subsidiaries) a majority of the outstanding equity securities or securities carrying a majority of the voting power in the election of the board of directors or other governing body of such Person, and with respect to which entity such first Person is not otherwise prohibited contractually or by other legally binding authority from exercising Control. For the avoidance of doubt, Wipro is, and shall be deemed, a Subsidiary of Seller, for all purposes under this Agreement.

Swedish IP Prepayment Amount” means the $400,000 paid by Global Life Sciences IP HoldCo LLC to GE Healthcare Bioprocess R&D AB pursuant to the Swedish IP Transfer Deed on March 30, 2020.

Taiwan Pension Liability Amount” means the amount of $954,000.

Target 2018 EBITDA” shall mean $1,220,000,000.


Target Working Capital” means the average of the Net Working Capital as of the last day of each of the four (4) calendar quarters ending on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020, calculated in accordance with the Transaction Accounting Principles.

Tax” or “Taxes” means all U.S. federal, state, local or non-U.S. income, alternative, excise, gross receipts, ad valorem, value-added, sales, use, employment, franchise, profits, gains, property, estimated transfer, use, payroll, intangibles, withholding or other taxes of any kind whatsoever (whether payable directly or by withholding), together with any interest and any penalties, additions to tax or additional amounts imposed by any Taxing Authority with respect thereto.

Tax Returns” means all returns and reports (including elections, declarations, disclosures, schedules, estimates, claims for refunds and information returns) required to be supplied to a Taxing Authority relating to the determination, assessment or collection of any Taxes.

Taxing Authority” means any U.S. federal, state or local or non-U.S. jurisdiction (including any subdivision and any revenue agency of a jurisdiction) imposing Taxes and the agencies, if any, charged with the collection of such Taxes for such jurisdiction.

Technology” means, collectively, all technology, designs, procedures, models, discoveries, processes, techniques, ideas, know-how, research and development, tools, materials, specifications, processes, inventions (whether patentable or unpatentable and whether or not reduced to practice) apparatus, creations, improvements, works of authorship in any media, confidential, proprietary or non-public information, and other similar materials, and all recordings, graphs, drawings, reports, analyses and other writings, and other tangible embodiments of the foregoing in any form whether or not listed herein, and all related technology, other than Software and Data.

third party” means any Person who is not a Party to this Agreement or an Affiliate of a Party to this Agreement.

Trade Payables Program” means the trade payables program for the Business administered by one or more Affiliates of Seller.

Trade Secrets” means confidential and proprietary information, including rights relating to know-how or trade secrets, including ideas, concepts, methods, techniques, inventions (whether patentable or unpatentable), and other works, whether or not developed or reduced to practice, rights in industrial property, customer, vendor, and prospect lists, and all associated information or databases, and other confidential or proprietary information.

Trademarks” means trademarks, service marks, trade names, service names, domain name registrations, trade dress, logos and other identifiers of same, including all goodwill associated therewith, and all common law rights, and registrations and applications for registration thereof, all rights therein provided by international treaties or conventions, and all reissues, extensions and renewals of any of the foregoing.

Transaction Accounting Principles” means those Transaction Accounting Principles set forth on Exhibit F.

Transaction Agreements” means this Agreement, the Intellectual Property Cross License Agreement, the Transitional Trademark License Agreement, the Transition Services Agreement, the Bill of Sale, Assignment and Assumption Agreement, the Local Transfer Agreements, IP Assignment Agreement, the Lease Assignments, the Shared Space Agreements and the Factored Receivables Bill of Sale, in each case including all exhibits and schedules thereto and all amendments thereto made in accordance with the respective terms thereof.

Transaction Deductions” means all deductions or expenses incurred by any Transferred Entity as a result of or in connection with the transactions contemplated by this Agreement to the extent “more likely than not” deductible (or deductible at a higher confidence level) under applicable Tax Law (including deductions related to the repayment of indebtedness, the payment of closing bonuses to management, and the payment of any fees or other costs and expenses associated with the transactions contemplated hereby not required to be capitalized).

Transaction Expenses” means, to the extent unpaid immediately prior to the later of the Effective Time and the Closing, all third party fees, costs and expenses incurred or payable by any Transferred Entity or otherwise constituting Assumed Liabilities (including investment bankers, attorneys, accountants and other consultants and advisors) in connection with the negotiation, execution and delivery of the Transaction Agreements and the execution or consummation of the Transactions, the solicitation of other potential buyers of the Business or consideration of other strategic alternatives (including Seller’s exploration of an initial public offering of its healthcare division).


Transactions” means the transactions contemplated by this Agreement and the other Transaction Agreements.

Transfer Taxes” means any sales Tax, bulk sales, use, transfer, excise, license, privilege, gross receipts, conveyance, land, customs, recording, registration or other similar Tax, direct or indirect real property transfer or gains Tax, documentary transfer stamp Tax, value added Tax, or similar Taxes and all related fees.

Transferred Books and Records” means all books, records, files and papers (or, in each case, any relevant portions thereof), whether in hard copy or computer format, including sales and promotional literature, manuals and data, sales and purchase correspondence, customer lists and lists of suppliers, in each case to the extent related to the Business, the Transferred Assets or Assumed Liabilities, other than any Tax Returns (other than Tax Returns exclusively of a Transferred Entity) and any Excluded Assets of the type described in Section 2.01(b)(xv) e Section 2.01(b)(xix).

Transferred Real Properties” means, collectively, the Transferred Owned Real Property and the Transferred Leased Real Property.

Treasury Regulations” means the regulations promulgated under the Code, as such regulations may be amended from time to time.

Uppsala Remediation Amount” has the meaning set forth on Schedule A-8.

U.S.” means the United States of America.

U.S. Business Plans means each Employee Plan (i) sponsored or maintained by a Transferred Entity or (ii) substantially covering current Business Employees who are employed in the Business in the United States.

Used” means used, practiced, licensed, sublicensed, reproduced, distributed, performed, displayed and otherwise exploited, made, had made, sold, had sold, imported and otherwise provided, and prepared modifications, derivative works or improvements or commercialized or legally disposed of products and services thereunder.

2018 Audited Balance Sheet

Exhibit A

2018 EBITDA

Exhibit A

2018 Unaudited Balance Sheet

Exhibit A

Accompanying Materials

Section 6.13(a)

Accrued Income Taxes

Exhibit A

Action

Exhibit A

Active Participants

Exhibit A

Affiliate

Exhibit A

Agreement

Exhibit A

Agreement Date

Preamble

Allocation Statement

Section 3.07

Anti-Corruption Laws

Exhibit A

Asset/Liability Transfer

Section 2.06(a)

Assumed Contracts

Section 2.01(a)(ii)

Assumed Liabilities

Section 2.01(c)

Audited Financial Statements

Exhibit A

Available Insurance Claims

Section 7.04(b)

Available Insurance Policies

Section 7.04(a)

Bankruptcy and Equity Exception

Exhibit A

Base Purchase Price

Section 3.01(a)

Bill of Sale, Assignment and Assumption Agreement

Section 3.02(a)(vi)

BP Entity

Exhibit A

Attività commerciale

Exhibit A


Business Day

Exhibit A

Business Employee

Exhibit A

Business Employee Records

Exhibit A

Business Insurance Policies

Section 4.19

Business Plans

Exhibit A

Business Subsidiaries

Section 2.06(a)

Business Systems

Exhibit A

Buyer

Preamble

Buyer Claims

Section 13.23

Buyer Indemnified Parties

Section 12.02(a)

Buyer Released Party

Section 13.23

Buyer Releasing Party

Section 13.23

Buyer Transaction Agreements

Exhibit A

Buyer Transactions

Exhibit A

Capex Budget

Section 6.01(a)(xii)

Cardiff Liability

Exhibit A

CBA

Section 4.13(a)(vii)

Cellulose Adjustment Amount

Exhibit A

Cellulose Termination Amount

Exhibit A

Claim

Exhibit A

Closing

Section 2.03

Closing Cash

Exhibit A

Closing Conditions

Exhibit A

Closing Date

Section 2.03

Closing Debt

Exhibit A

Closing Notice

Exhibit A

Closing Payment

Section 3.03

Closing Statements

Exhibit A

Code

Exhibit A

Commingled Entity

Section 6.16(c)

Aziende

Section 2.06(a)

Company

Section 2.06(a)

Company Intellectual Property

Exhibit A

Company Technology

Exhibit A

Confidential Information

Exhibit A

Confidentiality Agreement

Exhibit A

Consent

Exhibit A

Contracting Parties

Section 13.16

contracts or agreements

Exhibit A

Control

Exhibit A

Creditable VAT

Exhibit A

D&O Indemnified Parties

Section 7.03(a)

Data

Exhibit A

Data Room

Exhibit A

Data Security Requirements

Exhibit A

Debt

Exhibit A


Dedicated Pension Plans

Exhibit A

Deferred Business

Section 2.05(a)

Deferred Consideration

Section 2.05(e)

Deferred Effective Date

Section 2.05(j)

Deferred India Business

Section 2.05(d)

Deferred Transfer

Section 2.05(j)

Deferred Transfer Date

Section 2.05(j)

Disapplied Provisions

Section 6.09(c)(i)

Disclosure Schedules

Exhibit A

Dispute Notice

Section 3.04(c)

EBITDA Shortfall

Section 3.01(b)

EBITDA-Based Reduction

Section 3.01(b)

Employee Plans

Exhibit A

Environmental Law

Exhibit A

Environmental Permit

Exhibit A

Equity Transfer

Section 2.06(a)

ERISA

Exhibit A

Estimated 2018 EBITDA

Exhibit A

Estimated Closing Cash

Exhibit A

Estimated Closing Debt

Exhibit A

Estimated Closing Statement

Exhibit A

Estimated EBITDA-Based Reduction

Exhibit A

Estimated Purchase Price Adjustment

Exhibit A

Estimated Target Working Capital

Exhibit A

Estimated Transaction Expenses

Exhibit A

Estimated Working Capital

Exhibit A

Estimated Working Capital Decrease

Exhibit A

Estimated Working Capital Increase

Exhibit A

Excluded Assets

Section 2.01(b)

Excluded Liabilities

Section 2.01(d)

Exercise Notice

Section 6.10(iv)

Ex-Im Laws

Exhibit A

Expiry Date

Section 6.10(viii)

Factored Receivables

Exhibit A

Factored Receivables Bill of Sale

Exhibit A

Factoring Entity

Exhibit A

Final 2018 EBITDA

Exhibit A

Final Closing Cash

Exhibit A

Final Closing Debt

Exhibit A

Final Closing Statement

Exhibit A

Final EBITDA-Based Reduction

Exhibit A

Final Purchase Price Adjustment

Exhibit A

final Target Working Capital

Exhibit A

Final Transaction Expenses

Exhibit A

Final Working Capital

Exhibit A

Final Working Capital Decrease

Exhibit A


Final Working Capital Increase

Exhibit A

Financial Statements

Exhibit A

Financing

Section 6.12(a)

Fraud

Exhibit A

GAAP

Exhibit A

GitHub Repository

Section 6.18

Governing Documents

Exhibit A

Government Approvals

Section 6.04(a)

Government Authority

Exhibit A

Government Official

Section 4.10(b)

Hazardous Materials

Exhibit A

Healthcare Business Unit

Exhibit A

Hedging Contracts

Exhibit A

HMRC

Section 4.14(h)

HSR Act

Exhibit A

Indemnified Party

Section 12.04(a)

Indemnifying Party

Section 12.04(a)

Independent Accounting Firm

Section 3.04(d)

Insurance Policies

Section 2.01(b)(vii)

Intellectual Property

Exhibit A

Intellectual Property Cross License Agreement

Section 3.02(a)(iii)

Intercompany Agreements

Section 4.20(a)

Interest Rate

Exhibit A

International Business Plan

Exhibit A

IP Assignment Agreement

Section 3.02(a)(vii)

IRS

Exhibit A

Japan Pension Liability Amount

Exhibit A

JV

Exhibit A

JV Interests

Exhibit A

JV Partner

Exhibit A

Knowledge of Seller

Exhibit A

KUbio Contract

Exhibit A

Legge

Exhibit A

Lease Assignments

Section 3.02(a)(x)

Legacy Liability

Exhibit A

Legal Restraints

Exhibit A

Lender Related Parties

Exhibit A

Liabilities

Exhibit A

Lien

Exhibit A

Life Sciences Business Unit

Exhibit A

Lingang VAT

Exhibit A

Local Transfer Agreement

Exhibit A

Losses

Exhibit A

Manufacturing and Supply Agreement

Section 6.14(d)

Material Adverse Effect

Exhibit A

Material Contracts

Section 4.13(a)


Material Customer

Section 4.21

Material Permits

Exhibit A

Material Supplier

Section 4.21

Minority-Owned JV

13

Multiplier

Exhibit A

Net Working Capital

Exhibit A

New Corporate Names

Section 7.02(d)

New Zealand Local Agreement

Section 2.05(k)

Nonparty Affiliates

Section 13.16

OFAC

Exhibit A

Order

Exhibit A

Outside Date

Section 11.01(d)

Parent Plans

Exhibit A

Parties

Preamble

PBGC

Section 4.14(e)

Pension Scheme

Section 4.14(h)

Permits

Exhibit A

Permitted Liens

Exhibit A

Person

Exhibit A

Personally Identifiable Information

Exhibit A

Post-Closing Adjustment

Exhibit A

Pre-Closing Period

Exhibit A

Pre-Closing Restructuring Taxes

Exhibit A

Pre-Closing Taxes

Section 12.02(a)(iii)

Proposed Final Closing Cash

Exhibit A

Proposed Final Closing Debt

Exhibit A

Proposed Final Closing Statement

Exhibit A

Proposed Final Purchase Price Adjustment

Exhibit A

Proposed Final Transaction Expenses

Exhibit A

Proposed Final Working Capital Decrease

Exhibit A

Proposed Final Working Capital Increase

Exhibit A

Purchase Price

Section 3.01(a)

R&W Policy

Section 12.11

Recovery Expenses

Exhibit A

Registrable IP

Exhibit A

Regulation S-X

Exhibit A

Regulatory Law Impediment

Section 6.04(b)

Regulatory Laws

Exhibit A

Related Party

Exhibit A

Related Party Financing

Exhibit A

Related Party Financing Payment

Section 6.06(c)

Related to the Business

Exhibit A

Release

Exhibit A

Representative

Exhibit A

Required Approvals

Exhibit A

Resolution Period

Section 3.04(c)


Restricted Cash

Exhibit A

Retained Real Property

Exhibit A

Review Period

Section 3.04(b)

Sanctioned Country

Exhibit A

Sanctioned Person

Exhibit A

Sanctions Laws

Exhibit A

SEC

Exhibit A

Section 75 Liability

Exhibit A

Securities Act

Exhibit A

Seller

Preamble

Seller Bankers

Section 4.17

Seller Claims

Section 13.23

Seller Designee

Exhibit A

Seller Guarantees

Exhibit A

Seller Indemnified Parties

Section 12.03(a)

Seller Intellectual Property

Exhibit A

Seller Names and Seller Marks

Exhibit A

Seller Parties

Preamble

Seller Released Party

Section 13.23

Seller Releasing Party

Section 13.23

Seller Technology

Exhibit A

Seller Transaction Agreements

Exhibit A

Seller Transactions

Exhibit A

Seller Transfer Proposal

Section 2.06(b)

Shared Contracts

Exhibit A

Shared Entity

Section 2.05(d)

Shared Locations

Exhibit A

Shared Space Agreements

Exhibit A

Software

Exhibit A

Specified Assset

Section 2.05(c)

Specified Shared Contract

Section 2.02(b)

Straddle Period

Section 9.03

Strategic Sourcing Contracts

Exhibit A

Subject Jurisdiction

Exhibit A

Subject Jurisdiction Assumed Liabilities

Exhibit A

Subject Jurisdiction Business

Exhibit A

Subject Jurisdiction Employees

Exhibit A

Subject Jurisdiction Put Option

Section 6.10(i)

Subject Jurisdiction Transferred Assets

Exhibit A

Subject Jurisdiction Transferred Entities

Exhibit A

Subject Jurisdiction Transferred Equity Interests

Exhibit A

Subsidiary

Exhibit A

Swedish IP Prepayment Amount

Exhibit A

Taiwan Pension Liability Amount

Exhibit A

Target 2018 EBITDA

Exhibit A

Target Working Capital

Exhibit A


Tax

Exhibit A

Tax Claim

Section 9.04(a)

Tax Returns

Exhibit A

Taxes

Exhibit A

Taxing Authority

Exhibit A

Technology

Exhibit A

third party

Exhibit A

Third Party Claim

Section 12.04(a)

Title IV Plan

Section 4.14(b)

Trade Control Laws

Section 4.10(b)

Trade Payables Program

Exhibit A

Trade Secrets

Exhibit A

Trademarks

Exhibit A

Transaction Accounting Principles

Exhibit A

Transaction Agreements

Exhibit A

Transaction Deductions

Exhibit A

Transaction Dispute

Section 13.11

Transaction Expenses

Exhibit A

Transactions

Exhibit A

Transfer

Section 2.06(a)

Transfer Taxes

Exhibit A

Transferred Assets

Section 2.01(a)

Transferred Books and Records

Exhibit A

Transferred Entities

Section 2.06(a)

Transferred Equity Interests

Section 2.06(a)

Transferred Leased Real Property

Section 2.01(a)(i)(A)

Transferred Owned Real Property

Section 2.01(a)(i)(A)

Transferred Real Properties

Exhibit A

Transferred Real Property Leases

Section 2.01(a)(ii)

Transition Costs

Section 6.16(a)

Transition Services Agreement

Section 3.02(a)(iv)

Transitional Trademark License Agreement

Section 3.02(a)(v)

Treasury Regulations

Exhibit A

Trued-Up Taiwan Pension Amount

Section 3.05

U.S.

Exhibit A

U.S. Asset Treatment Election

Section 2.06(b)

U.S. Business Plans

Exhibit A

Unaudited Financial Statements

Section 4.07(a)

Uppsala Remediation Amount

Exhibit A

Used

Exhibit A

Wipro

Section 6.16(a)

Wipro Business

Section 6.16(a)

Works Councils

Section 6.10(vi)

GE BIOPHARMA

(A BUSINESS WITHIN THE GE HEALTHCARE SEGMENT OF GENERAL ELECTRIC COMPANY)

COMBINED FINANCIAL STATEMENTS

YEARS ENDED DECEMBER 31, 2019 AND 2018

(WITH INDEPENDENT AUDITORS’ REPORT THEREON)


INDEX TO THE COMBINED FINANCIAL STATEMENTS


KPMG LLP

Suite 1050

833 East Michigan Street

Milwaukee, WI 53202-5337

INDEPENDENT AUDITORS' REPORT

The Board of Directors

General Electric Company:

We have audited the accompanying combined financial statements of GE BioPharma (a carve-out business of General Electric Company), which comprise the combined statements of financial position as of December 31, 2019 and 2018, and the related combined statements of income, comprehensive income, changes in equity, and cash flows for the years then ended, and the related notes to the combined financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these combined financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of combined financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these combined financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the combined financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the combined financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the combined financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the combined financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the combined financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the combined financial statements referred to above present fairly, in all material respects, the financial position of GE BioPharma as of December 31, 2019 and 2018, and the results of its operations and its cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

/s/ KPMG LLP

Milwaukee, Wisconsin

February 27, 2020

KPMG LLP is a Delaware limited liability partnership and the U.S. member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity.


GE BIOPHARMA

COMBINED STATEMENTS OF INCOME

YEARS ENDED DECEMBER 31, 2019 AND 2018

(in millions)

2019

2018

Sales

$

3,289

$

3,010

Cost of sales

1,246

1,222

Gross profit

2,043

1,788

Selling, general and administrative expenses

567

557

Research and development expenses

169

144

Total operating expenses

736

701

Income from operations

1,307

1,087

Interest expense and other financial charges

30

32

Other (income) and expense-net

(75

)

(17

)

Income before taxes

1,352

1,072

Provision for income taxes

(378

)

(364

)

Net income

974

708

Net income (loss) attributable to non-controlling interests

(1

)

(1

)

Net income attributable to GE BioPharma

$

975

$

709

See Notes to the Combined Financial Statements


GE BIOPHARMA

COMBINED STATEMENTS OF COMPREHENSIVE INCOME

YEARS ENDED DECEMBER 31, 2019 AND 2018

(in millions)

2019

2018

Net income

$

974

$

708

Less net income (loss) attributable to non-controlling interests

(1

)

(1

)

Net income attributable to GE BioPharma

975

709

Other comprehensive income (loss)

Foreign currency translation adjustments

6

(157

)

Defined benefit plans-net of taxes

(42

)

(12

)

Net gain on derivative instruments-net of taxes

3

Other comprehensive income (loss) attributable to GE BioPharma

(33

)

(169

)

Comprehensive income attributable to GE BioPharma

$

942

$

540

See Notes to the Combined Financial Statements


GE BIOPHARMA

COMBINED STATEMENTS OF CHANGES IN EQUITY

YEARS ENDED DECEMBER 31, 2019 AND 2018

(in millions)

Net Parent

Investment

Accumulated

Altro

Comprehensive

Income / (Loss)

Redeemable

Non-

controlling

Interests

Totale

Equity

Balances as of January 1, 2018

$

7,553

$

(688

)

$

7

$

6,872

Cumulative effect of adoption of new accounting principles

708

(6

)

702

Net income

709

(1

)

708

Foreign currency translation adjustments

(157

)

(157

)

Cash flow hedges-net of taxes

Benefit plans-net of taxes

(12

)

(12

)

Transfers (to) Parent

(932

)

(932

)

Changes in equity attributable to non-controlling interests

(3

)

(3

)

Balances as of December 31, 2018

$

8,038

$

(863

)

$

3

$

7,178

Cumulative effect of adoption of new accounting principles

(3

)

(3

)

Net income

975

(1

)

974

Foreign currency translation adjustments

6

6

Cash flow hedges-net of taxes

3

3

Benefit plans-net of taxes

(42

)

(42

)

Transfers (to) Parent

(1,366

)

(1,366

)

Changes in equity attributable to non-controlling interests

Balances as of December 31, 2019

7,644

(896

)

2

6,750

See Notes to the Combined Financial Statements


GE BIOPHARMA

COMBINED STATEMENTS OF FINANCIAL POSITION

YEARS ENDED DECEMBER 31, 2019 AND 2018

(in millions)

2019

2018

Assets

Cash and cash equivalents

$

59

$

93

Current receivables-net (Note 5)

233

224

Inventories (Note 6)

400

313

Contract and other deferred assets (Note 3)

43

36

Other current assets (Note 9)

90

117

Total current assets

$

825

$

783

Property, plant and equipment-net (Note 7)

638

576

Operating lease assets (Note 7)

58

Goodwill (Note 8)

5,318

5,305

Intangible assets-net (Note 8)

483

538

Deferred income taxes (Note 11)

856

1,028

Other assets (Note 9)

111

152

Total assets

$

8,289

$

8,382

Liabilities and equity

Accounts payable

$

403

$

351

Progress collections and deferred income (Note 3)

259

164

Other current liabilities (Note 13)

208

198

Total current liabilities

$

870

$

713

Long-term progress collections and other deferred income (Note 3)

64

43

Operating lease liabilities (Note 7)

50

Non-current compensation and benefits

427

363

Deferred income taxes (Note 11)

110

65

Other liabilities (Note 13)

18

20

Total liabilities

$

1,539

$

1,204

Redeemable non-controlling interests

2

3

Net parent investment

7,644

8,038

Accumulated other comprehensive income (loss) (Note 12)

(896

)

(863

)

Total equity

6,750

7,178

Total liabilities and equity

$

8,289

$

8,382

See Notes to the Combined Financial Statements


GE BIOPHARMA

COMBINED STATEMENTS OF CASH FLOWS

YEARS ENDED DECEMBER 31, 2019 AND 2018

(in millions)

2019

2018

Cash flows – operating activities

Net income

$

974

$

708

Adjustments to reconcile net income to cash provided by operating activities:

Depreciation, amortization and related impairments

118

141

Gain on business and equity method investment dispositions

(58

)

Deferred income tax provision

213

246

Changes in operating assets and liabilities:

(Increase) in contract and other deferred assets

(2

)

(7

)

(Increase) in current receivables

(8

)

(44

)

(Increase) in inventories

(83

)

(36

)

Increase in accounts payable

47

1

Increase in progress collections and deferred income

119

48

Increase in taxes payable

18

27

All other operating activities

20

10

Cash provided by operating activities

$

1,358

$

1,094

Cash flows – investing activities

Additions to property, plant and equipment

(118

)

(122

)

Dispositions of property, plant and equipment

7

26

Proceeds from sales of business and equity method investments

95

Additions to internal-use software

(11

)

(12

)

All other investing activities

(3

)

Cash (used for) investing activities

$

(27

)

$

(111

)

Cash flows – financing activities

Transfers (to) Parent

(1,366

)

(932

)

All other financing activities

(1

)

(2

)

Cash (used for) financing activities

$

(1,367

)

$

(934

)

Effect of currency exchange rate changes on cash and cash equivalents

2

(3

)

Increase (decrease) in cash and cash equivalents

$

(34

)

$

46

Cash and cash equivalents at beginning of year

$

93

$

47

Cash and cash equivalents at end of year

$

59

$

93

Supplemental disclosure of cash flow information

Cash paid during the year for income taxes

$

35

$

23

See Notes to the Combined Financial Statements


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

NOTE 1

Description of Business and Basis of Presentation

Description of Business

GE BioPharma (the “Business”, “our” or “we”) is a business within the GE Healthcare segment of General Electric Company (“GE” or “Parent”).

The Business provides instruments, consumables and software that supports the research, discovery, process development and manufacturing workflows of biopharmaceuticals and 3rd party drug manufacturers. The Business comprises process chromatography hardware and consumables, cell culture media, single use technologies, development instrumentation and consumables, and service. We manufacture equipment and special resins that help pharmaceutical companies to discover and mass produce biopharmaceuticals which are designed to fight autoimmune diseases such as rheumatoid arthritis and psoriasis. We are also helping vaccine developers and researchers explore immunotherapy. This emerging type of treatment uses viruses and other tools to reprogram and harness the body’s immune cells to help the immune system.

Acquisition by Danaher

On February 25, 2019, GE announced a definitive agreement to sell the Business to Danaher Corporation for a total cash consideration of $21,000 million (subject to certain adjustments) as well as Danaher’s assumption of approximately $400 million of certain pension plans and related liabilities. The transaction is subject to regulatory approvals and other customary closing conditions.

Basis of Presentation

The combined financial statements have been derived from the consolidated financial statements and accounting records of GE including the historical cost basis of assets and liabilities comprising the Business, as well as attribution of revenues and direct costs and allocations of indirect costs attributable to the operations of the Business. These Combined financial statements do not purport to reflect what the results of operations, comprehensive income, financial position or cash flows would have been had the Business operated as a stand-alone company during the periods presented.

The Combined financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and SEC Rule 3-05, of Regulation S-X, and present the combined financial position, results of operations, comprehensive income and cash flows of the Business as of December 31, 2019 and 2018 and for the years ended December 31, 2019 and 2018.

All intercompany balances and transactions within the Business have been eliminated. As described in Note 4 Related Party Transactions, certain transactions between the Business and GE have been included in these Combined financial statements.

The Combined statements of financial position reflect, among other things, all the assets and liabilities of GE and the Business that are specifically identifiable as being directly attributable to the Business, including Net parent investment as a component of equity. Net parent investment represents GE’s historical investment in the Business and includes accumulated net income attributable to the Business, the net effect of transactions with GE and GE entities and cost allocations from GE that were not historically allocated to the Business.

GE uses a centralized approach to cash management and financing of its operations. These arrangements may not be reflective of the way the Business would have financed its operations had it been a stand-alone business during the periods presented. Cash pooling, related interest and intercompany arrangements are excluded from the asset and liability balances in the Combined statements of financial position. These amounts have instead been reported as Net parent investment as a component of equity.

GE and its affiliates (including GE Healthcare) provide a variety of services to the Business. The Business may also sell products in the ordinary course of business to GE and its affiliates. The Combined statements of income include expenses directly billed or allocated for services and certain support functions (“GE Corporate Overhead”) and other allocations that are provided on a centralized basis within GE such as legal, business development, insurance, human resources, corporate audit, treasury and various other GE corporate functions that are routinely allocated to the Business and reflected in the Combined


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

statements of income. See Note 4 Related Party Transactions. In addition to GE Corporate Overhead and other allocations, charges that would have been incurred in the ordinary course of business if the Business operated as a stand-alone company, such as compensation and benefits for employees of the Business further described in Note 15 Pension and Postretirement Benefit Plans, were included within the Combined financial statements based on either specific identification of direct expenses or an allocation using an approach related to the nature of the item (e.g., external revenue or headcount).

Where allocations of GE Corporate Overhead and other allocations amounts were necessary, the Business believes the allocation of these amounts were determined on a reasonable basis, reflecting all the costs of the Business and consistently applied in the periods presented. These allocated amounts, however, are not necessarily indicative of the actual amounts that might have been incurred had the Business operated as a separate stand-alone entity during the periods presented. Consequently, these Combined financial statements do not necessarily represent the results the Business would have achieved if the Business had operated as a separate stand-alone entity during the periods presented.

NOTE 2

Summary of Significant Accounting Policies

Estimates and Assumptions

The preparation of Combined financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported and disclosed in the financial statements and the accompanying notes. We base our estimates and judgments on historical experience and various other assumptions and information that we believe to be reasonable under the circumstances. Estimates and assumptions about future events and their effects cannot be perceived with certainty, and accordingly, these estimates may change as new events occur, as more experience is acquired, as additional information is obtained or our operating environment changes. While the Business believes that the estimates and assumptions used in the preparation of these Combined financial statements are appropriate, actual results could differ materially from those estimates.

Estimates are used for, but are not limited to, determining the following: distinct performance obligations, recoverability of long-lived assets and inventory, valuation of goodwill, useful lives used in depreciation and amortization, asset retirement obligations, income taxes and related valuation allowances, accruals for contingencies including legal and warranties, actuarial assumptions used to determine costs of pension and other post-retirement benefits, valuation and recoverability of receivables and valuation of derivatives and the fair value of assets acquired and liabilities assumed in acquisitions.

Revenue Recognition

On January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers, and the related amendments of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, which supersedes most previous U.S. GAAP revenue guidance. We elected to adopt the new standard on a retrospective basis. In addition, we elected the practical expedient for contract modifications, which essentially means that the terms of the contract that existed at the beginning of the earliest period presented can be assumed to have been in place since the inception of the contract (i.e., not practical to separately evaluate the effects of all prior contract modifications). Our revenues consist of sales of products (tangible goods) and sales of services to customers.

The Business recognizes a contract with a customer when there is a legally enforceable agreement between the Business and its customer, the rights of the parties are identified, the contract has commercial substance and collectability of the contract consideration is probable. The Business’ revenues are measured based on the consideration specified in the contract with each customer net of any sales incentives or credits, accounted for as estimated variable consideration, and taxes collected from customers that are remitted to government authorities. Payment terms are generally within 12 months.

Contracts for the sale of products and services generally include multiple distinct performance obligations most commonly involving an upfront deliverable of equipment and future performance obligations such as installation, training or the future delivery of products or services. If a contract contains more than one performance obligation, the transaction price of the contract is allocated to each performance obligation based on its relative stand-alone selling price. Stand-alone selling price is obtained from sources such as the separate selling price for that or a similar item or from competitor prices for similar items if reasonably available. If such evidence is not reasonably available, we use our best estimate of selling price, which is established consistent with the pricing strategy of the Business and considers product configuration, geography, customer type and other market specific factors. The majority of our revenues relate to product sales that are recognized at a point in time. Shipping and


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

handling costs to deliver products to customers are expensed as incurred and recorded in Cost of sales as these costs are generally not specifically billed to customers.

Performance Obligations Satisfied at a Point In Time

We recognize revenue for non-customized products at a point in time. The point in time is when the customer obtains control of the product, which is generally no earlier than when the customer has physical possession of the product at delivery. We use proof of delivery for certain large equipment with more complex logistics, whereas the delivery of other equipment is estimated based on historical averages of in-transit periods (i.e., time between shipment and delivery). In situations where arrangements include customer acceptance provisions based on customer-specified criteria, we recognize revenue when acceptance has occurred.

Our billing terms for point in time product performance obligations can vary but generally coincide with delivery to the customer; however, they also may occur upon final installation or acceptance of the products. Periodically, we receive down payments in advance of delivery at the time an order is received.

For standard, assurance-type warranties that are provided with products, we estimate the cost that may be incurred during the warranty period and record a liability at the time revenue is recognized. The provision recorded reflects the estimated costs of replacement and free-of-charge services that will be incurred related to the product sold (see Note 13 Other Liabilities).

In certain arrangements, along with our products, we provide service-type or extended warranties, which are considered separate performance obligations. As such, a portion of the overall contract transaction price is allocated to this performance obligation and recognized as revenue over time, as the performance obligation is satisfied.

Performance Obligations Satisfied Over Time

We recognize revenue for certain long-term product service agreements over time. Revenue for these arrangements is recognized on a straight-line basis consistent with the nature, timing and extent of our services, which primarily relate to routine maintenance and as needed product repairs. Our billing terms for these long-term product service contracts vary and can occur in advance of or following the period of service, but we generally invoice periodically as services are provided.

We also recognize revenue on agreements for the sale of certain customized products or services such as construction type contracts on an over time basis when applicable criteria are met under ASC 606. When those criteria are met, we recognize revenue using percentage of completion based on inputs, such as costs incurred, relative to total expected inputs. Our estimate of inputs to be incurred to fulfill our promise to a customer is based on our history of providing similar assets or services for customers and is updated routinely to reflect changes in quantity or pricing of the inputs. We provide for potential losses on any of these agreements when it is probable that we will incur the loss. Our billing terms for these customized products or services contracts vary but are generally based on achieving specified milestones.

The differences between the timing of our revenue recognized and customer billings result in changes to our contract asset or contract liability positions (see Note 3 Revenue Related to Contracts with Customers).

No customer accounted for more than 10% of the Business’ revenues for the years ended December 31, 2019 and 2018 or accounts receivable as of December 31, 2019 and 2018.

Foreign Currency

Certain of our international operations have determined that the local currency is the functional currency, whereas others have determined the U.S. dollar is their functional currency. The basis of this determination is where each of the international operations primarily generates and expends cash. When the functional currency is not the U.S. dollar, asset and liability accounts are translated at period-end exchange rates and the Business translates functional currency income and expense amounts to their U.S. dollar equivalents using average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates from functional currencies are recorded in Accumulated other comprehensive income (loss) in the Combined statements of financial position.

Gains and losses from foreign currency transactions, such as those resulting from the settlement of monetary items in the non-functional currency and those resulting from remeasurements of monetary items, are included in Cost of sales, Selling, general


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

and administrative expenses and Research and development expenses, depending on the underlying nature of the item. Losses of ($13) million and ($27) million were recorded in the years ended December 31, 2019 and 2018, respectively.

Acquisitions

Our Combined financial statements include the operations of acquired businesses from the date of acquisition. The Business accounts for acquired businesses using the acquisition method of accounting, which requires, among other things, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Transaction costs are expensed as incurred. Any excess of the fair value of consideration transferred over the assigned values of the net assets acquired is recorded as goodwill.

There were no acquisitions that were completed during the years ended December 31, 2019 and 2018 that affected our Combined financial statements.

Cash and Cash Equivalents

The cash presented on the Combined statements of financial position represents cash not subject to the GE centralized cash management process as described in Note 1 Description of Business and Basis of Presentation. Cash held in commingled accounts with our Parent, or its affiliates, is presented within Net parent investment in the Combined statements of financial position.

Allowance for Doubtful Accounts

We establish an allowance for doubtful accounts based on various factors including the payment history and financial condition of our debtors and the economic environment. Provisions for doubtful accounts are recorded based on the aging status of the customer accounts or when it becomes probable that the customer will not make the required payments at either contractual due dates or in the future. See Note 5 Current Receivables – Net.

Current Receivables Factoring Program

We monetize a portion of our accounts receivables through factoring programs established for GE and various GE subsidiaries that are administered by Working Capital Solutions (“WCS”), a GE Capital subsidiary. Under the factoring programs, we factor U.S. and Non-U.S. receivables to WCS on a nonrecourse and recourse basis. Generally, the recourse guarantees related to factored receivables are provided by GE, not the Business. Under the accounts receivable factoring programs, transfers of receivables meeting the applicable criteria of FASB ASC Topic 860, Transfers and Servicing are recognized as true sales, and cash inflows received are recorded within Cash provided by operating activities. The Business incurred interest and other related expense which are reflected as Interest and other financial charges in the Combined statements of income.

Inventories

Inventories are stated at the lower of cost or net realizable value. Production inventory is valued at cost using a first-in, first-out (“FIFO”) basis, including raw materials, work in process and finished goods.

As necessary, we record provisions and write-downs for excess, slow moving and obsolete inventory. To determine these amounts, we regularly review inventory quantities on-hand and compare them to historical utilization and estimates of future product demand, market conditions and technological developments. See Note 6 Inventories.

Equity Method Investments

Equity method investments are investments in entities in which we do not have a controlling financial interest, but over which we have significant influence. Equity method investments are assessed for other-than-temporary impairment. Equity method investments are recorded in Other assets in our Combined statements of financial position. See Note 9 Other Assets. Our share of the results of equity method investments are presented on a one-line basis in Other (income) and expense – net in the Combined statements of income.


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

Property, Plant and Equipment – Net

Property, plant and equipment is stated at cost and is depreciated over its estimated economic life. The straight-line method of depreciation is used for all property, plant and equipment. Repair and maintenance costs are expensed as incurred. See Note 7 Property, Plant and Equipment – Net and Operating Lease Assets and Liabilities.

Goodwill and Intangible Assets – Net

Goodwill represents the excess of the fair value of consideration transferred over the fair value of identifiable net assets acquired in a business combination. Goodwill is assigned to specific reporting units and is tested for impairment at the reporting unit level annually in the third quarter of each year using data as of July 1 or more frequently, if needed, based on changes in facts and circumstances. During 2019, we changed our annual testing date from the third quarter to the fourth quarter in order to improve alignment of our annual goodwill impairment test and our strategic planning processes. A reporting unit is an operating segment, or one level below that operating segment (the component level), if discrete financial information is prepared and regularly reviewed by segment management. The Business also tests goodwill for impairment when an event occurs, or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. The Business uses quantitative assessments and qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Business chooses to perform a qualitative assessment and concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a further quantitative fair value test is performed. The Business recognizes an impairment charge if the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill based on the results of our quantitative tests. The market approach is used for estimating the fair values for our reporting units. See Note 8 Goodwill and Intangible Assets – Net.

All intangible assets of the Business other than goodwill are subject to amortization. The cost of such intangible assets is amortized on a straight-line basis over the asset’s estimated economic life. Amortizable intangibles are reviewed for impairment annually and whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. In these circumstances, intangible assets are tested for impairment based on undiscounted cash flows and, if impaired, written down to the fair value based on either discounted cash flows or appraised values. See Note 8 Goodwill and Intangible Assets – Net.

Internal Use Software

Internal use software is software that is internally developed, purchased or modified to meet internal needs and for which no substantive plan exists to sell, lease or otherwise market the software externally. All costs associated with project tasks classified in the preliminary project development or post-implementation/operation stage are expensed as incurred. Capitalization of application development stage costs begin after both of the following occur: (a) the preliminary project development stage is completed, and (b) management authorizes and commits to funding the software project, and it is probable that the project will be completed, and the software will be used for the purpose for which it was intended. Capitalization ceases when the project is substantially complete. Capitalized amounts are amortized using the straight-line method over the asset’s estimated economic life. See Note 8 Goodwill and Intangible Assets – Net.

External Use Software

External use software is software that is (a) intended to be sold, licensed or marketed to our customers, or is (b) embedded and integral to our tangible products for which R&D has been completed. Costs that are related to the conceptual formulation and design of software are expensed as incurred. Costs that are incurred after technological feasibility has been established until general release of the product are capitalized as an intangible asset. Capitalized costs for software to be sold, leased, or otherwise marketed are amortized on an individual product basis using straight-line amortization over the estimated life of the product.

The Business performs regular reviews to ensure that unamortized capitalized software program costs remain recoverable through future cash flows. See Note 8 Goodwill and Intangible Assets.

Financial Instruments

We monitor our exposure to various business risks including foreign currency exchange rate fluctuations and regularly use derivative financial instruments to manage these risks. At the inception of a new derivative, we designate the derivative as a


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

hedge, or we determine the derivative to be undesignated as a hedging instrument. We use economic hedges when we have exposures to currency exchange risk for which we are unable to meet the requirements for hedge accounting. These derivatives are not designated as hedges from an accounting standpoint but otherwise serve the same economic purpose as other hedging arrangements.

For hedged items, we document the relationships between the hedging instruments and the hedged items, as well as our risk management objectives and strategy for undertaking various hedge transactions. We assess whether the derivatives that are used in hedging transactions are effective in offsetting changes in cash flows of the hedged item at both the inception of the hedge and on an ongoing basis.

We have a program that utilizes foreign currency derivative instruments to reduce the risks associated with the effects of certain foreign currency exposures. Under this program, our strategy is to have gains or losses on the foreign currency derivative instruments mitigate the foreign currency transaction and translation gains or losses to the extent practical. These foreign currency exposures typically arise from changes in the value of assets (e.g., current receivables) and liabilities (e.g., current payables) which are denominated in currencies other than the functional currency. We record all derivatives at fair value. For the derivative contracts held as undesignated hedging instruments, we record the changes in fair value of the derivative contracts in our Combined statements of income along with the change in fair value, related to foreign exchange movements, of the hedged item. Changes in the fair value of derivative contracts designated as cash flow hedging instruments are recognized in Accumulated other comprehensive income/(loss) until the hedged item is recognized in earnings.

Fair Value Measurements

For financial assets and liabilities measured at fair value on a recurring basis, fair value is the price the Business would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. In the absence of active markets for the identical assets or liabilities, such measurements involve developing assumptions based on market observable data and, in the absence of such data, internal information that is consistent with what market participants would use in a hypothetical transaction that occurs at the measurement date.

Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. Preference is given to observable inputs. These two types of inputs create the following fair value hierarchy:

Level 1 – Quoted prices for identical instruments in active markets.

Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

Level 3 – Significant inputs to the valuation model are unobservable.

We maintain policies and procedures to value instruments using the best and most relevant data available. In addition, the Business performs reviews to assess the reasonableness of the valuations. This detailed review may include the use of a third-party valuation firm.

Recurring Fair Value Measurements

The following sections describe the valuation methodologies used to measure different financial instruments at fair value on a recurring basis.

Financial Instruments – General

Our financial instruments include receivables, accounts payable, derivative financial instruments, loans and equity investments. The estimated fair value of these financial instruments approximates their carrying value as reflected in our Combined statements of financial position. See Note 5 Current Receivables – Net, Note 9 Other Assets, and Note 13 Other Liabilities.


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

Derivatives

When derivatives are traded either on exchanges or liquid over-the-counter markets, these derivatives are classified as Level 1, using closing prices to determine fair value. When derivatives are not traded on exchanges or over-the-counter markets, they are classified as Level 2, using internal models to determine fair value.

Currency exchange contracts and embedded derivatives are valued using Level 2 inputs. See Note 10 Derivatives and Hedging. There were no transfers between Levels 1, 2 and 3 during the years ended December 31, 2019 and 2018.

Non-Recurring Fair Value Measurements

Certain assets are measured at fair value on a non-recurring basis. These assets are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. These assets can include equity method investments and long-lived assets that are written down to fair value when they are impaired. Assets that are written down to fair value when impaired are not subsequently adjusted to fair value unless further impairment occurs. The following sections describe the valuation methodologies the Business uses to measure those assets not measured on an ongoing fair value basis.

Equity Method Investments

In instances of impairment, equity method investments are written down to fair value using market observable data such as quoted prices when available. When market observable data is unavailable, investments are valued using a discounted cash flow model, comparative market multiples or a combination of both approaches as appropriate and other third-party pricing sources. These investments are included in Level 3. See Note 9 Other Assets.

Long-Lived Assets

Long-lived assets, such as property, plant and equipment and intangible assets subject to depreciation and amortization, are reviewed for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Determining whether an impairment has occurred typically requires various estimates and assumptions, including determining which undiscounted cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount and the asset’s residual value, if any. In turn, measurement of an impairment loss requires a determination of fair value, which is based on the best information available. The required undiscounted cash flow estimates are derived from our historical experience and our internal business plans. To determine fair value, the Business uses quoted market prices when available, our internal cash flow estimates discounted at an appropriate discount rate, or independent appraisals, as appropriate. Fair values of long-lived assets are primarily derived internally and are based on observed sales transactions for similar assets. These assets are generally included in Level 3.

Restructuring Costs

We record liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee termination costs are accrued when the restructuring actions are probable and estimable. When accruing these costs, we recognize the amount within a range of costs that is the best estimate within the range. Restructuring costs incurred for the years ended December 31, 2019 and 2018 were not significant.

Research and Development Expenses (“R&D”)

The Business conducts R&D activities to create new products, develop new applications for existing products and enhance existing products to help improve outcomes for customers. This includes direct R&D expenses as well as expenses incurred for the use of services from GE Global Research Center. R&D costs are expensed when incurred.

Pension and Postretirement Benefits

Certain employees and retirees of the Business participate in postretirement benefit plans, sponsored by either the Business or GE:

Pension Benefits (sponsored by the Business)


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

These plans are accounted for under the provisions of FASB ASC Subtopic 715-20, Compensation Retirement Benefits: Defined Benefit Plans (see Note 15 Pension and Postretirement Benefit Plans). In accordance with FASB ASC Subtopic 715-20, management categorizes plan assets for disclosure purposes in accordance with the fair value hierarchy as set forth in FASB ASC Topic 820, Fair Value Measurements and Disclosures.

Pension and Other Postretirement Benefits Plans (sponsored by GE)

These plans are accounted in accordance with ASC Subtopic 715-80 Compensation – Retirement Benefits – Multiemployer Plans (see Note 15 Pension and Postretirement Benefit Plans).

Pension benefits are calculated using significant inputs to the actuarial models that measure pension benefit obligations and related effects on operations. Two assumptions – discount rate and expected return on assets – are important elements of plan expense and asset/liability measurement. The Business evaluates these critical assumptions at least annually on a plan and country-specific basis. The Business periodically evaluates other assumptions involving demographic factors such as retirement age, mortality and turnover, and updates them to reflect our experience and expectations for the future. Actual results in any given year often will differ from actuarial assumptions because of economic and other factors.

Projected benefit obligations are measured as the present value of expected payments. We discount those cash payments using the weighted average of market-observed yields for high-quality fixed-income securities with maturities that correspond to the payment of benefits.

The components of net periodic benefit costs, other than the service cost component, are included in Other (income) and expense-net in our Combined statements of income.

Income Taxes

The Business is included in the combined U.S. federal, foreign and state income tax returns of GE, where eligible. However, the Business determines its current and deferred taxes based on the separate return method (i.e., as if the Business were a taxpayer separate from GE). All income taxes due to or due from GE that have not been settled or recovered by the end of the period have been deemed settled and reflected in Net parent investment. Any differences between actual amounts paid or received by the Business and taxes accrued under the separate return method have been reflected in Net parent investment.

The Business accounts for income taxes under the asset and liability method. Under this method, deferred income taxes are recognized for temporary differences between the financial statement and tax return bases of assets and liabilities as well as from net operating losses and tax credit carryforwards, based on enacted tax rates and other provisions of the tax law expected to be in effect when taxes are paid or recovered. The effect of a change in tax rate or law on deferred tax assets and liabilities is recognized in income in the period in which such change is enacted. The Business currently intends to indefinitely reinvest substantially all the earnings of our foreign subsidiaries with operations outside the U.S. and, accordingly, has not provided U.S. income tax on such earnings. Future tax benefits are recognized to the extent that realization of such benefits is more likely than not, and a valuation allowance is established for any portion of a deferred tax asset that management believes is unlikely to be realized.

Significant judgment is required in determining our tax expense and in evaluating our tax positions, including evaluating uncertainties. The Business operates globally, and our tax filings are subject to audit by tax authorities in the jurisdictions where business is conducted. These audits may result in assessments of additional taxes, interest and penalties that are resolved with the tax authorities or through the courts. The Business has provided for the amounts believed that will ultimately result from these proceedings. The Business recognizes uncertain tax positions that are more likely than not to be sustained if the relevant tax authority were to audit the position with full knowledge of all the relevant facts and other information. For those tax positions that meet this threshold, the Business measures the amount of tax benefit based on the largest amount of tax benefit that the Business has a greater than 50% chance of realizing in a final settlement with the relevant authority. The Business classifies interest and penalties associated with uncertain tax positions as interest expense and provision for income taxes, respectively, on the Combined statements of income. The effects of tax adjustments and settlements from taxing authorities are presented in these Combined financial statements in the period they are recorded.

Due to the enactment of the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”), substantially all our previously unrepatriated foreign earnings were subject to U.S. federal income tax, and therefore we expect to have the ability to repatriate those earnings without incremental U.S. federal tax cost. Future repatriations of foreign earnings may incur other taxes, such as withholding or


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

state taxes. Indefinite reinvestment is determined by management’s judgments and intentions concerning the future operations of the Business. Most of these earnings have been reinvested in active Non-U.S. business operations. In the Combined financial statements, foreign earnings are considered indefinitely reinvested which is consistent with the assertion made by GE relative to the Business’ foreign operations as of December 31, 2019. It is not practicable to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely. The undistributed earnings disclosure and the transition tax recorded in the Combined financial statements are based on the cumulative Earnings and Profits allocated to the Business. It is not practicable to re-determine earnings and profits on a pure separate return method.

Additionally, as part of U.S. tax reform, the U.S. has enacted a “base erosion anti-abuse tax” requiring U.S. corporations to make an alternative determination of taxable income without regard to tax deductions for certain payments to affiliates and a minimum tax on certain earnings considered to be “global intangible low-taxed income.” We have made an accounting policy election to treat this new minimum tax as a period cost.

Commitments and Contingencies

Liabilities for loss contingencies arising from product warranties, claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. See Note 14 Commitments and Contingencies.

Lease Accounting

We determine if an arrangement is a lease or a service contract at inception. Where an arrangement is a lease, at commencement, we determine the classification to be either an operating lease or a finance lease. Subsequently, if the arrangement is modified, we reevaluate our classification. Throughout the normal course of business, we are involved in certain service contracts primarily as a Lessee. At lease commencement, we record a lease liability and corresponding right-of-use (“ROU”) asset. Lease liabilities represent the present value of our future lease payments over the expected lease term which includes options to extend or terminate the lease when it is reasonably certain those options will be exercised. We have elected to include lease and non-lease components in determining our lease liability for all leased assets except our vehicle leases. Non-lease components are generally services that the lessor performs for the Business associated with the leased asset. For those leases with payments based on an index, the lease liability is determined using the index at lease commencement. Lease payments based on increases in the index subsequent to lease commencement are recognized as variable lease expense as they occur. The present value of our lease liability is determined using our incremental collateralized borrowing rate at lease inception. ROU assets represent our right to control the use of the leased asset during the lease and are recognized in an amount equal to the lease liability. Over the lease term we use the effective interest rate method to account for the lease liability as lease payments are made and the ROU asset is amortized to earnings in a manner that results in a straight-line expense recognition in the Combined statements of income. A ROU asset and lease liability is not recognized for leases with an initial term of 12 months or less and we recognized lease expense for those leases on a straight-line basis over the lease term. See Note 7 Property, Plant and Equipment – Net and Operating Lease Assets and Liabilities.

Recent Accounting Pronouncements Reflected in these Combined Financial Statements

In October 2016, the FASB issued ASU 2016-16, Accounting for Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory, which amends existing guidance on income taxes to require the accounting for the income tax effects of intercompany sales and transfers of assets other than inventory when the transfer occurs. As a result, the tax expense from the intercompany sale of assets, other than inventory, and associated changes to deferred taxes will be recognized when the sale occurs even though the pre-tax effects of the transaction have not been recognized. The pronouncement is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods, with early adoption permitted at the beginning of an annual period for which no financial statements have already been issued. The Business adopted the new standard on a modified retrospective basis for the period beginning January 1, 2018 and recorded an impact to increase assets by approximately $702 million, with an offset to Net parent investment, as of the beginning of the period of adoption. This impact is reflected in the Combined statements of changes in equity.

On October 1, 2018, we adopted ASU No. 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The ASU provides that the stranded tax effects from the 2017 Tax Act on the balance of accumulated other comprehensive income (“AOCI”) may be reclassified to Net parent investment. The stranded tax effects relate primarily to pension and other employee benefit plans and absent the ASU, our policy is to release stranded tax effects on plan termination. We elected to early adopt the standard and reclassified


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

the tax effect recorded within AOCI associated primarily with the change in tax rate under U.S tax reform to Net parent investment. The adoption resulted in a decrease to AOCI and an increase to Net parent investment of $4 million.

On January 1, 2019, we prospectively adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases. Our ROU assets and operating lease liabilities at adoption were $62 million and $65 million, respectively. The impact upon adoption had an immaterial effect to our Net parent investment and cashflows.

On January 1, 2019, we adopted ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. This ASU requires certain changes to the presentation of hedge accounting in the financial statements and some new or modified disclosures. The ASU also simplifies the application of hedge accounting and expands the strategies that qualify for hedge accounting. The impact upon adoption had an immaterial effect to our Net parent investment.

Other Recent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses. The ASU introduces a new accounting model, the Current Expected Credit Losses model (“CECL”), which requires earlier recognition of credit losses and additional disclosures related to credit risk. The CECL model utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses for loans and other receivables at the time the financial asset is originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. This model replaces the multiple existing impairment models in current GAAP, which generally require that a loss be incurred before it is recognized. The new standard also applies to receivables arising from revenue transactions such as contract assets and accounts receivables and is effective for fiscal years beginning after December 15, 2019. The standard will be applied prospectively with an adjustment to Net parent investment. As we finalize our process, we expect the adoption of the ASU to have an immaterial effect to our Net parent investment.

NOTE 3

Revenue Related to Contracts with Customers

The Combined financial statements are presented in accordance with FASB ASC Topic 606. See Note 2 Summary of Significant Accounting Policies.

Disaggregation of Revenues

The following table disaggregates the Business’ revenue based on geographical region for the years ended December 31:

(in millions)

2019

2018

U.S./Canada/LATAM

$

1,313

$

1,248

Europe/Middle East/Africa

954

892

Asia/Other

1,022

870

Total Revenue

$

3,289

$

3,010

Contract-Related Balances

Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the Business’ right to consideration becomes unconditional.

Other deferred assets consist of costs to obtain contracts, cost deferrals for shipped products and deferred service, labor and direct overhead costs.

Contract liabilities include billings in excess of revenue recognized, such as those resulting from customer advances and deposits and unearned revenue on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers.


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

The differences between the timing of our product and service revenue recognized and customer billings, which can occur in advance of or following the transfer of control, result in changes to our contract asset or contract liability positions. The current Progress collections and deferred income balance relates to customer billings where the service or equipment is expected to be delivered within 12 months. The long-term portion relates primarily to extended warranties for services expected to be provided in periods greater than 12 months.

Contract asset and liability balances, as of December 31, 2019 and 2018, are as follows:

(in millions)

2019

2018

Contract assets

$

16

$

18

Other deferred assets

27

18

Total Contract and other deferred assets

$

43

$

36

In addition, contract assets that are long-term in nature have been recorded within Other assets in the Combined statements of financial position. See Note 9, Other Assets.

Progress collections

$

71

$

70

Other deferred income

188

94

Progress collections and deferred income

$

259

$

164

Long-term other deferred income

$

64

$

43

Total progress collections and other deferred income

$

323

$

207

Progress collections and current deferred income balances at the beginning of each year were substantially recognized as revenue within the following year. Total progress collections and other deferred income increased by $116 million in 2019 primarily due to milestone payments received in China, Europe and the United States as well as advance billing for service contracts.

Remaining Performance Obligations

As of December 31, 2019, substantially all the remaining performance obligations are expected to be satisfied within one year. The Long-term other deferred income primarily relates to extended warranty or other service contracts and is expected to be substantially recognized within 3 years.

NOTE 4

Related Party Transactions

The Combined financial statements include related party transactions with GE and GE entities (including GE Healthcare). As such, they do not necessarily represent all the costs that would have been incurred had the Business been a separate, stand-alone entity. As discussed in Note 1 Description of Business and Basis of Presentation, GE and GE Healthcare provide the Business with a number of services. Some of these services are provided directly by GE or GE Healthcare, and others are managed by GE or GE Healthcare through third-party service providers. The cost of certain of these services is either:

(a)

recognized through our allocated portion of GE’s or GE Healthcare’s corporate overhead or

(b)

billed directly to the Business (such as most of our employee benefit costs).

The cost of other services is included within the service itself and the incremental cost for GE or GE Healthcare to provide the service is not discernible (such as payroll processing services included within the cost of payroll). In addition, we and our affiliates obtain a variety of goods (such as supplies and equipment) and services under various master purchasing and service agreements to which GE or GE Healthcare (and not the Business) is a party. We are billed directly for services we procure under these arrangements.


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

We receive an allocated share of GE’s corporate overhead for certain services provided to the Business, but which are not specifically billed to the Business, such as public relations, investor relations, treasury and cash management, executive management compensation, security, government relations, business development, community outreach, certain research activities and corporate internal audit services.

Costs of $32 million for each of the years ended December 31, 2019 and 2018, were recorded in our Combined statements of income for our allocated share of GE’s corporate overhead and such expenses have been classified as Selling, general and administrative expenses.

We receive an allocated share of GE Healthcare’s and other GE Healthcare entities’ corporate overhead for certain services provided to the Business, but are not specifically billed to the business, such as finance, supply chain, quality, marketing and technology.

Costs of $226 million and $214 million for the years ended December 31, 2019 and 2018, respectively, were recorded in our Combined statements of income for our allocated share of GE Healthcare’s and other GE Healthcare entities’ corporate overhead. These expenses are classified in our Combined statements of income as follows:

(in millions)

2019

2018

Cost of sales

$

53

$

63

Selling, general and administrative expenses

152

131

Research and development expenses

$

21

$

20

The Combined financial statements include additional related party transactions with GE and GE entities (including GE Healthcare) that include the following:

Employees of the Business participate in pensions and benefit plans that are sponsored by GE. See Note 15 Pension and Postretirement Benefit Plans.

The Business factors U.S. and non-U.S. receivables through WCS on a recourse and nonrecourse basis pursuant to various factoring and servicing agreements The Business had factored receivables of $396 million, of which substantially all were without recourse, as of December 31, 2019. The Business had factored receivables of $398 million ($352 million without recourse and $46 million with recourse) as of December 31, 2018. Losses recognized related to receivables factored with recourse were immaterial during the years ended December 31, 2019 and 2018. For agreements with recourse, the Business establishes an allowance for doubtful accounts based on its aging policy. Historically, the Business has outsourced its servicing responsibilities to GE Global Operations for a market-based fee and therefore no servicing asset or liability has been recorded as of December 31, 2019 and 2018. Under the programs, the Business incurred interest expense and other financial charges of $14 million and $17 million for the years ended December 31, 2019 and 2018, respectively, which are included in Interest expense and other financial charges in the Combined statements of income.

All adjustments relating to certain transactions among the Business, GE and GE entities, which include the transfer of cash balances to GE, transfer of the balance of cash held in cash pooling arrangements to GE, settlement of intercompany debt between the Business and GE, or other GE entities and pushdown of all costs of doing business that were paid on behalf of the Business by GE or GE entities, are classified as Net parent investment in the Combined statements of financial position.

The Business participates in GE Treasury centralized hedging and offsetting programs. See Note 10 Derivatives and Hedging.

The Business’ U.S. and Canada operations, and certain of its suppliers, participated in the Trade Payables Services (“TPS”) accounts payable programs with GE Capital until April 1, 2019. Supplier invoices were at times settled early by TPS to obtain early pay cash discounts. The Business settled its obligations by reimbursing TPS on the invoice’s contractual due date. As the payables in the TPS program related to operating activities incurred in the ordinary course of business and retain the principal characteristics of a trade payable, the results of this program are included within Cash provided by operating activities in our Combined statements of cash flows. Amounts due to affiliates are recorded in Accounts payable and are settled in cash. The amounts due to affiliates in Accounts payable were $41 million and $50 million as of


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

December 31, 2019 and 2018, respectively. Accounts payable includes the Business’ funded participation in accounts payable programs with TPS of $0 million and $30 million as of December 31, 2019 and 2018, respectively.

NOTE 5

Current Receivables – Net

Current receivables – net, as of December 31, 2019 and 2018, consist of the following:

(in millions)

2019

2018

Customer receivables

$

120

$

99

Due from GE and affiliates

4

30

Sundry receivables

112

98

Current receivables – gross

236

227

Less allowance for doubtful accounts

(3

)

(3

)

Current receivables – net

$

233

$

224

Customer receivables are recorded at the invoiced amount. Additionally, Sundry receivables primarily consist of value added tax receivables.

NOTE 6 Inventories

Inventories as of December 31, 2019 and 2018 consists of the following:

(in millions)

2019

2018

Raw materials

$

114

$

77

Work in process

49

22

Finished goods

237

214

Total inventories

$

400

$

313

Certain inventory items are long-term in nature and therefore have been classified within Other assets in the Combined statements of financial position. See Note 9 Other Assets.

NOTE 7

Property, Plant and Equipment – Net and Operating Lease Assets and Liabilities

Property, plant and equipment – net as of December 31, 2019 and 2018, consists of the following:

2019

2018

(in millions)

Depreciable

Life

(in years)

Original

Cost

Accumulated Depreciation

Netto

Carrying

Value

Original

Cost

Accumulated

Depreciation

Netto

Carrying

Value

Land

$

24

$

$

24

$

24

$

$

24

Buildings, structures and related equipment

8-40

471

(199

)

272

394

(173

)

221

Machinery and equipment

3-20

401

(252

)

149

429

(256

)

173

Construction in process

193

193

158

158

Property, plant and equipment

$

1,089

$

(451

)

$

638

$

1,005

$

(429

)

$

576

During 2019, certain assets totaling $30 million of net carrying value were recategorized from Machinery and equipment to Buildings, structures and related equipment due to refinement of the Business’ classification of related assets. Total depreciation expense was $46 million for each of the years ended December 31, 2019 and 2018, respectively. Additionally, during the year


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

ended December 31, 2018, we recorded an impairment totaling approximately $19 million related to business reprioritization of certain capital projects.

Operating Lease Assets and Liabilities

Our ROU assets were $58 million while related lease liabilities were $61 million as of December 31, 2019. Lease liabilities of $11 million as of December 31, 2019 are short-term and have been recorded within Other current liabilities in the Combined statements of financial position. See Note 13, Other Liabilities. Substantially all our operating leases have remaining lease terms of 10 years or less, some of which may include options to extend.

Operating lease expense consists of the following for the years ended December 31:

(in millions)

2019

2018

Long-term (fixed)

$

17

$

16

Long-term (variable)

7

5

Total operating lease expense

$

24

$

21

Maturity of Lease Liabilities

(in millions)

2020

14

2021

11

2022

9

2023

6

2024

6

2025 and thereafter

30

Total undiscounted lease payments

76

Less: imputed interest

(15

)

Total lease liability as of December 31, 2019

$

61

Supplemental Information Related to Operating Leases

(in millions)

Operating cash flows used for operating leases for the year ended December 31, 2019

$

16

Right-of-use assets obtained in exchange for new lease liabilities for the year ended December 31, 2019

9

Weighted-average remaining lease term at December 31, 2019

7.6 years

Weighted-average discount rate at December 31, 2019

5.4

%


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

NOTE 8

Goodwill and Intangible Assets – Net

Goodwill

Changes in the carrying amount of goodwill for the years ended December 31, 2019 and 2018 are as follows:

(in millions)

Goodwill – January 1, 2018

$

5,334

Foreign currency translation

(29

)

Goodwill – December 31, 2018

$

5,305

Disposals (a)

(9

)

Foreign currency translation

22

Goodwill – December 31, 2019

$

5,318

(a)

On August 30, 2019, we sold our interest in GE Healthcare Biotechnologies LLC, GE Healthcare Biotechnologies Systems Limited and GE Healthcare Biotechnologies Limited (collectively, our “Forensics Business”) to Qiagen GmbH and Qiagen North American Holdings Inc., for cash consideration of $34 million. As a result of the transaction, we recognized a pre-tax gain of approximately $23 million within Other (income) and expense-net in our Combined statements of income.

In performing the annual goodwill impairment test during 2019 and 2018, we determined that the fair value of the reporting units was more than their carrying amounts and no impairment charges were recorded.

Intangible Assets – Net

Intangible assets and accumulated amortization as of December 31 consist of the following:

2019

2018

(in millions)

Weighted

Media

Remaining

Lives

(in years)

Gross

Carrying

Amount

Accumulated

Amortization

Netto

Gross

Carrying

Amount

Accumulated

Amortization

Netto

Customer-related

13

$

345

$

(139

)

$

206

$

342

$

(119

)

$

223

Patents & technology

6

969

(783

)

186

967

(745

)

222

Capitalized software – internal-use

4

181

(141

)

40

166

(130

)

36

Capitalized software – external-use

1

46

(45

)

1

47

(44

)

3

Trademarks & other

8

130

(80

)

50

127

(73

)

54

Intangible Assets

$

1,671

$

(1,188

)

$

483

$

1,649

$

(1,111

)

$

538

Amortization expense was $72 million and $76 million for the years ended December 31, 2019 and 2018, respectively.

Estimated annual amortization for intangible assets over the next five calendar years consists of the following:

(in millions)

2020

2021

2022

2023

2024

Estimated annual amortization expense

$

71

$

64

$

58

$

54

$

51


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

Other Current Assets

Other current assets as of December 31, 2019 and 2018, consists of the following:

(in millions)

2019

2018

Prepaid taxes and other prepaid items

$

58

$

71

Derivative assets

2

14

Other (a)

30

32

Other current assets

$

90

$

117

(a)

Other primarily consists of investment securities and miscellaneous deferred charges.

Other Assets

Other assets as of December 31, 2019 and 2018, consists of the following:

(in millions)

2019

2018

Equity method investments (a)

$

$

28

Long-term inventory

70

79

Long-term contract assets

5

11

Other (b)

36

34

Other assets

$

111

$

152

(a) On June 13, 2019, we signed an agreement to sell our 30% equity method investment in Zenith Technologies Limited to Cognizant Worldwide Limited for cash consideration of approximately $61 million. The transaction subsequently closed on July 31, 2019 and as a result of the transaction, we recognized a pre-tax gain of approximately $35 million within Other (income) and expense-net in our Combined statements of income.

(b) Other primarily consists of pension assets, unlisted investments and prepayments that are long-term in nature.


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

NOTE 10

Derivatives and Hedging

Our policy requires that derivatives are used solely for managing risks and not for speculative purposes. Our notional relates primarily to managing currency risk. The table below summarizes the fair value of all derivatives, including hedging instruments and embedded derivatives as of December 31, 2019 and 2018, respectively.

2019

2018

(in millions)

Gross Notional

Other current assets

Other current liabilities

Gross Notional

Other current assets

Other current liabilities

Derivatives accounted for as hedges

Currency exchange contracts

$

547

$

$

(10

)

$

1,011

$

12

$

(26

)

Derivatives not accounted for as hedges

Embedded derivatives

24

2

19

2

Totale

$

571

$

2

$

(10

)

$

1,030

$

14

$

(26

)

Derivatives are classified in the captions “Other current assets” and “Other current liabilities” in the Combined statements of financial position.

Risk Management Strategy

We buy, manufacture and sell components and products across global markets. These activities expose us to changes in foreign currency exchange rates which can adversely affect revenues earned and costs of operating our business. Our manufacturing entities sell internally to our distribution entities, who ultimately sell to the end customer. Much of our foreign currency risk is generated on the intercompany side as our manufacturing entities have different functional currencies than our distribution entities, leaving one party exposed to the foreign exchange risk on their margins. These sales and purchase transactions also create receivables and payables denominated in foreign currencies, which expose us to foreign currency gains and losses based on changes in exchange rates. Changes in the price of raw materials that we use in manufacturing can affect the cost of manufacturing. We use derivatives to mitigate these exposures.

Cash Flow Hedges

We use cash flow hedging primarily to reduce the effects of foreign exchange rate changes on purchase and sale contracts. Accordingly, the majority of our derivative activities in this category consist of foreign currency exchange contracts.

Under cash flow hedge accounting as permitted by U.S. GAAP, the derivative carrying amount is measured at fair value each period and any resulting gain or loss is recorded in a separate component of equity. When the hedged transaction occurs, these amounts are released from equity, in order that the transaction will be reflected in earnings at the rate locked in by the derivative. The effect of the hedge is reported in the same financial statement line item as the earnings effects of the hedged transaction.

The table below explains the effects of market rate changes on the fair value of derivatives we use most commonly in cash flow hedging arrangements.

Currency forwards/swaps

U.S. dollar strengthens

U.S. dollar weakens

Sell revenue currency (EUR & JPY) vs. USD

Fair value increases

Fair value decreases

Buy cost currency (SEK ) vs. USD

Fair value decreases

Fair value increases

Changes in the fair value of cash flow hedges are recorded in Accumulated Other Comprehensive Income (“AOCI”) and recorded in earnings in the period in which the hedged transaction occurs. The gain (loss) recognized in AOCI was $(26) million and $(29) million for the years ended December 31, 2019 and 2018, respectively. The gain (loss) reclassified from


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

AOCI to earnings was $(29) million and $(24) million for the years ended December 31, 2019 and 2018, respectively. These amounts were related to currency exchange contracts.

The total amount in AOCI related to cash flow hedges of forecasted transactions was a $(7) million loss at December 31, 2019. We expect to reclassify $(7) million of loss to earnings in the next 12 months contemporaneously with the earnings effects of the related forecasted transactions. For the years ended December 31, 2019 and 2018, we recognized insignificant gains and losses related to hedged forecasted transactions and firm commitments that did not occur by the end of the originally specified period. The maximum term of derivative instruments that hedge forecasted transactions was twelve months and eighteen months as of December 31, 2019 and December 31, 2018, respectively.

Effects of Derivatives on Earnings

All derivatives are marked to fair value on our Combined statements of financial position, whether they are designated in a hedging relationship for accounting purposes or are used as economic hedges. For derivatives not designated as hedging instruments, substantially all the gain or loss recognized in earnings is offset by either the current period change in value of underlying exposures which is recorded in earnings in the current period or a future period when the recording of the exposures occurs. The total effect of derivatives not designated as hedges on earnings was insignificant for the years ended December 31, 2019 and 2018, respectively.

The table below presents the effect of our cash flow hedges on our Combined statements of income for the years ended December 31:

2019

2018

(in millions)

Cost of Sales

Other (income) and expense-net

Cost of Sales

Other (income) and expense-net

Total amounts presented in the Combined statements of income

$

1,246

$

(75

)

$

1,222

$

(17

)

Total gain (loss) on cash flow hedges

$

(28

)

$

(1

)

$

(18

)

$

(6

)

Counterparty Credit Risk

Fair value of our derivatives can change significantly from period to period based on, among other factors, market movements and changes in our positions. GE manages counterparty credit risk on our behalf – the risk that counterparties will default and not make payments to us according to the terms of our agreements – on an individual counterparty basis.

The tax provisions have been prepared on a separate return basis as if the Business were a separate group of companies under common ownership. The operations have been combined as if the Business were filing on a combined basis for U.S. Federal, U.S. state and non-U.S. income tax purposes, where allowable by law. The Business is subject to income taxes in the U.S. (both Federal and state) and in numerous foreign jurisdictions. Changes in the tax laws or regulations in these jurisdictions, or changes in position by the relevant authority regarding their application, administration or interpretation, may affect our tax liability, return on investments and business operations.

To reflect the costs that would have been incurred in the ordinary course of business if the Business operated as a stand-alone business, GE Corporate overhead and other pretax costs were allocated to the Business. These costs were not specifically allocated to individual BioPharma entities; accordingly, the tax effect of these charges was calculated by allocating the costs to jurisdictions based on where the intellectual property of the Business was owned, and tax effected at those statutory rates. Under this approach, Swedish and U.S. entities received the majority of the allocations.

During the year ended December 31, 2019, in preparation for the planned sale of the Business to Danaher, GE engaged in and completed various internal restructuring activities. The U.S. income tax impact of these internal restructuring activities, which specifically have tax implications relating to the GE consolidated group, have not been reflected in the Combined financial statements. These restructuring activities were executed to facilitate the planned disposition of the Business, were not taken at the discretion of the Business and do not directly impact the ongoing operations of the Business.


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

The Business’ income tax provision was prepared following the separate return method, which management believes should exclude the GE internal restructuring activities noted above.

Combined Income Before Income Taxes

(in millions)

2019

2018

U.S.

$

95

$

93

Non-U.S.

1,257

979

Total income

$

1,352

$

1,072

Combined Expense Provision for Income Taxes

(in millions)

2019

2018

Current

U.S. Federal

$

110

$

81

U.S. State and Local

5

4

Non-U.S.

50

33

Deferred

U.S. Federal

2

4

U.S. State and Local

1

(1

)

Non-U.S.

210

243

Totale

$

378

$

364

Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate

(in millions)

2019

2018

Income before taxes

1,352

1,072

U.S. Statutory Rate

21%

21

%

Tax expected at Statutory Rate

284

225

Foreign Operations and Foreign Tax Credits

6

21

Global Intangible Low Taxed Income

86

72

Non-U.S. Rate Change

51

Altro

2

(5

)

Total income tax

378

364

Actual Income tax rate

28

%

34

%

Unrecognized Tax Positions

The Business is subject to periodic tax audits by tax authorities in the U.S. (both Federal and state) and the numerous countries in which we operate. While the Business currently is being audited in several jurisdictions, we believe that there are no jurisdictions in which the outcome of unresolved issues or claims is likely to be material to the results of operations, financial position or cash flows. We further believe that we have made adequate provisions for all income tax uncertainties.


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

At December 31, 2019 and December 31, 2018, the amount of unrecognized tax benefits and accrued interest was not material. We classify interest on tax deficiencies as interest expense; we classify income tax penalties as a provision for income taxes.

Deferred Income Taxes

Deferred income tax balances reflect the effects of temporary differences between the carrying amounts of assets and liabilities and their tax bases, as well as from net operating losses and tax credit carryforwards, and are stated at enacted tax rates expected to be in effect when taxes are paid or recovered. Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years. Tax attribute carryforwards reflected in deferred income taxes include the balances historically recorded by the Business, adjusted for pretax expenses directly attributable or allocated to the Business for the periods presented. The Business did not operate as a stand-alone entity (or group of entities) in the past and, accordingly, the amount and composition of our tax losses, receivables and other deferred tax assets included in the Combined financial statements may change as the result of the Business’ separation from GE.

We regularly evaluate the recoverability of our deferred tax assets and establish valuation allowances, where necessary, to reduce the deferred tax assets to amounts that are more likely than not to be realized (a likelihood of more than 50%). Significant judgment is required in determining whether a valuation allowance is necessary and the amount of such valuation allowance. In assessing the recoverability of our deferred tax assets at December 31, 2019 and 2018, we considered all available evidence, including the nature of financial statement losses, reversing taxable temporary differences and estimated future operating profits. We believe it is more likely than not that the results of future operations will generate sufficient taxable income to realize the Business’ net deferred tax assets. Aggregated deferred income tax amounts are summarized below.

Components of the Net Deferred Income Tax Asset (Liability)

(in millions)

2019

2018

Deferred income taxes

Employee Benefits

$

2

$

2

Deferred Revenue

3

13

Goodwill & Other Intangibles

498

487

Inventory

6

7

Operating Loss Carryforwards

199

423

Other & Accrued Expenses

(15

)

(15

)

Pension Plans

58

43

Property

(2

)

4

Receivables

4

4

Total deferred income tax

753

968

Valuation allowances

(7

)

(5

)

Net deferred income tax asset after valuation allowance

$

746

$

963

Net Operating Losses

At December 31, 2019, the Business had net operating loss carryforwards of $(945) million primarily related to Sweden, which can be carried forward indefinitely. The gross net operating loss carryforwards resulted in a deferred tax asset of $199 million at December 31, 2019.

Undistributed Earnings

In the Combined financial statements, foreign earnings are considered indefinitely reinvested which is consistent with the assertion made by GE relative to the Business’ foreign operations as of December 31, 2019. Due to the enactment of U.S. tax reform during 2017, substantially all our previously unrepatriated foreign earnings were subject to U.S. Federal income tax, and


GE BIOPHARMA

NOTES TO THE COMBINED FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

therefore we expect to have the ability to repatriate those earnings without an incremental U.S. Federal tax cost except for foreign withholding taxes. As of December 31, 2019, the cumulative amount of indefinitely reinvested foreign earnings was approximately $2,660 million. Computation of any deferred tax liability associated with and any other remaining basis differences is not practicable.

Tax Reform

On December 22, 2017, the U.S. enacted the 2017 Tax Act which made significant changes to the U.S. corporate income tax system, including reducing the corporate tax rate to 21%, limiting the tax deduction for interest expense to 30% of adjusted earnings, implementing a “base erosion anti-abuse tax” requiring U.S. corporations to make an alternative determination of taxable income without regard to tax deductions for certain payments to affiliates, taxing certain earnings considered to be “global intangible low-taxed income,” changing the limitation on deductions for certain executive compensation, imposing a one-time tax on offshore earnings at reduced rates and allowing an immediate deduction for certain new investments instead of deductions for depreciation expense over time. The impact of enactment of U.S. tax reform was recorded in 2017 on a provisional basis as the legislation provided for additional guidance to be issued by the U.S. Department of the Treasury on several provisions including the computation of the transition tax.

In 2018 we finalized our accounting for the 2017 Tax Act and recorded immaterial adjustments. We have completed our accounting related to the effects of the 2017 Tax Act, based on current law and our current interpretation of the law. Additional guidance may be provided by the U.S. Treasury and IRS that could materially impact amounts previously provided. Consistent with GE Corporate's election, we account for the new minimum tax on global intangible low taxed income as a period cost.

NOTE 12

Accumulated Other Comprehensive Income (Loss)

The changes in the components of Accumulated other comprehensive income (loss) are as follows:

(in millions)

Gains (Losses) on

Cash Flow

Hedges

Unrealized

Gains

(Losses) on

Investment

Securities

Defined

Benefit

Plan

Pension

Items

Foreign

Currency

Items

Totale

As of January 1, 2018

$